


Covid-19 Literature Update



A CURATED SELECTION AND OVERVIEW OF COVID-19 PUBLICATIONS

Update October 26 - November 1, 2020,

Dr. Peter J. Lansberg MD, PhD

Weekly COVID-19 Literature Update

will keep you up-to-date with all recent PubMed publications
categorized by relevant topics

COVID-19 publications - Week 44 2020 1088 Publications

PubMed based Covid-19 weekly literature update

For those interested in receiving weekly updates
click [here](#)

For questions and requests for topics to add send an e-mail
lansberg@gmail.com

Reliable on-line resources for Covid 19

[WHO](#)

[Daily dashboard](#)

[Country Guidance](#)

[Travel restriction](#)

[Covid Counter](#)

[Covid forecasts](#)

[CDC](#)

[AHA](#)

[ESC](#)

[EMA](#)

[Evidence EPPI](#)

[Wikipedia](#)

[Cardionerds - COVID-19](#)

[Genomic epidemiology](#)

[Oxygenation Ventilation toolkit](#)

[Cochrane](#)

[BMJ](#)

[The Lancet](#)

[New England Journal of Medicine](#)

[JAMA](#)

[Cell](#)

[Science](#)

[Oxford University Press](#)

[Cambridge University Press](#)

[Springer Nature](#)

[Elsevier](#)

[Wiley](#)

[PLOS](#)

[LitCovid NIH-NLM](#)

[SSRN \(Pre-prints\)](#)

[German \(ICU\) bed capacity](#)

[COVID reference \(Steinhauser Verlag\)](#)

[COVID-19 Projections tracker](#)

[Retracted papers](#)

[AAN - Neurology resources](#)

[COVID-19 risk tools - Apps](#)

[COVID-19 resources \(Harvard\)](#)

[COVID-19 resources \(McMasters\)](#)

[COVID-19 resources \(NHLBI\)](#)

[COVID-19 resources \(MEDSCAPE\)](#)

[COVID-19 Diabetes \(JDRF\)](#)

[COVID-19 TELEMEDICINE \(BMJ\)](#)

[Global Causes of death \(Johns Hopkins\)](#)

[COVID-19 calculators \(Medscape\)](#)

Guidelines

[NICE Guidelines Covid-19](#)

[Korean CDC Covid-19 guidelines](#)

[Flattening the curve - Korea](#)

[IDSA COVID-19 Guidelines](#)

[Airway Management Clinical Practice Guidelines \(SIAARTI/EAMS, 2020\)](#)

[ESICM Ventilation Guidelines](#)

[Performing Procedures on Patients With Known or Suspected COVID-19 \(ASA, 2020\)](#)

[OSHA Guidance on Preparing the Workplace for COVID-19 \(2020\)](#)

[Policy for Sterilizers, Disinfectant Devices, and Air Purifiers \(FDA, 2020\)](#)

[Breast Cancer Patient Triage Guidelines \(CPBCC, 2020\)](#)

[clinical guidance for adult Belgian patients with suspected or confirmed COVID-19](#)

[National Covid-19 Testing Action Plan \(Rockefeller Foundation\)](#)

[ASE issues Echo-cardiography guidance](#)

Trials & Registries

[CAPACITY European registry COVID 19 patients](#)

[WHO launches global megatrial](#)

[FDA launches Convalescent plasma trial](#)

[Lets Beat Covid-19 Survey to help plan hospital services](#)

[COVID IBD registry](#)

[Google mobility reports per country COVID 19](#)

[World's largest trial of potential coronavirus treatments rolled out across the UK](#)

[Pregnancy Registry \(US\)](#)

[ICNARC report on COVID-19 in critical care - NHS April 24](#)

[COVID-19 Human Genetics - Biobanks](#)

[COVID19 settings of transmission database](#)

[COVID-19 prevention network](#)

Mainstream Media

New York Times - Corona update

The Pandemic's Future — and Ours

With Winter Coming and Trump Still in Charge, Virus Experts Fear the Worst

Coronavirus Study in Germany Offers Hope for Concertgoers

Birx Issues Blunt Coronavirus Warning Starkly at Odds With Trump

Pregnant Women Face Increased Risks From Covid-19

The Virus Rate in One Area Plummeted. Experts Wonder Why.

As the Virus Rages, Some Are Convinced It's Too Late to Stop It

At late-night rally, Trump suggests he may fire Fauci 'after the election.'

Russian Provinces Hit by a Second Wave of Coronavirus

Coronavirus Vaccine Tracker

Coronavirus Drug and Treatment Tracker

Washington Post - Corona update

Coronavirus updates: Exit polls show pandemic not the top priority for many voters as hospitals sound alarm

Isolating after a positive coronavirus test? The CDC says you can still vote in person.

As rich countries hoard potential coronavirus vaccine doses, rest of world could go without

MedStar Health reaches 500,000 telehealth visits during pandemic

With coronavirus exploding in Europe, hospitals calculate how long until they hit capacity.

Artificial intelligence and covid-19: Can the machines save us?

'A whole lot of hurt': Fauci warns of covid-19 surge, offers blunt assessment of Trump's response

Guardian - Corona update

Tiny air pollution rise linked to 11% more Covid-19 deaths – study

NHS leaders warn of surge in serious Covid-19 cases in England

Only 'small chance' Oxford Covid vaccine ready by Christmas

Italy registers 30,550 daily cases on eve of new curbs

Boris Johnson warns that NHS will become overwhelmed without England lockdown

Key Articles

- 1. Filling the gaps in the characterization of the clinical management of COVID-19: 30-day hospital admission and fatality rates in a cohort of 118 150 cases diagnosed in outpatient settings in Spain.** *Int J Epidemiol* 2020; Prieto-Alhambra D, Balló E, Coma E *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33118037>

In this extensive Spanish primary care registry (>6 million people), patients diagnosed (RT-PCR) were linked with hospital emergency, inpatient, and mortality registries. The majority were women in their middle ages (58.7%). Severe disease (hospital admissions and death) were more common in elderly males and nursing home residents. Almost 15% of the patients that tested

positive were admitted to hospital; the 30-day fatality rate was 4%

2. **Triglyceride to High-Density Lipoprotein Cholesterol Ratio is an Important Determinant of Cardiovascular Risk and Poor Prognosis in Coronavirus Disease-19: A Retrospective Case Series Study.** Diabetes Metab. Syndr. Obes. 2020; 13:3925-3936 Zhang B, Dong C, Li S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33122929>
Lipid biomarkers were used to predict CVD complications related to COVID-19. The TG/HDL-c ratio at admission showed a promising, independent association with acute cardiac injury, heart failure, disease severity, and mortality. The TG/HDL-c ratio may be considered a useful marker to identify patients at admission with an increased risk for COVID-19 related complications.
3. **Gender Effect on Political Leaders' Nonverbal Communicative Structure during the COVID-19 Crisis.** Int J Environ Res Public Health 2020; 17: Grebelsky-Lichtman T, Katz R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114350>
Leadership during crisis must not only project a clear vision of what actions and restrictions are needed but even more so, able to gain the support of those you lead. In earlier commentaries it was noted that countries that were very successful with their COVID-19 strategies were governed by female leaders (Taiwan, New Zealand, Iceland, Hong Kong, Germany). This analysis compared 20 televised appearances by 10 heads of state (five male and five female). Comparing non-verbal communications structure (NCS) showed that the male leaders were competition, warning, threatening, and scaring behaviour, broad proxemics, tension leakage, and illustrative gestures, while female leaders presented feminine NCS of cooperativeness, emotional communication, empathy, optimism, eye contact, and flexible expressions.
4. **[Risk stratification of emergencies during the COVID-19 pandemic within the emergency department].** Med Klin Intensivmed Notfmed 2020; 119: Wieckenberg M, Meier V, Pfeiffer S, Blaschke S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33112980>
5. **Circulating Levels of Interleukin-6 and Interleukin-10, But Not Tumor Necrosis Factor-Alpha, as Potential Biomarkers of Severity and Mortality for COVID-19: Systematic Review with Meta-analysis.** J. Clin. Immunol. 2020; 1-12 Udomsinprasert W, Jittikoon J, Sangroongruangsri S, Chaikledkaew U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128665>
6. **Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis.** Life Sci 2020; 118663 Shrestha DB, Budhathoki P, Syed NI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121991>
7. **The burden of type 2 diabetes pre-and during the COVID-19 pandemic - a review.** J Diabetes Metab Disord 2020; 1-9 Sciberras J, Camilleri LM, Cuschieri S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102262>

8. **Low Seroprevalence of SARS-CoV-2 Antibodies during Systematic Antibody Screening and Serum Responses in Patients after COVID-19 in a German Transplant Center.** J Clin Med 2020; 9Choi M, Bachmann F, Naik MG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114149>

9. **Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19.** J Am Coll Cardiol 2020; 76:2060-2072Piazza G, Campia U, Hurwitz S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121712>

10. **Troponin and Other Biomarker Levels and Outcomes Among Patients Hospitalized with COVID-19: Derivation and Validation of the HA(2)T(2) COVID-19 Mortality Risk Score.** J Am Heart Assoc 2020:e018477Manocha KK, Kirzner J, Ying X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121304>

11. **Optical Biosensors for Virus Detection: Prospects for COVID-19.** Chembiochem 2020; Maddali H, Miles CE, Kohn J, O'Carroll DM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119960>

12. **Role of vitamin D in pathogenesis and severity of COVID-19 infection.** Arch. Physiol. Biochem. 2020;1-7Honardoost M, Ghavideldarestani M, Khamseh ME. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125298>

13. **Bibliometric Analysis of Early COVID-19 Research: The Top 50 Cited Papers.** Infect Dis (Auckl) 2020; 13:1178633720962935ElHawary H, Salimi A, Diab N, Smith L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110348>

14. **Is there a role for childhood vaccination against COVID-19?** Pediatr. Allergy Immunol. 2020; Eberhardt CS, Siegrist CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113210>

15. **Recurrence of SARS-CoV-2 viral RNA in recovered COVID-19 patients: a narrative review.** Eur J Clin Microbiol Infect Dis 2020:1-13Dao TL, Hoang VT, Gautret P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113040>

Basic Science (74 articles)

1. **In silico analysis of ACE2 orthologues to predict animal host range with high susceptibility to SARS-CoV-2.** 3 Biotech 2020; 10:483Bouricha EM, Hakmi M, Akachar J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101829>
2. **Can Neurotropic Free-Living Amoeba Serve as a Model to Study SARS-CoV-2 Pathogenesis?** ACS Chem Neurosci 2020; Baig AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119251>
3. **Profiling SARS-CoV-2 Main Protease (M(PRO)) Binding to Repurposed Drugs Using Molecular Dynamics Simulations in Classical and Neural Network-**

- Trained Force Fields.** *ACS Comb Sci* 2020; Gupta A, Zhou HX.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33119257>
4. **Hypoxia, HIF-1 α , and COVID-19: from pathogenic factors to potential therapeutic targets.** *Acta Pharmacol. Sin.* 2020:1-8 Serebrovska ZO, Chong EY, Serebrovska TV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110240>
 5. **Identification of SARS-CoV-2 entry inhibitors among already approved drugs.** *Acta Pharmacol. Sin.* 2020; Yang L, Pei RJ, Li H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33116249>
 6. **Single-cell expression profiles of ACE2 and TMPRSS2 reveals potential vertical transmission and fetus infection of SARS-CoV-2.** *Aging (Albany NY)*. 2020; 12Lü M, Qiu L, Jia G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104520>
 7. **Angiotensin-converting enzyme 2 (ACE2) expression in COPD and IPF fibroblasts- the forgotten cell in COVID-19.** *Am J Physiol Lung Cell Mol Physiol* 2020; Aloufi N, Traboulsi H, Ding J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33112187>
 8. **The role of nicotinic receptors in SARS-CoV-2 receptor ACE2 expression in intestinal epithelia.** *Bioelectron Med* 2020; 6:20 Ten Hove AS, Brinkman DJ, Li Yim A YF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123616>
 9. **Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm.** *Biomaterials* 2020; 267:120389 Lee YY, Park HH, Park W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130319>
 10. **Production of Trimeric SARS-CoV-2 Spike Protein by CHO Cells for Serological COVID-19 Testing.** *Biotechnol. Bioeng.* 2020; Johari YB, Jaffé SRP, Scarrott JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128388>
 11. **Biophysical analysis of SARS-CoV-2 transmission and theranostic development via N protein computational characterization.** *Biotechnol. Prog.* 2020:e3096 Sabbih GO, Korsah MA, Jeevanandam J, Danquah MK.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33118327>
 12. **High-Density Amplicon Sequencing Identifies Community Spread and Ongoing Evolution of SARS-CoV-2 in the Southern United States.** *Cell Rep.* 2020:108352 McNamara RP, Caro-Vegas C, Landis JT *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33113345>
 13. **SARS-CoV-2 Infects the Brain Choroid Plexus and Disrupts the Blood-CSF Barrier in Human Brain Organoids.** *Cell Stem Cell* 2020; Pellegrini L, Albecka A, Mallery DL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113348>
 14. **The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.** *Cells* 2020; 9Papageorgiou AC, Mohsin I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33105869>
 15. **Molecular Docking Studies of Bioactive Nicotiflorin against 6W63 Novel Coronavirus 2019 (COVID-19).** *Comb. Chem. High Throughput Screen.* 2020; Dubey R, Dubey K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109057>
 16. **Mechanistic Insights to the Binding of Antibody CR3022 Against RBD from SARS-CoV and HCoV-19/SARS-CoV-2: A Computational Study.** *Comb. Chem. High Throughput Screen.* 2020; Yu W, Wu X, Ren J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33106140>
 17. **Probing infectious disease by single-cell RNA sequencing: progresses and perspectives.** *Comput Struct Biotechnol J* 2020; Luo G, Gao Q, Zhang S, Yan B.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33106757>

18. **COVID-19: Participation of neuroglia could explain common neurological symptoms.** Deutsches Arzteblatt International 2020; 117:A1988Meyer R.
19. **SARS-CoV-2 evades immune detection in alveolar macrophages.** EMBO Rep 2020:e51252Dalskov L, Møhlenberg M, Thyrssted J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33112036>
20. **A SARS-CoV-2 variant with the 12-bp deletion at E gene.** Emerg Microbes Infect 2020; 9:2361-2367Sun YS, Xu F, An Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118859>
21. **In silico identification of strong binders of the SARS-CoV-2 receptor-binding domain.** Eur. J. Pharmacol. 2020:173701Behloul N, Baha S, Guo Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33130279>
22. **Unravelling high-affinity binding compounds towards transmembrane protease serine 2 enzyme in treating SARS-CoV-2 infection using molecular modelling and docking studies.** Eur. J. Pharmacol. 2020:173688M P, Reddy GJ, Hema K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130280>
23. **Within-Host Diversity of SARS-CoV-2 in COVID-19 Patients With Variable Disease Severities.** Front Cell Infect Microbiol 2020; 10:575613Al Khatib HA, Benslimane FM, Elbashir IE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123498>
24. **Infectivity and Progression of COVID-19 Based on Selected Host Candidate Gene Variants.** Front Genet 2020; 11:861Iyer GR, Samajder S, Zubeda S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101356>
25. **Genomic Cues From Beta-Coronaviruses and Mammalian Hosts Sheds Light on Probable Origins and Infectivity of SARS-CoV-2 Causing COVID-19.** Front Genet 2020; 11:902Narh CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110415>
26. **Genetic Association of ACE2 rs2285666 Polymorphism With COVID-19 Spatial Distribution in India.** Front Genet 2020; 11:564741Srivastava A, Bandopadhyay A, Das D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101387>
27. **Animal Models for COVID-19: More to the Picture Than ACE2, Rodents, Ferrets, and Non-human Primates. A Case for Porcine Respiratory Coronavirus and the Obese Ossabaw Pig.** Front. Microbiol. 2020; 11:573756Heegaard PMH, Sturek M, Alloosh M, Belsham GJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101246>
28. **Rapid Genomic Characterization of SARS-CoV-2 by Direct Amplicon-Based Sequencing Through Comparison of MinION and Illumina iSeq100(TM) System.** Front. Microbiol. 2020; 11:571328Hourdel V, Kwasiborski A, Balière C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101244>
29. **Genetic Spectrum and Distinct Evolution Patterns of SARS-CoV-2.** Front. Microbiol. 2020; 11:593548Liu S, Shen J, Fang S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101264>
30. **SAMHD1 as the Potential Link Between SARS-CoV-2 Infection and Neurological Complications.** Front. Neurol. 2020; 11:562913Khan A, Sergi C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101175>
31. **Transcriptomic analysis reveals novel mechanisms of SARS-CoV-2 infection in human lung cells.** Immun Inflamm Dis 2020; Yang S, Wu S, Yu Z *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33124193>
32. **Unbiased Screens Show CD8(+) T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein.**

- [Immunity](#) 2020; Ferretti AP, Kula T, Wang Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33128877>
33. **Plasma Proteomics Identify Biomarkers and Pathogenesis of COVID-19.** [Immunity](#) 2020; Shu T, Ning W, Wu D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128875>
 34. **A connectivity map-based drug repurposing study and integrative analysis of transcriptomic profiling of SARS-CoV-2 infection.** [Infect Genet Evol](#) 2020:104610 Mousavi SZ, Rahmanian M, Sami A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33130005>
 35. **In silico identification of drug candidates against COVID-19.** [Inform Med Unlocked](#) 2020; 21:100461 Wu Y, Chang KY, Lou L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33102688>
 36. **Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients.** [Int Immunopharmacol](#) 2020; 89:107088 Valizadeh H, Abdolmohammadi-Vahid S, Danshina S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33129099>
 37. **Interleukin-6: Molecule in the Intersection of Cancer, Ageing and COVID-19.** [Int J Mol Sci](#) 2020; 21:Brábek J, Jakubek M, Vellieux F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33114676>
 38. **SARS-CoV-2/Renin-Angiotensin System: Deciphering the Clues for a Couple with Potentially Harmful Effects on Skeletal Muscle.** [Int J Mol Sci](#) 2020; 21:Gonzalez A, Orozco-Aguilar J, Achiardi O *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33114359>
 39. **Identification of therapeutic drugs against COVID-19 through computational investigation on drug repurposing and structural modification.** [J. Biomed. Res.](#) 2020:1-12 Yun Y, Song H, Ji Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33122473>
 40. **High-throughput virtual screening of drug databanks for potential inhibitors of SARS-CoV-2 spike glycoprotein.** [J Biomol Struct Dyn](#) 2020:1-14 Awad IE, Abu-Saleh AAA, Sharma S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103586>
 41. **In silico analysis of the interactions of certain flavonoids with the receptor-binding domain of 2019 novel coronavirus and cellular proteases and their pharmacokinetic properties.** [J Biomol Struct Dyn](#) 2020:1-15 Istifli ES, Netz PA, Sihoglu Tepe A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111622>
 42. **Binding mechanism and structural insights into the identified protein target of COVID-19 and importin- α with in-vitro effective drug ivermectin.** [J Biomol Struct Dyn](#) 2020:1-10 Sen Gupta PS, Biswal S, Panda SK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33111618>
 43. **Supervised molecular dynamics for exploring the druggability of the SARS-CoV-2 spike protein.** [J. Comput. Aided Mol. Des.](#) 2020; Deganutti G, Prischi F, Reynolds CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103220>
 44. **Macrophages in diabetes mellitus (DM) and COVID-19: do they trigger DM?** [J Diabetes Metab Disord](#) 2020:1-4 Kloc M, Ghobrial RM, Lewicki S, Kubiak JZ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33102261>
 45. **Computational studies reveal mechanism by which quinone derivatives can inhibit SARS-CoV-2. Study of embelin and two therapeutic compounds of interest, methyl prednisolone and dexamethasone.** [J Infect Public Health](#) 2020; Caruso F, Rossi M, Pedersen JZ, Incerpi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109497>

46. **Inflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy.** *J Inflamm Res* 2020; 13:673-680Shibabaw T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116747>
47. **Falling Dynamics of SARS-CoV-2 as a Function of Respiratory Droplet Size and Human Height.** *J Med Biol Eng* 2020:1-7Aydin M, Evrendilek F, Savas SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100940>
48. **Synthesis, anti-bacterial evaluation, DFT study and molecular docking as a potential 3-chymotrypsin-like protease (3CLpro) of SARS-CoV-2 inhibitors of a novel Schiff bases.** *J. Mol. Struct.* 2020:129454Al-Janabi ASM, Elzupir AO, Yousef TA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100378>
49. **Identification of alkaloids from Justicia adhatoda as potent SARS CoV-2 main protease inhibitors: An in silico perspective.** *J. Mol. Struct.* 2020:129489Ghosh R, Chakraborty A, Biswas A, Chowdhuri S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100380>
50. **A deep learning model and machine learning methods for the classification of potential coronavirus treatments on a single human cell.** *J Nanopart Res* 2020; 22:313Khalifa NEM, Taha MHN, Manogaran G, Loey M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100894>
51. **Molecular Basis of SARS-CoV-2 Infection and Rational Design of Potential Antiviral Agents: Modeling and Simulation Approaches.** *J. Proteome Res.* 2020; Francés-Monerris A, Hognon C, Miclot T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119313>
52. **Computational Identification of Human Biological Processes and Protein Sequence Motifs Putatively Targeted by SARS-CoV-2 Proteins Using Protein-Protein Interaction Networks.** *J. Proteome Res.* 2020; Nadeau R, Shahryari Fard S, Scheer A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103435>
53. **Noncoding RNAs implication in cardiovascular diseases in the COVID-19 era.** *J Transl Med* 2020; 18:408Greco S, Madè A, Gaetano C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129318>
54. **The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection.** *JACC Basic Transl Sci* 2020; Beddingfield BJ, Iwanaga N, Chapagain PP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102950>
55. **Mathematical modeling of COVID-19 transmission: the roles of intervention strategies and lockdown.** *Math Biosci Eng* 2020; 17:5961-5986Bugalia S, Bajiya VP, Tripathi JP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120585>
56. **Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area.** *mBio* 2020; 11Long SW, Olsen RJ, Christensen PA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127862>
57. **Pervasive RNA Secondary Structure in the Genomes of SARS-CoV-2 and Other Coronaviruses.** *mBio* 2020; 11Simmonds P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127861>
58. **Protein-driven mechanism of multiorgan damage in COVID-19.** *Med Drug Discov* 2020:100069Estrada E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103107>
59. **Mutations Observed in the SARS-CoV-2 Spike Glycoprotein and Their Effects in the Interaction of Virus with ACE-2 Receptor.** *Medeni Med J* 2020; 35:253-260Durmaz B, Abdulmajed O, Durmaz R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110678>

60. **Antibody binding epitope Mapping (AbMap) of hundred antibodies in a single run.** Mol. Cell. Proteomics 2020; Qi H, Ma M, Hu C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33109704>
61. **Potential of Ficus microcarpa metabolites against SARS-CoV-2 main protease supported by docking studies.** Nat Prod Res 2020:1-5 Hassan HA, Abdelmohsen UR, Aly OM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121282>
62. **Biochemical parameters and pathogenesis of SARS-CoV-2 infection in vital organs: COVID-19 outbreak in Iran.** New Microbes New Infect 2020:100792 Mirmohammadi S, Kianmehr A, Arefi M, Mahrooz A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101694>
63. **New Insights on the Mobility of Viral and Host Non-Coding RNAs Reveal Extracellular Vesicles as Intriguing Candidate Antiviral Targets.** Pathogens 2020; 9 Wower IK, Brandebourg TD, Wower J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114356>
64. **A Proline-Based Tectons and Supramolecular Synthons for Drug Design 2.0: A Case Study of ACEI.** Pharmaceuticals (Basel) 2020; 13 Bojarska J, Remko M, Breza M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114370>
65. **Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease.** Pharmgenomics Pers. Med. 2020; 13:463-484 Cafiero C, Re A, Micera A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33116761>
66. **Potential SARS-CoV-2 interactions with proteins involved in trophoblast functions - An in-silico study.** Placenta 2020; 103:141-151 Seethy AA, Singh S, Mukherjee I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126048>
67. **N-Terminomics for the Identification of in vitro Substrates and Cleavage Site Specificity of the SARS-CoV-2 Main Protease.** Proteomics 2020:e2000246 Koudelka T, Boger J, Henkel A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33111431>
68. **Computational selection of flavonoid compounds as inhibitors against SARS-CoV-2 main protease, RNA-dependent RNA polymerase and spike proteins: A molecular docking study.** Saudi J. Biol. Sci. 2020; Ragavan Rameshkumar M, Indu P, Arunagirinathan N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110386>
69. **COVID-19-Induced Neurovascular Injury: a Case Series with Emphasis on Pathophysiological Mechanisms.** SN Compr Clin Med 2020:1-17 Gutierrez Amezcua JM, Jain R, Kleinman G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106782>
70. **Discovery of small molecule PLpro inhibitor against COVID-19 using structure-based virtual screening, molecular dynamics simulation, and molecular mechanics/Generalized Born surface area (MM/GBSA) calculation.** Struct Chem 2020:1-8 Pang J, Gao S, Sun Z, Yang G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33106741>
71. **A natural food preservative peptide nisin can interact with the SARS-CoV-2 spike protein receptor human ACE2.** Virology 2020; 552:107-111 Bhattacharya R, Gupta AM, Mitra S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130382>
72. **SARS-CoV, MERS-CoV, and 2019-nCoV viruses: an overview of origin, evolution, and genetic variations.** Virusdisease 2020:1-13 Krishnamoorthy S, Swain B, Verma RS, Gunthe SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102628>

73. **Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization.** *Viruses* 2020; 12Ding S, Laumaea A, Benlarbi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114742>
74. **Viewpoint: Origin of SARS-CoV-2.** *Viruses* 2020; 12Lundstrom K, Seyran M, Pizzol D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33105685>

Biomarkers - Genetics (107 articles)

1. **Roadmap to the Bioanalytical Testing of COVID-19: From Sample Collection to Disease Surveillance.** *ACS Sens* 2020; Hosseini A, Pandey R, Osman E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33124797>
2. **COVID-19 rapid diagnostic test could contain transmission in low- and middle-income countries.** *Afr J Lab Med* 2020; 9:1255Olalekan A, Iwalokun B, Akinloye OM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102170>
3. **The Lab Must Go On.** *Am J Clin Pathol* 2020; Jackson BR, Genzen JR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118009>
4. **Laboratory Biomarkers in the Management of Patients With COVID-19.** *Am J Clin Pathol* 2020; Weidmann MD, Ofori K, Rai AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107558>
5. **Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study.** *Am. J. Med.* 2020; Mahajan S, Srinivasan R, Redlich CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130124>
6. **Comparing Nasopharyngeal and Bronchoalveolar Lavage SARS-CoV-2 Assays in Respiratory Failure.** *Am J Respir Crit Care Med* 2020; Gao C, Cuttica M, Malsin E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125256>
7. **COVID-19 in men: With or without virus in semen, spermatogenesis may be impaired.** *Andrologia* 2020:e13878Bendayan M, Robin G, Hamdi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125771>
8. **Aminotransferases disorders associated with venous thromboembolic events in patients infected with COVID-19.** *Ann. Hepatol.* 2020; Hamadé A, Woehl B, Talbot M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130333>
9. **The role of nicotinic receptors in SARS-CoV-2 receptor ACE2 expression in intestinal epithelia.** *Bioelectron Med* 2020; 6:20Ten Hove AS, Brinkman DJ, Li Yim AYF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123616>
10. **Change of Antigenic Determinants of SARS-CoV-2 Virus S-Protein as a Possible Cause of Antibody-Dependent Enhancement of Virus Infection and Cytokine Storm.** *Biophysics (Oxf.)* 2020; 65:703-709Nechipurenko YD, Anashkina AA, Matveeva OV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100352>
11. **Diverse Responses of the Biobanks in Indo-Pacific Rim Region During the COVID-19 Pandemic: Case Scenarios from Two Low- and Middle-Income Countries and Two High-Income Countries in the Indo-Pacific Rim Region.** *Biopreserv. Biobank.* 2020; Yadav BK, Ng W, Fachiroh J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118846>
12. **One-step rapid quantification of SARS-CoV-2 virus particles via low-cost nanoplasmonic sensors in generic microplate reader and point-of-care device.** *Biosens. Bioelectron.* 2020; 171:112685Huang L, Ding L, Zhou J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113383>

13. **Dual lateral flow optical/chemiluminescence immunosensors for the rapid detection of salivary and serum IgA in patients with COVID-19 disease.** Biosens. Bioelectron. 2020; 172:112765Roda A, Cavalera S, Di Nardo F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126179>
14. **Production of Trimeric SARS-CoV-2 Spike Protein by CHO Cells for Serological COVID-19 Testing.** Biotechnol. Bioeng. 2020; Johari YB, Jaffé SRP, Scarrott JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128388>
15. **Hospitalised COVID-19 patients of the Mount Sinai Health System: a retrospective observational study using the electronic medical records.** BMJ Open 2020; 10:e040441Wang Z, Zheutlin A, Kao YH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109676>
16. **Optical Biosensors for Virus Detection: Prospects for COVID-19.** Chembiochem 2020; Maddali H, Miles CE, Kohn J, O'Carroll DM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119960>
17. **Evidence for increased circulating procoagulant phospholipids in patients with COVID-19 pneumonia and their prognostic role.** Clin Chem Lab Med 2020; Assimakopoulos SF, Emmanuil A, Tsimeka A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33112778>
18. **Anti-SARS-CoV-2 antibody detection in healthcare workers of two tertiary hospitals in Athens, Greece.** Clin Immunol 2020; 221:108619Vlachoyiannopoulos P, Alexopoulos H, Apostolidi E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127563>
19. **Anti-SARS-CoV-2 antibody detection in healthcare workers of two tertiary hospitals in Athens, Greece.** Clin Immunol 2020; 221:108619Vlachoyiannopoulos P, Alexopoulos H, Apostolidi I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127563>
20. **Repeat COVID-19 Molecular Testing: Correlation of SARS-CoV-2 Culture with Molecular Assays and Cycle Thresholds.** Clin Infect Dis 2020; Gniazdowski V, Morris CP, Wohl S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104776>
21. **Complement and protection from tissue injury in COVID-19.** Clin Kidney J 2020; 13:734-738Ortiz A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123353>
22. **Temporal changes in complement activation in haemodialysis patients with COVID-19 as a predictor of disease progression.** Clin Kidney J 2020; 13:889-896Predecki M, Clarke C, Medjeral-Thomas N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123364>
23. **Measuring the Serologic Response to Severe Acute Respiratory Syndrome Coronavirus 2: Methods and Meaning.** Clin. Lab. Med. 2020; 40:603-614Pecora ND, Zand MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121625>
24. **Coronavirus Detection in the Clinical Microbiology Laboratory: Are We Ready for Identifying and Diagnosing a Novel Virus?** Clin. Lab. Med. 2020; 40:459-472Uhteg K, Carroll KC, Mostafa HH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121615>
25. **Side chain similarity comparisons for integrated drug repositioning and potential toxicity assessments in epidemic response scenarios: the case for COVID-19.** Comput Struct Biotechnol J 2020; Syatila Ab Ghani N, Emrizal R, Makmur H, Firdaus-Raih M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101604>
26. **Should We Rely on Screening Tests for Further Management Alone in Polymerase Chain Reaction Negative COVID-19 Patients? A Case Series.**

- Cureus 2020; 12:e10555Iqbal P, Ata F, Rose S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101802>
27. **Unexpected Ground-Glass Opacities on Abdominopelvic CT of a Patient With a Negative SARS-CoV-2 Antigen Test Result and No Respiratory Symptoms Upon Admission.** Cureus 2020; 12:e11044Soler-Luna C, Reynoso-Saldana D, Burgos MI, Gutierrez CH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101790>
 28. **The Interferon-induced transmembrane protein 3 gene (IFITM3) rs12252 C variant is associated with COVID-19.** Cytokine 2020; 137:155354Gómez J, Albaiceta GM, Cuesta-Llavona E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113474>
 29. **Monocyte HLA-DR measurement by flow cytometry in COVID-19 patients: an interim review.** Cytometry A 2020; Benlyamani I, Venet F, Coudereau R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125816>
 30. **Quadruple negative SARS-CoV-2-PCR: Still COVID-19 pneumonia!** Deutsche Medizinische Wochenschrift 2020; 145:1498-1502Dubbke-Laule A, Gnauck M, Straub R *et al.*
 31. **Short term follow-up of patients presenting with acute onset diabetes and diabetic ketoacidosis during an episode of COVID-19.** Diabetes Metab Syndr 2020; 14:2039-2041Kuchay MS, Reddy PK, Gagneja S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113470>
 32. **Nucleic Acid and Immunological Diagnostics for SARS-CoV-2: Processes, Platforms and Pitfalls.** Diagnostics (Basel) 2020; 10Premraj A, Aleyas AG, Nautiyal B, Rasool TJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114057>
 33. **Hematologic parameters in coronavirus infection (COVID-19) and their clinical implications.** Discoveries (Craiova) 2020; 8:e117Waleed RM, Ittikhar W, Sehar I, Khan HS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110936>
 34. **The value of COVID-19 tests in Latin America.** Econ. Hum. Biol. 2020; 39:100931Trudeau JM, Alicea-Planas J, Vásquez WF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126025>
 35. **SARS-CoV-2 evades immune detection in alveolar macrophages.** EMBO Rep 2020:e51252Dalskov L, Møhlenberg M, Thyrssted J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33112036>
 36. **A SARS-CoV-2 variant with the 12-bp deletion at E gene.** Emerg Microbes Infect 2020; 9:2361-2367Sun YS, Xu F, An Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118859>
 37. **Recurrence of SARS-CoV-2 viral RNA in recovered COVID-19 patients: a narrative review.** Eur J Clin Microbiol Infect Dis 2020:1-13Dao TL, Hoang VT, Gautret P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113040>
 38. **Designing a Network Proximity-Based Drug Repurposing Strategy for COVID-19.** Front Cell Dev Biol 2020; 8:545089Stolfi P, Manni L, Soligo M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123533>
 39. **Blood Test Results of Pregnant COVID-19 Patients: An Updated Case-Control Study.** Front Cell Infect Microbiol 2020; 10:560899Sun G, Zhang Y, Liao Q, Cheng Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117727>
 40. **The Impact of COVID-19 on Blood Glucose: A Systematic Review and Meta-Analysis.** Front. Endocrinol. (Lausanne) 2020; 11:574541Chen J, Wu C, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123093>
 41. **Infectivity and Progression of COVID-19 Based on Selected Host Candidate Gene Variants.** Front Genet 2020; 11:861Iyer GR, Samajder S, Zubeda S *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101356>
42. **Genetic Association of ACE2 rs2285666 Polymorphism With COVID-19 Spatial Distribution in India.** *Front Genet* 2020; 11:564741Srivastava A, Bandopadhyay A, Das D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101387>
 43. **Increased Plasma Heparanase Activity in COVID-19 Patients.** *Front. Immunol.* 2020; 11:575047Buijsers B, Yanginlar C, de Nooijer A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123154>
 44. **An Asymptomatic SARS-CoV-2-Infected Infant With Persistent Fecal Viral RNA Shedding in a Family Cluster: A Rare Case Report.** *Front Med (Lausanne)* 2020; 7:562875Chen S, Si J, Tang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102500>
 45. **Association of Peripheral Lymphocyte and the Subset Levels With the Progression and Mortality of COVID-19: A Systematic Review and Meta-Analysis.** *Front Med (Lausanne)* 2020; 7:558545Lu Q, Wang Z, Yin Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102499>
 46. **Rapid Genomic Characterization of SARS-CoV-2 by Direct Amplicon-Based Sequencing Through Comparison of MinION and Illumina iSeq100(TM) System.** *Front. Microbiol.* 2020; 11:571328Hourdel V, Kwasiborski A, Balière C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101244>
 47. **COVID-19 Genetic and Environmental Risk Factors: A Look at the Evidence.** *Front. Pharmacol.* 2020; 11:579415Abdelzaher H, Saleh BM, Ismail HA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117174>
 48. **ACE2, COVID-19 Infection, Inflammation, and Coagulopathy: Missing Pieces in the Puzzle.** *Front. Physiol.* 2020; 11:574753Abassi Z, Higazi AAR, Kinaneh S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123031>
 49. **Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: results of the ACE-CoV study.** *Fundam. Clin. Pharmacol.* 2020; Lafaurie M, Martin-Blondel G, Delobel P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111329>
 50. **Aligning SARS-CoV-2 indicators via an epidemic model: application to hospital admissions and RNA detection in sewage sludge.** *Health Care Manag Sci* 2020;1-10Kaplan EH, Wang D, Wang M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111195>
 51. **Transcriptomic analysis reveals novel mechanisms of SARS-CoV-2 infection in human lung cells.** *Immun Inflamm Dis* 2020; Yang S, Wu S, Yu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33124193>
 52. **Unbiased Screens Show CD8(+) T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein.** *Immunity* 2020; Ferretti AP, Kula T, Wang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128877>
 53. **Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity.** *Immunity* 2020; Ripberger TJ, Uhrlaub JL, Watanabe M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129373>
 54. **Plasma Proteomics Identify Biomarkers and Pathogenesis of COVID-19.** *Immunity* 2020; Shu T, Ning W, Wu D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128875>

55. **Potential drawbacks of frequent asymptomatic COVID-19 testing.** Infect Control Hosp Epidemiol 2020;1-6Lippi G, Henry BM, Sanchis-Gomar F.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33115549>
56. **Ensemble learning model for diagnosing COVID-19 from routine blood tests.** Inform Med Unlocked 2020; 21:100449AlJame M, Ahmad I, Imtiaz A, Mohammed A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33102686>
57. **Cerebrospinal fluid findings in neurological diseases associated with COVID-19 and insights into mechanisms of disease development.** Int J Infect Dis 2020; Espindola OM, Brandão CO, Gomes YCP *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33127503>
58. **Adjusting RT-qPCR conditions to avoid unspecific amplification in SARS-CoV-2 diagnostic.** Int J Infect Dis 2020; Jaeger LH, Nascimento TC, Rocha FD *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33130201>
59. **Field Evaluation of the Performance of a SARS-CoV-2 Antigen Rapid Diagnostic Test in Uganda using Nasopharyngeal Samples.** Int J Infect Dis 2020; Nalumansi A, Lutalo T, Kayiwa J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130198>
60. **Residual SARS-CoV-2 RNA in nasal swabs of convalescent COVID-19: is prolonged quarantine always justified?** Int J Infect Dis 2020; Piralla A, Ricchi M, Cusi MG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130202>
61. **How useful is serology for COVID-19?** Int J Infect Dis 2020; Raoult D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33129960>
62. **Performance evaluation of five ELISA kits for detecting anti-SARS-COV-2 IgG antibodies.** Int J Infect Dis 2020; Yassine HM, Al-Jighefee H, Al-Sadeq DW *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33127504>
63. **SARS-CoV-2/Renin-Angiotensin System: Deciphering the Clues for a Couple with Potentially Harmful Effects on Skeletal Muscle.** Int J Mol Sci 2020; 21Gonzalez A, Orozco-Aguilar J, Achiardi O *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33114359>
64. **Renin-Angiotensin System: An Important Player in the Pathogenesis of Acute Respiratory Distress Syndrome.** Int J Mol Sci 2020; 21Hrenak J, Simko F.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33126657>
65. **Characterization of Myocardial Injury in Patients With COVID-19.** J Am Coll Cardiol 2020; 76:2043-2055Giustino G, Croft LB, Stefanini GG *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33121710>
66. **Troponin and Other Biomarker Levels and Outcomes Among Patients Hospitalized with COVID-19: Derivation and Validation of the HA(2)T(2) COVID-19 Mortality Risk Score.** J Am Heart Assoc 2020:e018477Manocha KK, Kirzner J, Ying X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121304>
67. **Detection of SARS-CoV-2 Antibodies in Kidney Transplant Recipients.** J Am Soc Nephrol 2020; Predecki M, Clarke C, Gleeson S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33122285>
68. **Development of a preoperative Early Warning Scoring System to identify highly suspect COVID-19 patients.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S62-s74Ali Z, Goneppanavar U, Dongare PA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100649>
69. **Circulating Levels of Interleukin-6 and Interleukin-10, But Not Tumor Necrosis Factor-Alpha, as Potential Biomarkers of Severity and Mortality for COVID-19: Systematic Review with Meta-analysis.** J. Clin. Immunol. 2020:1-

- 12Udomsinprasert W, Jittikoon J, Sangroongruangsri S, Chaikledkaew U.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33128665>
70. **Laboratory markers associated with COVID-19 progression in patients with or without comorbidity: A retrospective study.** *J. Clin. Lab. Anal.* 2020:e23644Chen Z, Zhang F, Hu W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33112011>
 71. **Expression of eosinophil in peripheral blood of patients with COVID-19 and its clinical significance.** *J. Clin. Lab. Anal.* 2020:e23620Mu T, Yi Z, Wang M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118666>
 72. **Mean platelet volume/platelet count ratio predicts severe pneumonia of COVID-19.** *J. Clin. Lab. Anal.* 2020:e23607Zhong Q, Peng J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128497>
 73. **Low Seroprevalence of SARS-CoV-2 Antibodies during Systematic Antibody Screening and Serum Responses in Patients after COVID-19 in a German Transplant Center.** *J Clin Med* 2020; 9Choi M, Bachmann F, Naik MG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114149>
 74. **Similar Clinical Course and Significance of Circulating Innate and Adaptive Immune Cell Counts in STEMI and COVID-19.** *J Clin Med* 2020; 9de Dios E, Rios-Navarro C, Perez-Sole N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126723>
 75. **Coagulation Parameters: An Efficient Measure for Predicting the Prognosis and Clinical Management of Patients with COVID-19.** *J Clin Med* 2020; 9Quintana-Díaz M, Andrés-Esteban EM, Ramírez-Cervantes KL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126706>
 76. **Covid-19-Associated Coagulopathy: Biomarkers of Thrombin Generation and Fibrinolysis Leading the Outcome.** *J Clin Med* 2020; 9Ranucci M, Sitzia C, Baryshnikova E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126772>
 77. **Estimation of Covid-19 prevalence from serology tests: A partial identification approach.** *J Econom* 2020; Toulis P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100477>
 78. **Neutralizing Antibody Responses in COVID-19 Convalescent Sera.** *J Infect Dis* 2020; Lee WT, Girardin RC, Dupuis li AP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104179>
 79. **Cytokine Response in SARS-CoV-2 Infection in the Elderly.** *J Inflamm Res* 2020; 13:737-747Sherwani S, Khan MWA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116752>
 80. **Unexpected high frequency of unspecific reactivities by testing pre-epidemic blood specimens from Europe and Africa with SARS-CoV-2 IgG-IgM antibody rapid tests points IgM as Achilles heel.** *J Med Virol* 2020; Bouassa RM, Péré H, Tonen-Wolyec S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107601>
 81. **Comparing two sample pooling strategies for SARS-CoV-2 RNA detection for efficient screening of COVID-19.** *J Med Virol* 2020; Chen F, Geng Z, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107614>
 82. **Comparison of VEGF-A Values between Pregnant Women with COVID-19 and Healthy Pregnancies and Its Association with Composite Adverse Outcomes.** *J Med Virol* 2020; Yazihan N, Tanacan A, Erol SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107604>
 83. **Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study.** *J Transl Med* 2020; 18:406Zhang J, Hao Y, Ou W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121497>

84. **Anti-SARS-CoV-2 IgG antibody response among Indian COVID-19 patients using β -propiolactone-inactivated, whole virus-based indirect ELISA.** J. Virol. Methods 2020; 287:113996Kulkarni R, Patil HP, Palkar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126149>
85. **End-point RT-PCR: a potential alternative for diagnosing coronavirus disease 2019 (COVID-19).** J. Virol. Methods 2020:114007Silva Júnior JVJ, Merchioratto I, de Oliveira PSB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130151>
86. **New-onset pustular psoriasis in the setting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing Coronavirus Disease 2019 (COVID-19).** JAAD Case Rep 2020; Mathieu RJ, Cobb CBC, Telang GH, Firoz EF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102669>
87. **Expanding Access to COVID-19 Tests through US Postal Service Facilities.** Med. Decis. Making 2020:272989x20969690Singh B, Risanger S, Morton D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33124494>
88. **Protein-driven mechanism of multiorgan damage in COVID-19.** Med Drug Discov 2020:100069Estrada E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103107>
89. **Mutations Observed in the SARS-CoV-2 Spike Glycoprotein and Their Effects in the Interaction of Virus with ACE-2 Receptor.** Medeni Med J 2020; 35:253-260Durmaz B, Abdulmajed O, Durmaz R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110678>
90. **IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19.** Mol. Med. 2020; 26:97Chen Y, Wang J, Liu C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121429>
91. **Biochemical parameters and pathogenesis of SARS-CoV-2 infection in vital organs: COVID-19 outbreak in Iran.** New Microbes New Infect 2020:100792Mirmohammadi S, Kianmehr A, Arefi M, Mahrooz A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101694>
92. **Epidemiological and Clinical Findings of Short-Term Recurrence of Severe Acute Respiratory Syndrome Coronavirus 2 Ribonucleic Acid Polymerase Chain Reaction Positivity in 1282 Discharged Coronavirus Disease 2019 Cases: A Multicenter, Retrospective, Observational Study.** Open Forum Infect Dis 2020; 7:ofaa432Chen SL, Xu H, Feng HY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123610>
93. **Upper Respiratory Tract Viral Ribonucleic Acid Load at Hospital Admission Is Associated With Coronavirus Disease 2019 Disease Severity.** Open Forum Infect Dis 2020; 7:ofaa282Guo X, Jie Y, Ye Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117856>
94. **Association of Early Nasopharyngeal Immune Markers With COVID-19 Clinical Outcome: Predictive Value of CCL2/MCP-1.** Open Forum Infect Dis 2020; 7:ofaa407Sierra B, Pérez AB, Aguirre E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123608>
95. **COVID-19 Patients: A Systematic Review and Meta-Analysis of Laboratory Findings, Comorbidities, and Clinical Outcomes Comparing Medical Staff versus the General Population.** Osong Public Health Res Perspect 2020; 11:269-279Ebrahimi M, Malehi AS, Rahim F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117631>
96. **2019 Tabletop Exercise for Laboratory Diagnosis and Analyses of Unknown Disease Outbreaks by the Korea Centers for Disease Control and Prevention.**

- Osong Public Health Res Perspect 2020; 11:280-285 Kim IH, Jang JH, Jo SK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33117632>
97. **The challenge of producing an EQA for the COVID-19 pandemic.** Pract Lab Med 2020; 22:e00179 Badrick T, Wienholt L, Fone D, Holzhauser D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33102672>
 98. **Lack of Serologic Evidence of Infection Among Health Care Personnel and Other Contacts of First 2 Confirmed Patients With COVID-19 in Illinois, 2020.** Public Health Rep. 2020:33354920966064 McPherson TD, Ghinai I, Binder AM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33108976>
 99. **Responding to COVID-19 in an Uninsured Hispanic/Latino Community: Testing, Education and Telehealth at a Free Clinic in Providence.** R I Med J (2013) 2020; 103:41-46 Barry K, McCarthy M, Melikian G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33126788>
 100. **Prediction of survival odds in COVID-19 by zinc, age and selenoprotein P as composite biomarker.** Redox Biol 2020; 38:101764 Heller RA, Sun Q, Hackler J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126054>
 101. **[CURB-65 as a predictor of 30-day mortality in patients hospitalized with COVID-19 in Ecuador: COVID-EC Study Abstract].** Rev Clin Esp 2020; Carriel J, Muñoz-Jaramillo R, Bolaños-Ladinez O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110273>
 102. **rRT-PCR Results of a Covid-19 Diagnosed Geriatric Patient.** SN Compr Clin Med 2020:1-4 Görgülü Ö, Duyan M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103060>
 103. **Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan.** Transfusion 2020; Kubota-Koketsu R, Terada Y, Yunoki M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104267>
 104. **Analytical insights of COVID-19 pandemic.** Trends Analyt. Chem. 2020:116072 Chellasamy G, Arumugasamy SK, Govindaraju S, Yun K.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100439>
 105. **Vascular injury in acute infections and COVID-19: everything old is new again.** Trends Cardiovasc. Med. 2020; Levy JH, Iba T, Connors JM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33129973>
 106. **Sewage surveillance system using urological wastewater: Key to COVID-19 monitoring?** Urol. Oncol. 2020; de Jong FC, GeurtsvanKessel CH, Molenkamp R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127302>
 107. **Lack of association between ABO blood groups and susceptibility to SARS-CoV-2 infection.** Vox Sang 2020; Levi JE, Telles PR, Scrivani H, Campana G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33103769>

Children (30 articles)

1. **Comparison of clinical characteristics of COVID-19 between elderly patients and young patients: a study based on a 28-day follow-up.** Aging (Albany NY) 2020; 12 Zhang L, Fan T, Yang S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106442>
2. **SARS-CoV-2 INFECTION IN AN INFANT WITH SEVERE DILATED CARDIOMYOPATHY.** Cardiol. Young 2020:1-9 Kristoffersen AW, Knudsen PK,

- Møller T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118485>
3. **Multisystem Inflammatory Syndrome in Children Temporally Related to COVID-19: A Case Report From Saudi Arabia.** Cureus 2020; 12:e10589Al Ameer HH, AlKadhem SM, Busaleh F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110725>
 4. **Child protection: When something gets stuck.** Deutsches Arzteblatt International 2020; 117:A1732-A1734.
 5. **Transmission of SARS-CoV-2 by children.** Deutsches Arzteblatt International 2020; 117:553-560Merckx J, Labrecque JA, Kaufman JS.
 6. **Thoughts on the future medical care pattern of paediatrics in China based on the outbreak of COVID-19.** Disaster Med Public Health Prep 2020:1-5Liu H, Wang L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100260>
 7. **Case report of an isolated myocarditis due to COVID-19 infection in a paediatric patient.** Eur Heart J Case Rep 2020; 4:1-5Fischer Q, Brillat-Savarin N, Ducrocq G, Ou P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117957>
 8. **Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium.** Eur. J. Cancer 2020; 141:82-91Rubio-San-Simón A, André N, Cefalo MG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129040>
 9. **An Asymptomatic SARS-CoV-2-Infected Infant With Persistent Fecal Viral RNA Shedding in a Family Cluster: A Rare Case Report.** Front Med (Lausanne) 2020; 7:562875Chen S, Si J, Tang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102500>
 10. **A Suggested Approach for Management of Pediatric Asthma During the COVID-19 Pandemic.** Front Pediatr 2020; 8:563093Ding B, Lu Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102407>
 11. **Study Protocol for the COVID-19 Pandemic Adjustment Survey (CPAS): A Longitudinal Study of Australian Parents of a Child 0-18 Years.** Front Psychiatry 2020; 11:555750Westrupp EM, Karantzas G, Macdonald JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110413>
 12. **Parents and Children During the COVID-19 Lockdown: The Influence of Parenting Distress and Parenting Self-Efficacy on Children's Emotional Well-Being.** Front. Psychol. 2020; 11:584645Morelli M, Cattelino E, Baiocco R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123063>
 13. **Assessment of the Anxiety Level of Andalusian Podiatrists during the COVID-19 Pandemic: The Increase Phase.** Healthcare (Basel) 2020; 8Vilar-Palomo S, Pabón-Carrasco M, Gonzalez-Elena ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114550>
 14. **The Protective Roles of Exercise and Maintenance of Daily Living Routines for Chinese Adolescents During the COVID-19 Quarantine Period.** J. Adolesc. Health 2020; Ren H, He X, Bian X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121902>
 15. **What a pediatric anesthesiologist should know about COVID-19.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S85-s91Jain A, Bhardwaj N, Yaddanapudi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100654>
 16. **Recovery from COVID-19 in a Child with Chronic Granulomatous Disease and T Cell Lymphopenia.** J. Clin. Immunol. 2020:1-3Mantravadi V, Nguyen ST, Morley SC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33108551>

17. **Pediatric Inflammatory Multisystem Syndrome (PIMS) Did Occur in Poland during Months with Low COVID-19 Prevalence, Preliminary Results of a Nationwide Register.** J Clin Med 2020; 9Okarska-Napierała M, Ludwikowska KM, Szenborn L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33105634>
18. **From Pandemic to Progression: An Educational Framework for the Implementation of Virtual Mental Healthcare for Children and Youth as a Response to COVID-19.** J Contemp Psychother 2020;1-7Doan BT, Yang YB, Romanchych E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110276>
19. **COVID-19 infection prevalence in pediatric population: Etiology, clinical presentation, and outcome.** J Infect Public Health 2020; Alsohime F, Temsah MH, Al-Nemri AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127335>
20. **Disparities and ethical considerations for children with tracheostomies during the COVID-19 pandemic.** J. Pediatr. Rehabil. Med. 2020; Kana LA, Shuman AG, Helman J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104051>
21. **Video visits and access to care in pediatric rehabilitation therapies in the time of a pandemic.** J. Pediatr. Rehabil. Med. 2020; Nulle J, Nelson VS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104052>
22. **Telemedicine for pediatric physiatry: How social distancing can bring physicians and families closer together.** J. Pediatr. Rehabil. Med. 2020; Sukhov R, Asante A, Ilizarov G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104050>
23. **Coronavirus-2019 Disease (COVID-19) in Children.** Medeni Med J 2020; 35:242-252Ovali F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110677>
24. **Lung Ultrasound in Children with Respiratory Tract Infections: Viral, Bacterial or COVID-19? A Narrative Review.** Open Access Emerg. Med. 2020; 12:275-285Kharasch S, Duggan NM, Cohen AR, Shokoohi H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116963>
25. **Is there a role for childhood vaccination against COVID-19?** Pediatr. Allergy Immunol. 2020; Eberhardt CS, Siegrist CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113210>
26. **Telemedicine in pediatric rheumatology: this is the time for the community to embrace a new way of clinical practice.** Pediatr. Rheumatol. Online J. 2020; 18:85Shenoi S, Hayward K, Curran ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129319>
27. **Correlates of children's physical activity during the COVID-19 confinement in Portugal.** Public Health 2020; 189:14-19Pombo A, Luz C, Rodrigues LP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126117>
28. **Child Protection: A Guide for Navigating a Disclosure of Sexual Abuse in Rhode Island Amid the COVID-19 Pandemic.** R I Med J (2013) 2020; 103:47-51Manickam S, Slingsby B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126789>
29. **Reduced Number of Pediatric Orthopedic Trauma Requiring Operative Treatment during COVID-19 Restrictions: A Nationwide Cohort Study.** Scand. J. Surg. 2020;1457496920968014Raitio A, Ahonen M, Jääskelä M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100133>
30. **Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2: a New Challenge amid the Pandemic.** SN Compr Clin Med 2020;1-9Lawrensia S, Henrina J, Wijaya E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106783>

Clinical Features (37 articles)

1. **Loss of smell in COVID-19 patients: a critical review with emphasis on the use of olfactory tests.** Acta Otorhinolaryngol. Ital. 2020; 40:241-247 Marchese-Ragona R, Restivo DA, De Corso E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100334>
2. **Comparison of clinical characteristics of COVID-19 between elderly patients and young patients: a study based on a 28-day follow-up.** Aging (Albany NY). 2020; 12Zhang L, Fan T, Yang S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106442>
3. **Translation and validation of the short version of the Questionnaire of Olfactory Disorders-Negative Statements to Spanish.** Am. J. Otolaryngol. 2020; 42:102775 Chiesa-Estomba CM, Lechien JR, Calvo-Henríquez C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125905>
4. **Rheumatic manifestations of COVID-19: a systematic review and meta-analysis.** BMC Rheumatol 2020; 4:65 Ciaffi J, Meliconi R, Ruscitti P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123675>
5. **Hospitalised COVID-19 patients of the Mount Sinai Health System: a retrospective observational study using the electronic medical records.** BMJ Open 2020; 10:e040441 Wang Z, Zheutlin A, Kao YH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109676>
6. **Temporal and spatial concomitance of exanthema and dysesthesia in a patient with SARS-Cov-2 infection.** Brain Behav Immun Health 2020; 9:100165 Denes E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111131>
7. **COVID-19 Status, Symptom Burden, and Characteristics of Dialysis Patients Residing in Areas of Community Transmission: Research Letter.** Can J Kidney Health Dis 2020; 7:2054358120964178 Gale J, Clark DA, Bohm C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117550>
8. **Fractional Order Model for the Role of Mild Cases in the Transmission of COVID-19.** Chaos Solitons Fractals 2020:110374 Baba IA, Nasidi BA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100604>
9. **Three Quarters of People with SARS-CoV-2 Infection are Asymptomatic: Analysis of English Household Survey Data.** Clin. Epidemiol. 2020; 12:1039-1043 Petersen I, Phillips A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116898>
10. **Isolated maculopapular eruption localized to head and neck: A cutaneous sign of COVID-19 infection.** Dermatol Ther 2020; Farabi B, Atak MF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33112023>
11. **The Manifestation of Oral Mucositis in COVID-19 Patients: A case-series.** Dermatol Ther 2020:e14479 Riad A, Kassem I, Badrah M, Klugar AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125803>
12. **Analysis of clinical features and pulmonary CT features of coronavirus disease 2019 (COVID-19) patients with diabetes mellitus.** Endokrynol. Pol. 2020; 71:367-375 Yan Y, Yang F, Zhu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125688>
13. **As Plain as the Nose on Your Face: The Case for A Nasal (Mucosal) Route of Vaccine Administration for Covid-19 Disease Prevention.** Front. Immunol. 2020; 11:591897 Travis CR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117404>
14. **Prognostic Factors for COVID-19 Pneumonia Progression to Severe Symptoms Based on Earlier Clinical Features: A Retrospective Analysis.** Front Med (Lausanne) 2020; 7:557453 Huang H, Cai S, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123541>

15. **Clinical manifestations and factors associated with mortality from COVID-19 in older adults: Retrospective population-based study with 9807 older Brazilian COVID-19 patients.** Geriatr Gerontol Int 2020; de Souza CD, de Arruda Magalhães AJ, Lima AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111433>
16. **Frequency of COVID-19 Symptoms in Healthcare Workers in a Large Health System.** Infect Control Hosp Epidemiol 2020;1-6Malenfant JH, Newhouse CN, Kuo AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100258>
17. **Clinical characteristics and progression of COVID-19 confirmed cases admitted to a single British clinical centre-a brief case series report.** Int J Clin Pract 2020:e13807Conway J, Gould A, Westley R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128856>
18. **Epidemiologic and Clinical Characteristics of COVID-19 Patients from a Quarantine Center in a Developing Community: A Retrospective Study.** Int. J. Gen. Med. 2020; 13:937-944Khraise WN, Khraise TW, Starling Emerald B, Allouh MZ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116785>
19. **The characteristics and clinical course of patients with COVID-19 who received invasive mechanical ventilation in Osaka, Japan.** Int J Infect Dis 2020; Hirayama A, Masui J, Murayama A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127502>
20. **Renin-Angiotensin System: An Important Player in the Pathogenesis of Acute Respiratory Distress Syndrome.** Int J Mol Sci 2020; 21Hrenak J, Simko F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126657>
21. **Anterior Acute Uveitis Report in a SARS-CoV-2 Patient Managed with Adjunctive Topical Antiseptic Prophylaxis Preventing 2019-nCoV Spread Through the Ocular Surface Route.** Int Med Case Rep J 2020; 13:513-520Mazzotta C, Giancipoli E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116943>
22. **"The Importance of Considering Olfactory Dysfunction During the COVID-19 Pandemic and in Clinical Practice".** J Allergy Clin Immunol Pract 2020; Desai M, Oppenheimer J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130145>
23. **Respiratory and cardiovascular effects of COVID-19 infection and their management.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S21-s28Kapoor MC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100642>
24. **Clinical data of early COVID-19 cases receiving extracorporeal membrane oxygenation in Wuhan, China.** J. Clin. Anesth. 2020; 68:110044Huang S, Xia H, Wu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130357>
25. **COVID-19 in patients with cutaneous immune-mediated diseases in The Netherlands: real-world observational data.** J Eur Acad Dermatol Venereol 2020; de Wijs LEM, Joustra MM, Olydam JI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33131098>
26. **SARS-CoV-2 re-infection: a case report from Qatar.** J Infect 2020; AlFehaidi A, Ahmad SA, Hamed E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115660>
27. **Critically ill patients with COVID-19 in Tokyo, Japan: A single-center case series.** J Infect Chemother 2020; Miike S, Sakamoto N, Washino T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121864>
28. **Trend of Olfactory and Gustatory Dysfunction in COVID-19 Patients in a Quarantine Facility.** J Korean Med Sci 2020; 35:e375Seo MY, Seok H, Hwang SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107232>
29. **Can SARS-CoV-2 trigger reactive arthritis?** Joint Bone Spine 2020;105086Wendling D, Verhoeven F, Chouk M, Prati C.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127461>
30. **Alteration, Reduction and Taste Loss: Main Causes and Potential Implications on Dietary Habits.** *Nutrients* 2020; 12:Risso D, Drayna D, Morini G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120898>
 31. **Epidemiological and Clinical Findings of Short-Term Recurrence of Severe Acute Respiratory Syndrome Coronavirus 2 Ribonucleic Acid Polymerase Chain Reaction Positivity in 1282 Discharged Coronavirus Disease 2019 Cases: A Multicenter, Retrospective, Observational Study.** *Open Forum Infect Dis* 2020; 7:ofaa432Chen SL, Xu H, Feng HY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123610>
 32. **Symptoms of COVID-19 Outpatients in the United States.** *Open Forum Infect Dis* 2020; 7:ofaa271Pullen MF, Skipper CP, Hullsiek KH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117855>
 33. **COVID-19 Patients: A Systematic Review and Meta-Analysis of Laboratory Findings, Comorbidities, and Clinical Outcomes Comparing Medical Staff versus the General Population.** *Osong Public Health Res Perspect* 2020; 11:269-279Ebrahimi M, Malehi AS, Rahim F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117631>
 34. **Non-invasive hemodynamic profile of early COVID-19 infection.** *Physiol Rep* 2020; 8:e14628Busana M, Schiavone M, Lanfranchi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113285>
 35. **Hospital admission rates, length of stay, and in-hospital mortality for common acute care conditions in COVID-19 vs. pre-COVID-19 era.** *Public Health* 2020; 189:6-11Butt AA, Kartha AB, Masoodi NA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126120>
 36. **Prediction of survival odds in COVID-19 by zinc, age and selenoprotein P as composite biomarker.** *Redox Biol* 2020; 38:101764Heller RA, Sun Q, Hackler J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126054>
 37. **Characteristics and evaluation of the effectiveness of monitoring and control measures for the first 69 Patients with COVID-19 from 18 January 2020 to 2 March in Wuxi, China.** *Sustain Cities Soc* 2021; 64:102559Shi P, Gao Y, Shen Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101882>

CNS (22 articles)

1. **Loss of smell in COVID-19 patients: a critical review with emphasis on the use of olfactory tests.** *Acta Otorhinolaryngol. Ital.* 2020; 40:241-247Marchese-Ragona R, Restivo DA, De Corso E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100334>
2. **Translation and validation of the short version of the Questionnaire of Olfactory Disorders-Negative Statements to Spanish.** *Am. J. Otolaryngol.* 2020; 42:102775Chiesa-Estomba CM, Lechien JR, Calvo-Henríquez C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125905>
3. **A Rare Axonal Variant of Guillain-Barré Syndrome as a Neurological Complication of COVID-19 Infection.** *Arch Iran Med* 2020; 23:718-721Agha Abbaslou M, Karbasi M, Mozhdehipanah H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107316>
4. **Cognitive profile following COVID-19 infection: Clinical predictors leading to neuropsychological impairment.** *Brain Behav Immun Health* 2020;

- 9:100163Almeria M, Cejudo JC, Sotoca J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33111132>
5. **SARS-CoV-2 Infects the Brain Choroid Plexus and Disrupts the Blood-CSF Barrier in Human Brain Organoids.** Cell Stem Cell 2020; Pellegrini L, Albecka A, Mallery DL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113348>
 6. **COVID-19-Associated Neurological Disorders: The Potential Route of CNS Invasion and Blood-Brain Relevance.** Cells 2020; 9Achar A, Ghosh C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33120941>
 7. **COVID-19: Participation of neuroglia could explain common neurological symptoms.** Deutsches Arzteblatt International 2020; 117:A1988Meyer R.
 8. **Postinfectious Onset of Myasthenia Gravis in a COVID-19 Patient.** Front. Neurol. 2020; 11:576153Huber M, Rogozinski S, Puppe W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33123081>
 9. **SAMHD1 as the Potential Link Between SARS-CoV-2 Infection and Neurological Complications.** Front. Neurol. 2020; 11:562913Khan A, Sergi C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101175>
 10. **Making the Case for Centralized Dementia Care Through Adaptive Reuse in the Time of COVID-19.** Inquiry 2020; 57:46958020969305Roberts E, Carter HC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33124477>
 11. **Asymptomatic hypoxia in COVID-19 is associated with poor outcome.** Int J Infect Dis 2020; Brouqui P, Amrane S, Million M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33130200>
 12. **Cerebrospinal fluid findings in neurological diseases associated with COVID-19 and insights into mechanisms of disease development.** Int J Infect Dis 2020; Espindola OM, Brandão CO, Gomes YCP *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33127503>
 13. **"The Importance of Considering Olfactory Dysfunction During the COVID-19 Pandemic and in Clinical Practice".** J Allergy Clin Immunol Pract 2020; Desai M, Oppenheimer J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130145>
 14. **A Comprehensive Review of Neurologic Manifestations of COVID-19 and Management of Pre-existing Neurologic Disorders in Children.** J. Child Neurol. 2020:883073820968995Kim Y, Walser SA, Asghar SJ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33112694>
 15. **Trend of Olfactory and Gustatory Dysfunction in COVID-19 Patients in a Quarantine Facility.** J Korean Med Sci 2020; 35:e375Seo MY, Seok H, Hwang SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107232>
 16. **Neurological manifestations of patients infected with the SARS-CoV-2: a systematic review of the literature.** J. Neurol. 2020:1-10Cagnazzo F, Arquizan C, Derraz I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125542>
 17. **Encephalopathy associated with COVID-19 in a patient with multiple sclerosis.** J. Neurovirol. 2020; Naser Moghadasi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118141>
 18. **Guillain-Barré syndrome associated with SARS-CoV-2 infection: a systematic review and individual participant data meta-analysis.** J. Peripher. Nerv. Syst. 2020; Hasan I, Saif-Ur-Rahman KM, Hayat S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33112450>
 19. **Brainstem Dysfunction in SARS-COV-2 Infection can be a Potential Cause of Respiratory Distress.** Neurol. India 2020; 68:989-993Machado C, DeFina PA, Chinchilla M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109839>

20. **Acute Demyelinating Encephalomyelitis (ADEM) in COVID-19 Infection: A Case Series.** Neurol. India 2020; 68:1192-1195 McCuddy M, Kelkar P, Zhao Y, Wicklund D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109874>
21. **Systematic review of EEG findings in 617 patients diagnosed with COVID-19.** Seizure 2020; Antony AR, Haneef Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121875>
22. **COVID-19-Induced Neurovascular Injury: a Case Series with Emphasis on Pathophysiological Mechanisms.** SN Compr Clin Med 2020;1-17 Gutierrez Amezcua JM, Jain R, Kleinman G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106782>

Coagulation (21 articles)

1. **Aminotransferases disorders associated with venous thromboembolic events in patients infected with COVID-19.** Ann. Hepatol. 2020; Hamadé A, Woehl B, Talbot M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130333>
2. **Unfractionated heparin inhibits live wild-type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations.** Br. J. Pharmacol. 2020; Tree JA, Turnbull JE, Buttigieg KR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125711>
3. **COVID-19 - Endothelial Axis and Coronary Artery Bypass Graft Patency: a Target for Therapeutic Intervention?** Braz J Cardiovasc Surg 2020; 35:757-763 Topal G, Loesch A, Dashwood MR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118741>
4. **Evidence for increased circulating procoagulant phospholipids in patients with COVID-19 pneumonia and their prognostic role.** Clin Chem Lab Med 2020; Assimakopoulos SF, Emmanuil A, Tsimeka A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33112778>
5. **To Anticoagulate or Not: Acute Stroke in a COVID-19 Patient With Gastrointestinal Bleed.** Cureus 2020; 12:e10554 George J, Kirkland Z, Lattanzio N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101801>
6. **Central Nervous System Manifestations Associated with COVID-19.** Curr. Neurol. Neurosci. Rep. 2020; 20:60 Divani AA, Andalib S, Biller J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128130>
7. **COVID-19 mortality: Full heparinization.** Deutsches Arzteblatt International 2020; 117:A1873 Kiesewetter H.
8. **Unfractionated Heparin in SARS-CoV-2 Pneumonia: Ischemic Stroke Case Report.** Front. Neurol. 2020; 11:573356 Efendizade A, Dmytriw AA, Hewitt K, Davies GA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101181>
9. **Thrombosis and COVID-19: The Potential Role of Nutrition.** Front Nutr 2020; 7:583080 Tsoupras A, Lordan R, Zabetakis I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102511>
10. **ACE2, COVID-19 Infection, Inflammation, and Coagulopathy: Missing Pieces in the Puzzle.** Front. Physiol. 2020; 11:574753 Abassi Z, Higazi AAR, Kinaneh S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123031>
11. **Central retinal vein occlusion with COVID-19 infection as the presumptive etiology.** Indian J Ophthalmol 2020; 68:2572-2574 Walinjar JA, Makhija SC, Sharma HR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120696>

12. **Superior Mesenteric Artery Thrombosis in COVID-19 Pneumonia: an Underestimated Diagnosis-First Case Report in Asia.** Indian J Surg 2020;1-3Karna ST, Panda R, Maurya AP, Kumari S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100738>
13. **Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19.** J Am Coll Cardiol 2020; 76:2060-2072Piazza G, Campia U, Hurwitz S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121712>
14. **Stroke and Thromboprophylaxis in the Era of COVID-19.** J. Stroke Cerebrovasc. Dis. 2020; 30:105392Ma A, Kase CS, Shoamanesh A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130478>
15. **Is there a role for the ACE2 receptor in SARS-CoV-2 interactions with platelets?** J Thromb Haemost 2020; Campbell RA, Boilard E, Rondina MT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119197>
16. **Acute Aortoiliac and Infrainguinal Arterial Thrombotic Events in Four Patients Diagnosed with the Novel Coronavirus 2019 (COVID-19).** J Vasc Surg Cases Innov Tech 2020; Wengerter SP, Wengerter KR, Masoudpoor H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102991>
17. **Bilateral pulmonary artery thrombectomy with saddle embolism and COVID-19 infection.** Proc. (Bayl. Univ. Med. Cent.) 2020; 33:666-667Vyas V, Kanagalingam G, Yadava S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100564>
18. **Coagulopathy of Patients with COVID-19 is Associated with Infectious and Inflammatory Markers.** Risk Manag. Healthc. Policy 2020; 13:1965-1975Long X, Zhang Z, Zou W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116977>
19. **Life-threatening COVID-19 presenting as stroke with antiphospholipid antibodies and low ADAMTS-13 activity, and the role of therapeutic plasma exchange: A case series.** SAGE Open Med Case Rep 2020; 8:2050313x20964089Alharthy A, Faqihi F, Balhamar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101686>
20. **Frequently Asked Questions about Thrombosis during COVID-19 Pandemic.** TH Open 2020; 4:e303-e304Golemi L, Hanson P, Tafur A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103049>
21. **"But all are pungent and flatulent...". Historical sidelight on garlic, onions and nasturtiums in the era of SARS-CoV-2 and Covid-19.** Zeitschrift fur Phytotherapie 2020; 41:165-169Niedenthal T.

Complications (89 articles)

1. **A single-centre, prospective cohort study of COVID-19 patients admitted to ICU for mechanical ventilatory support.** Acta Anaesthesiol. Scand. 2020; Søvik S, Bådstøløkken PM, Sørensen V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128800>
2. **The Risk and Impact of COVID-19 Pandemic on Immunosuppressed Patients: Cancer, HIV, and Solid Organ Transplant Recipients.** AIDS Rev. 2020; 22:151-157Mohammed AH, Blebil A, Dujaili J, Rasool-Hassan BA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118527>
3. **Case Fatality Rates for COVID-19 Patients Requiring Invasive Mechanical Ventilation: A Meta-analysis.** Am J Respir Crit Care Med 2020; Lim ZJ, Subramaniam A, Reddy MP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119402>

4. **Covid 19 and its cardiovascular effects.** Ann. Card. Anaesth. 2020; 23:401-408 Rastogi A, Tewari P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109794>
5. **A Rare Axonal Variant of Guillain-Barré Syndrome as a Neurological Complication of COVID-19 Infection.** Arch Iran Med 2020; 23:718-721 Agha Abbaslou M, Karbasi M, Mozhdehipanah H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107316>
6. **Hospitalised COVID-19 patients of the Mount Sinai Health System: a retrospective observational study using the electronic medical records.** BMJ Open 2020; 10:e040441 Wang Z, Zheutlin A, Kao YH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109676>
7. **COVID-19: a potential driver of immune-mediated breast cancer recurrence?** Breast Cancer Res. 2020; 22:117 Francescangeli F, De Angelis ML, Zeuner A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126915>
8. **SARS-CoV-2 INFECTION IN AN INFANT WITH SEVERE DILATED CARDIOMYOPATHY.** Cardiol. Young 2020;1-9 Kristoffersen AW, Knudsen PK, Møller T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118485>
9. **Journal Club-Severe Acute Respiratory Syndrome Coronavirus-2: Impact on COPD Patients.** Chronic Obstr Pulm Dis 2020; 7:413-419 Balkissoon R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33108113>
10. **Evidence for increased circulating procoagulant phospholipids in patients with COVID-19 pneumonia and their prognostic role.** Clin Chem Lab Med 2020; Assimakopoulos SF, Emmanuil A, Tsimeka A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33112778>
11. **The relationship between severe or dead COVID-19 and asthma: a meta-analysis.** Clin. Exp. Allergy 2020; Wang Y, Ao G, Qi X, Ma M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33131117>
12. **Chest high-resolution computed tomography is associated to short-time progression to severe disease in patients with COVID-19 pneumonia.** Clin Imaging 2020; 70:61-66 Cereser L, Da Re J, Zuiani C, Girometti R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125986>
13. **Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19.** Clin Infect Dis 2020; Malsy J, Veletzky L, Heide J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103195>
14. **Complement and protection from tissue injury in COVID-19.** Clin Kidney J 2020; 13:734-738 Ortiz A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123353>
15. **Association of bioelectric impedance analysis body composition and disease severity in COVID-19 hospital ward and ICU patients: The BIAC-19 study.** Clin. Nutr. 2020; Moonen H, van Zanten FJL, Driessen L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129597>
16. **To Anticoagulate or Not: Acute Stroke in a COVID-19 Patient With Gastrointestinal Bleed.** Cureus 2020; 12:e10554 George J, Kirkland Z, Lattanzio N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101801>
17. **Subcutaneous Emphysema in Patients With COVID-19 Infection: A Report of Three Cases.** Cureus 2020; 12:e10559 Toquica Gahona CC, Raj K, Bhandari K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101806>
18. **Cutaneous lymphomas and COVID-19: What is known so far?** Dermatol Ther 2020; Elmasry MF, Youssef R, Elbendary A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33112053>

19. **Pustular psoriasis exacerbated by COVID-19 in a patient with the history of psoriasis.** Dermatol Ther 2020; Shakoei S, Ghanadan A, Hamzelou S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33112048>
20. **Visual loss following assisted mechanical ventilation due to SARS-CoV-2 - A case series.** Deutsches Arzteblatt International 2020; 117:561-562 Reich M, Pauleikhoff L, Schröter N *et al.*
21. **Acute respiratory syndrome in COVID-19: Autopsies show some pathophysiological differences to influenza.** Deutsches Arzteblatt International 2020; 117:A1746 Siegmund-Schultze N.
22. **Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes.** Diabetes Metab. 2020; Sathish T, Tapp RJ, Cooper ME, Zimmet P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33129968>
23. **Short term follow-up of patients presenting with acute onset diabetes and diabetic ketoacidosis during an episode of COVID-19.** Diabetes Metab Syndr 2020; 14:2039-2041 Kuchay MS, Reddy PK, Gagneja S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33113470>
24. **Delayed acute myocarditis and COVID-19-related multisystem inflammatory syndrome.** ESC Heart Fail 2020; Nicol M, Cacoub L, Baudet M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33107217>
25. **ST-elevation myocardial infarction in a young patient with anomalous right coronary artery and COVID-19 pneumonia.** Eur Heart J Case Rep 2020; 4:1-2 Garg A, Hakeem H, Divita M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117958>
26. **Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders.** Eur. J. Neurol. 2020; Louapre C, Maillart E, Papeix C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103295>
27. **Conscious prone positioning during non-invasive ventilation in COVID-19 patients: experience from a single centre.** F1000Res 2020; 9:859 Burton-Papp HC, Jackson AIR, Beecham R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110499>
28. **Euthyroid Sick Syndrome in Patients With COVID-19.** Front. Endocrinol. (Lausanne) 2020; 11:566439 Zou R, Wu C, Zhang S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33117282>
29. **Short-Term Outcomes of Patients With COVID-19 Undergoing Invasive Mechanical Ventilation: A Retrospective Observational Study From Wuhan, China.** Front Med (Lausanne) 2020; 7:571542 Zhao S, Lin Y, Zhou C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33117833>
30. **Unfractionated Heparin in SARS-CoV-2 Pneumonia: Ischemic Stroke Case Report.** Front. Neurol. 2020; 11:573356 Efendizade A, Dmytriw AA, Hewitt K, Davies GA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101181>
31. **Postinfectious Onset of Myasthenia Gravis in a COVID-19 Patient.** Front. Neurol. 2020; 11:576153 Huber M, Rogozinski S, Puppe W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33123081>
32. **ACE2, COVID-19 Infection, Inflammation, and Coagulopathy: Missing Pieces in the Puzzle.** Front. Physiol. 2020; 11:574753 Abassi Z, Higazi AAR, Kinaneh S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33123031>
33. **Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: results of the ACE-CoV study.** Fundam. Clin. Pharmacol. 2020; Lafaurie M,

- Martin-Blondel G, Delobel P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111329>
34. **Superior Mesenteric Artery Thrombosis in COVID-19 Pneumonia: an Underestimated Diagnosis-First Case Report in Asia.** *Indian J Surg* 2020;1-3 Karna ST, Panda R, Maurya AP, Kumari S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100738>
 35. **Predictors of Severity and Co-Infection Resistance Profile in COVID-19 Patients: First Report from Upper Egypt.** *Infect Drug Resist* 2020; 13:3409-3422 Ramadan HK, Mahmoud MA, Aburahma MZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116660>
 36. **Clinical characteristics and progression of COVID-19 confirmed cases admitted to a single British clinical centre-a brief case series report.** *Int J Clin Pract* 2020:e13807 Conway J, Gould A, Westley R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128856>
 37. **Asymptomatic hypoxia in COVID-19 is associated with poor outcome.** *Int J Infect Dis* 2020; Brouqui P, Amrane S, Million M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130200>
 38. **SARS-CoV-2/Renin-Angiotensin System: Deciphering the Clues for a Couple with Potentially Harmful Effects on Skeletal Muscle.** *Int J Mol Sci* 2020; 21 Gonzalez A, Orozco-Aguilar J, Achiardi O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114359>
 39. **Renin-Angiotensin System: An Important Player in the Pathogenesis of Acute Respiratory Distress Syndrome.** *Int J Mol Sci* 2020; 21 Hrenak J, Simko F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126657>
 40. **Intensive Care Unit-Acquired Weakness: Not just Another Muscle Atrophying Condition.** *Int J Mol Sci* 2020; 21 Lad H, Saumur TM, Herridge MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33105809>
 41. **Beyond the mask: a multidisciplinary reflection on palliating patients with COVID-19 receiving continuous positive airway pressure ventilation.** *Int. J. Palliat. Nurs.* 2020; 26:336-340 Hough A, Dell GD, Blaber M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33108921>
 42. **Clinical outcomes of dialysis patients with COVID-19 in the initial phase of the COVID-19 outbreak in Wuhan, China.** *Int. Urol. Nephrol.* 2020; Zeng X, Huang X, Xu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123844>
 43. **An unexplained death after routine cardiac surgery: how long have we dealt with coronavirus disease 2019?** *Interact. Cardiovasc. Thorac. Surg.* 2020; Varela Barca L, Torralba Cloquell I, Herrero Cereceda J, Sáez de Ibarra JI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130891>
 44. **Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: a Biobadaderm cohort analysis.** *J Am Acad Dermatol* 2020; Baniandr s-Rodr guez O, Vilar-Alejo J, Rivera R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33122022>
 45. **Intensive care management of patients with COVID-19.** *J. Anaesthesiol. Clin. Pharmacol.* 2020; 36:S29-s38 Trikha A, Singh AK, Khanna P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100643>
 46. **Management of a COVID-19 Patient during ECMO: Paying Attention to Acquired von Willebrand Syndrome.** *J Atheroscler Thromb* 2020; Hayakawa M, Takano K, Kayashima M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116032>

47. **ECMO therapy in COVID-19: The Zurich experience.** J. Card. Surg. 2020;
Sromicki J, Schmiady M, Maisano F, Mestres CA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33124076>
48. **Clinical data of early COVID-19 cases receiving extracorporeal membrane oxygenation in Wuhan, China.** J. Clin. Anesth. 2020; 68:110044Huang S, Xia H, Wu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130357>
49. **Recovery from COVID-19 in a Child with Chronic Granulomatous Disease and T Cell Lymphopenia.** J. Clin. Immunol. 2020:1-3Mantravadi V, Nguyen ST, Morley SC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33108551>
50. **Circulating Levels of Interleukin-6 and Interleukin-10, But Not Tumor Necrosis Factor-Alpha, as Potential Biomarkers of Severity and Mortality for COVID-19: Systematic Review with Meta-analysis.** J. Clin. Immunol. 2020:1-12Udomsinprasert W, Jittikoon J, Sangroongruangsri S, Chaikledkaew U.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33128665>
51. **Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection.** J. Clin. Invest. 2020; Files JK, Boppana S, Perez MD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119547>
52. **Pediatric Inflammatory Multisystem Syndrome (PIMS) Did Occur in Poland during Months with Low COVID-19 Prevalence, Preliminary Results of a Nationwide Register.** J Clin Med 2020; 9Okarska-Napierała M, Ludwikowska KM, Szenborn L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33105634>
53. **Coagulation Parameters: An Efficient Measure for Predicting the Prognosis and Clinical Management of Patients with COVID-19.** J Clin Med 2020; 9Quintana-Díaz M, Andrés-Esteban EM, Ramírez-Cervantes KL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126706>
54. **Knowledge, Attitude, and Practice Towards COVID-19 Among People Living with HIV/AIDS in Kigali, Rwanda.** J. Community Health 2020:1-6Iradukunda PG, Pierre G, Muhozi V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106963>
55. **It's X-Related: Biological Bases of Increased COVID-19 Morbidity and Mortality in Men.** J Endocr Soc 2020; 4:bvaa133Angelides PK, Jindal I, Karaviti L, Geffner ME. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117953>
56. **Derivation and Internal Validation of a Model to Predict the Probability of Severe Acute Respiratory Syndrome Coronavirus-2 Infection in Community People.** J Gen Intern Med 2020:1-8van Walraven C, Manuel DG, Desjardins M, Forster AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107007>
57. **The COVID-19 Own Risk Appraisal Scale (CORAS): Development and validation in two samples from the United Kingdom.** J Health Psychol 2020:1359105320967429Jaspal R, Fino E, Breakwell GM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33111594>
58. **Critically ill patients with COVID-19 in Tokyo, Japan: A single-center case series.** J Infect Chemother 2020; Miike S, Sakamoto N, Washino T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121864>
59. **Evidence-Based Management of the Critically Ill Adult With SARS-CoV-2 Infection.** J. Intensive Care Med. 2020:885066620969132Chivukula RR, Maley JH, Dudzinski DM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111601>
60. **Corticosteroids for COVID-19 patients requiring oxygen support? Yes, but not for everyone: Effect of corticosteroids on mortality and Intensive Care Unit admission in patients with COVID-19 according to patients' oxygen**

- requirements.** J Med Virol 2020; Tortajada C, Colomer E, Andreu-Ballester JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107607>
61. **Discharge may not be the end of treatment: pay attention to pulmonary fibrosis caused by severe COVID-19.** J Med Virol 2020; Zhang C, Wu Z, Li JW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107641>
 62. **Renal infarction in COVID-19 patient.** J Nephrol 2020; Ammous A, Ghaffar MA, El-Charabaty E, El-Sayegh S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119839>
 63. **Encephalopathy associated with COVID-19 in a patient with multiple sclerosis.** J. Neuroviro. 2020; Naser Moghadasi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118141>
 64. **Disparities and ethical considerations for children with tracheostomies during the COVID-19 pandemic.** J. Pediatr. Rehabil. Med. 2020; Kana LA, Shuman AG, Helman J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104051>
 65. **Is there a role for the ACE2 receptor in SARS-CoV-2 interactions with platelets?** J Thromb Haemost 2020; Campbell RA, Boilard E, Rondina MT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119197>
 66. **New-onset pustular psoriasis in the setting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing Coronavirus Disease 2019 (COVID-19).** JAAD Case Rep 2020; Mathieu RJ, Cobb CBC, Telang GH, Firoz EF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102669>
 67. **Can SARS-CoV-2 trigger reactive arthritis?** Joint Bone Spine 2020;105086Wendling D, Verhoeven F, Chouk M, Prati C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127461>
 68. **The first cancer patient with COVID-19 in Slovakia.** Klin Onkol 2020; 33:386-389Ján S, Tomáš Š, Natália P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33108884>
 69. **Protein-driven mechanism of multiorgan damage in COVID-19.** Med Drug Discov 2020:100069Estrada E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103107>
 70. **[Clinical analysis of early damage in multiple extra-pulmonary organs in COVID-19].** Nan Fang Yi Ke Da Xue Xue Bao 2020; 40:1518-1524Fan J, Zhang Y, Pan Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118517>
 71. **COVID-19 and Acute Kidney Injury.** Nephrol. Nurs. J. 2020; 47:481-482Robbins KC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107721>
 72. **Biochemical parameters and pathogenesis of SARS-CoV-2 infection in vital organs: COVID-19 outbreak in Iran.** New Microbes New Infect 2020:100792Mirmohammadi S, Kianmehr A, Arefi M, Mahrooz A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101694>
 73. **SARS-CoV-2 infection in a patient with propionic acidemia.** Orphanet J. Rare Dis. 2020; 15:306Caciotti A, Procopio E, Pochiero F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115512>
 74. **A Public-Private Partnership Model to Build a Triage System in Response to a COVID-19 Outbreak in Hanam City, South Korea.** Osong Public Health Res Perspect 2020; 11:339-342Ku SS, Choe YJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117640>
 75. **COVID-19 and fortuitous discovery of chronic lymphocytic leukemia: biological findings and therapeutic challenges.** Pan Afr. Med. J. 2020; 36:286Charra B, Ellouadghiri A, Magramane A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117480>

76. **Happy hypoxia in critical COVID-19 patient: A case report in Tangerang, Indonesia.** *Physiol Rep* 2020; 8:e14619Widysanto A, Wahyuni TD, Simanjuntak LH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33112512>
77. **Hospital admission rates, length of stay, and in-hospital mortality for common acute care conditions in COVID-19 vs. pre-COVID-19 era.** *Public Health* 2020; 189:6-11Butt AA, Kartha AB, Masoodi NA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126120>
78. **Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae.** *Respir. Med.* 2020; 174:106197Daher A, Balfanz P, Cornelissen C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120193>
79. **[CURB-65 as a predictor of 30-day mortality in patients hospitalized with COVID-19 in Ecuador: COVID-EC StudyAbstract].** *Rev Clin Esp* 2020; Carriel J, Muñoz-Jaramillo R, Bolaños-Ladinez O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110273>
80. **Coagulopathy of Patients with COVID-19 is Associated with Infectious and Inflammatory Markers.** *Risk Manag. Healthc. Policy* 2020; 13:1965-1975Long X, Zhang Z, Zou W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116977>
81. **Life-threatening COVID-19 presenting as stroke with antiphospholipid antibodies and low ADAMTS-13 activity, and the role of therapeutic plasma exchange: A case series.** *SAGE Open Med Case Rep* 2020; 8:2050313x20964089Alharthy A, Faqihi F, Balhamar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101686>
82. **It's complicated: A case report on a COVID-19-positive HIV patient presenting with rhabdomyolysis and acute kidney injury.** *SAGE Open Med Case Rep* 2020; 8:2050313x20965423Foster A, Khan Z, Siddiqui A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117541>
83. **No association between COVID-19 related liver injury and the course of disease: a retrospective study.** *Scand. J. Gastroenterol.* 2020:1-4Sikkema BJB, Sint Nicolaas JJ, van Wijngaarden PP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119428>
84. **COVID-19-Induced Neurovascular Injury: a Case Series with Emphasis on Pathophysiological Mechanisms.** *SN Compr Clin Med* 2020:1-17Gutierrez Amezcua JM, Jain R, Kleinman G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106782>
85. **Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2: a New Challenge amid the Pandemic.** *SN Compr Clin Med* 2020:1-9Lawrensia S, Henrina J, Wijaya E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106783>
86. **Coinfection of Tuberculosis Pneumonia and COVID-19 in a Patient Vaccinated with Bacille Calmette-Guérin (BCG): Case Report.** *SN Compr Clin Med* 2020:1-4Luciani M, Bentivegna E, Spuntarelli V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103062>
87. **Frequently Asked Questions about Thrombosis during COVID-19 Pandemic.** *TH Open* 2020; 4:e303-e304Golemi L, Hanson P, Tafur A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103049>
88. **Vascular injury in acute infections and COVID-19: everything old is new again.** *Trends Cardiovasc. Med.* 2020; Levy JH, Iba T, Connors JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129973>

89. **Shorter incubation period is associated with severe disease progression in patients with COVID-19.** *Virulence* 2020; 11:1443-1452Lai C, Yu R, Wang M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33108255>

Cured – Recovered (11 articles)

1. **Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study.** *Am. J. Med.* 2020; Mahajan S, Srinivasan R, Redlich CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130124>
2. **Stabilizing mast cells by commonly used drugs: a novel therapeutic target to relieve post-COVID syndrome?** *Drug Discov Ther* 2020; Kazama I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116043>
3. **Recurrence of SARS-CoV-2 viral RNA in recovered COVID-19 patients: a narrative review.** *Eur J Clin Microbiol Infect Dis* 2020:1-13Dao TL, Hoang VT, Gautret P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113040>
4. **30-Day Readmission Rate Of Covid-19 Patients Discharged From A Tertiary Care University Hospital In Turkey; An Observational, Single-Center Study.** *Int. J. Qual. Health Care* 2020; Uyaroğlu OA, Başaran N, Özişik L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104780>
5. **Characterization of Myocardial Injury in Patients With COVID-19.** *J Am Coll Cardiol* 2020; 76:2043-2055Giustino G, Croft LB, Stefanini GG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121710>
6. **A case of SARS-CoV-2 re-infection.** *J Infect* 2020; AlFehaidi A, Ahmed SA, Hamed E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115660>
7. **Discharge may not be the end of treatment: pay attention to pulmonary fibrosis caused by severe COVID-19.** *J Med Virol* 2020; Zhang C, Wu Z, Li JW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107641>
8. **Immunity after COVID-19: Protection or sensitization?** *Math. Biosci.* 2020:108499Danchin A, Turinici G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129826>
9. **Changes in quality of life and dyspnoea after hospitalization in COVID-19 patients discharged at home.** *Multidiscip Respir Med* 2020; 15:713Santus P, Tursi F, Croce G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117535>
10. **Epidemiological and Clinical Findings of Short-Term Recurrence of Severe Acute Respiratory Syndrome Coronavirus 2 Ribonucleic Acid Polymerase Chain Reaction Positivity in 1282 Discharged Coronavirus Disease 2019 Cases: A Multicenter, Retrospective, Observational Study.** *Open Forum Infect Dis* 2020; 7:ofaa432Chen SL, Xu H, Feng HY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123610>
11. **Are there pulmonary sequelae in patients recovering from COVID-19?** *Respir Res* 2020; 21:286Rogliani P, Calzetta L, Coppola A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126869>

Cardiovascular disease (57 articles)

1. **Cardiothoracic surgery during COVID-19: Our experience with different strategies.** *Ann. Card. Anaesth.* 2020; 23:485-492Ralhan S, Arya RC, Gupta R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109808>

2. **Covid 19 and its cardiovascular effects.** Ann. Card. Anaesth. 2020; 23:401-408 Rastogi A, Tewari P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109794>
3. **Aminotransferases disorders associated with venous thromboembolic events in patients infected with COVID-19.** Ann. Hepatol. 2020; Hamadé A, Woehl B, Talbot M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130333>
4. **Don't sugar coat the COVID (only the vasculature).** Biomed J 2020; Häfner SJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115641>
5. **Unfractionated heparin inhibits live wild-type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations.** Br. J. Pharmacol. 2020; Tree JA, Turnbull JE, Buttigieg KR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125711>
6. **Coronary Artery Bypass Graft During the COVID-19 Pandemic.** Braz J Cardiovasc Surg 2020; Silveira L, Guerreiro GP, Lisboa LAF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113324>
7. **COVID-19 - Endothelial Axis and Coronary Artery Bypass Graft Patency: a Target for Therapeutic Intervention?** Braz J Cardiovasc Surg 2020; 35:757-763 Topal G, Loesch A, Dashwood MR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118741>
8. **SARS-CoV-2 INFECTION IN AN INFANT WITH SEVERE DILATED CARDIOMYOPATHY.** Cardiol. Young 2020; 1-9 Kristoffersen AW, Knudsen PK, Møller T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118485>
9. **To Anticoagulate or Not: Acute Stroke in a COVID-19 Patient With Gastrointestinal Bleed.** Cureus 2020; 12:e10554 George J, Kirkland Z, Lattanzio N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101801>
10. **Acute myocardial infarction admissions in Berlin during the COVID-19 pandemic.** Deutsches Arzteblatt International 2020; 117:597-598 Dreger H, Bruch L, Maier B, Schühlen H.
11. **BRACE-CORONA trial - COVID-19: No severe course in patients undergoing RAS inhibition.** Deutsches Arzteblatt International 2020; 117:A1816 Eckert N.
12. **Incidence of Myocardial Injury in COVID-19-Infected Patients: A Systematic Review and Meta-Analysis.** Diseases 2020; 8 Prasitlumkum N, Chokesuwattanaskul R, Thongprayoon C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120956>
13. **Is amiloride a promising cardiovascular medication to persist in the COVID-19 crisis?** Drug Discov Ther 2020; Adil MS, Narayanan SP, Somanath PR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116037>
14. **Cardiopulmonary resuscitation during the COVID-19 pandemic: a scientific statement on CPR management protocol of Kasr Al-Ainy University Hospital is presented.** Egypt Heart J 2020; 72:73 Taha HS, Shaker MM, Abdelghany MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33108568>
15. **Delayed acute myocarditis and COVID-19-related multisystem inflammatory syndrome.** ESC Heart Fail 2020; Nicol M, Cacoub L, Baudet M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107217>
16. **Relating angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID-19.** ESC Heart Fail 2020; 7:3119-3123 Wong MCS, Wong S, Huang J, Yan B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121220>
17. **Case report of an isolated myocarditis due to COVID-19 infection in a paediatric patient.** Eur Heart J Case Rep 2020; 4:1-5 Fischer Q, Brillat-Savarin N,

- Ducrocq G, Ou P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117957>
18. **ST-elevation myocardial infarction in a young patient with anomalous right coronary artery and COVID-19 pneumonia.** Eur Heart J Case Rep 2020; 4:1-2 Garg A, Hakeem H, Divita M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117958>
 19. **COVID-19 myocarditis and prospective heart failure burden.** Expert Rev. Cardiovasc. Ther. 2020; Shchedrygina A, Nagel E, Puntmann VO, Valbuena-Lopez S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119418>
 20. **Cardiovascular Changes in Patients With COVID-19 From Wuhan, China.** Front Cardiovasc Med 2020; 7:150 Song L, Zhao S, Wang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102532>
 21. **Unfractionated Heparin in SARS-CoV-2 Pneumonia: Ischemic Stroke Case Report.** Front. Neurol. 2020; 11:573356 Efendizade A, Dmytriw AA, Hewitt K, Davies GA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101181>
 22. **Stroke and Novel Coronavirus Infection in Humans: A Systematic Review and Meta-Analysis.** Front. Neurol. 2020; 11:579070 Lee KW, Yusof Khan AHK, Ching SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123082>
 23. **Acute Ischemic Stroke in COVID-19: A Case-Based Systematic Review.** Front. Neurol. 2020; 11:1031 Wijeratne T, Sales C, Karimi L, Crewther SG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101164>
 24. **Cardiology and COVID-19: do we have sufficient information?** Future Cardiol 2020; Garg N, McClafferty B, Ramgobin D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33124920>
 25. **Letter to the Editor regarding: Critical Considerations for Stroke Management During COVID-19 Pandemic in response to Inglis et al., Heart Lung Circ.** 2020;29(9): 1263-1267. Heart Lung Circ. 2020; Coote S, Cadilhac DA, O'Brien E, Middleton S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129695>
 26. **Central retinal vein occlusion with COVID-19 infection as the presumptive etiology.** Indian J Ophthalmol 2020; 68:2572-2574 Walinjar JA, Makhija SC, Sharma HR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120696>
 27. **Superior Mesenteric Artery Thrombosis in COVID-19 Pneumonia: an Underestimated Diagnosis-First Case Report in Asia.** Indian J Surg 2020;1-3 Karna ST, Panda R, Maurya AP, Kumari S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100738>
 28. **Management perspectives from the 2019 Wuhan international workshop on fulminant myocarditis.** Int J Cardiol 2020; Veronese G, Ammirati E, Chen C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33122017>
 29. **Changing to remote management of a community heart failure population during COVID-19 - Clinician and Patient perspectives'. Int J Cardiol Heart Vasc** 2020:100665 Kerr B, Pharithi RB, Barrett M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106775>
 30. **EXPRESS: Stroke in COVID-19: a systematic review and meta-analysis.** Int. J. Stroke 2020:1747493020972922 Nannoni S, de Groot R, Bell S, Markus HS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103610>
 31. **An unexplained death after routine cardiac surgery: how long have we dealt with coronavirus disease 2019?** Interact. Cardiovasc. Thorac. Surg. 2020; Varela Barca L, Torralba Cloquell I, Herrero Cereceda J, Sáez de Ibarra JI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130891>

32. **Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19.** J Am Coll Cardiol 2020; Alvarez-Garcia J, Lee S, Gupta A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33129663>
33. **Characterization of Myocardial Injury in Patients With COVID-19.** J Am Coll Cardiol 2020; 76:2043-2055 Giustino G, Croft LB, Stefanini GG *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33121710>
34. **Cardiac Injury in COVID-19-Echoing Prognostication.** J Am Coll Cardiol 2020; 76:2056-2059 Lavie CJ, Sanchis-Gomar F, Lippi G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33121711>
35. **Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19.** J Am Coll Cardiol 2020; 76:2060-2072 Piazza G, Campia U, Hurwitz S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121712>
36. **Troponin and Other Biomarker Levels and Outcomes Among Patients Hospitalized with COVID-19: Derivation and Validation of the HA(2)T(2) COVID-19 Mortality Risk Score.** J Am Heart Assoc 2020:e018477 Manocha KK, Kirzner J, Ying X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121304>
37. **Peripartum cardiomyopathy mimicking COVID-19 infection.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S44-s47 Garg S, Singh A, Kalita M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100645>
38. **Respiratory and cardiovascular effects of COVID-19 infection and their management.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S21-s28 Kapoor MC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100642>
39. **COVID-19 cardiopulmonary resuscitation: Guidelines and modifications.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S39-s44 Kundra P, Vinayagam S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100644>
40. **Iranian Society of Cardiac Surgeons COVID-19 task force version II, restarting elective surgeries.** J Cardiovasc Thorac Res 2020; 12:158-164 Alizadeh Ghavidel A, Mirzaaghaian M, Yousefnia MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123320>
41. **Outcomes of COVID-19 Hospitalized Patients Previously Treated with Renin-Angiotensin System Inhibitors.** J Clin Med 2020; 9:Cordeanu EM, Jambert L, Severac F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126565>
42. **Similar Clinical Course and Significance of Circulating Innate and Adaptive Immune Cell Counts in STEMI and COVID-19.** J Clin Med 2020; 9:de Dios E, Rios-Navarro C, Perez-Sole N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126723>
43. **Covid-19-Associated Coagulopathy: Biomarkers of Thrombin Generation and Fibrinolysis Leading the Outcome.** J Clin Med 2020; 9:Ranucci M, Sitzia C, Baryshnikova E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126772>
44. **COVID-19 pandemic: usefulness of telemedicine in management of arrhythmias in elderly people.** J Geriatr Cardiol 2020; 17:593-596 Mattioli AV, Cossarizza A, Boriani G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117426>
45. **Remote operation for non-fluoroscopic navigation of complex tachycardias.** J. Interv. Card. Electrophysiol. 2020:1-6 García-Bolao I, Moñino D, Marsal R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33125607>
46. **T-wave inversion as a manifestation of COVID-19 infection: a case series.** J. Interv. Card. Electrophysiol. 2020:1-9 Romero J, Alviz I, Parides M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33128658>

47. **Stroke and Thromboprophylaxis in the Era of COVID-19.** J. Stroke Cerebrovasc. Dis. 2020; 30:105392Ma A, Kase CS, Shoamanesh A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33130478>
48. **Acute Aortoiliac and Infrainguinal Arterial Thrombotic Events in Four Patients Diagnosed with the Novel Coronavirus 2019 (COVID-19).** J Vasc Surg Cases Innov Tech 2020; Wengerter SP, Wengerter KR, Masoudpoor H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33102991>
49. **Consensus Statement on Coronary Intervention during the Coronavirus Disease 2019 (COVID-19) Pandemic: from the Korean Society of Interventional Cardiology (KSIC).** Korean Circ J 2020; 50:974-983Lee KY, Lee BK, Kim WJ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33118332>
50. **Non-invasive hemodynamic profile of early COVID-19 infection.** Physiol Rep 2020; 8:e14628Busana M, Schiavone M, Lanfranchi A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33113285>
51. **Bilateral pulmonary artery thrombectomy with saddle embolism and COVID-19 infection.** Proc. (Bayl. Univ. Med. Cent.) 2020; 33:666-667Vyas V, Kanagalingam G, Yadava S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100564>
52. **Effects of COVID-19 pandemic on out-of-hospital cardiac arrests: A systematic review.** Resuscitation 2020; Scquizzato T, Landoni G, Paoli A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33130157>
53. **Intricate interplay between Covid-19 and cardiovascular diseases.** Rev Med Virol 2020; Keri VC, Hooda A, Kodan P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128859>
54. **Coagulopathy of Patients with COVID-19 is Associated with Infectious and Inflammatory Markers.** Risk Manag. Healthc. Policy 2020; 13:1965-1975Long X, Zhang Z, Zou W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116977>
55. **Life-threatening COVID-19 presenting as stroke with antiphospholipid antibodies and low ADAMTS-13 activity, and the role of therapeutic plasma exchange: A case series.** SAGE Open Med Case Rep 2020; 8:2050313x20964089Alharthy A, Faqihi F, Balhamar A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101686>
56. **Ischemic Stroke Occurs Less Frequently in Patients With COVID-19: A Multicenter Cross-Sectional Study.** Stroke 2020:Strokeaha120031217Bekelis K, Missios S, Ahmad J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106109>
57. **Vascular injury in acute infections and COVID-19: everything old is new again.** Trends Cardiovasc. Med. 2020; Levy JH, Iba T, Connors JM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33129973>

Diagnosis (6 articles)

1. **COVID-19 diagnosis -A review of current methods.** Biosens. Bioelectron. 2020; 172:112752Yüce M, Filiztekin E, Özkaya KG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126180>
2. **Adaptive, diverse and de-centralized diagnostics are key to the future of outbreak response.** BMC Biol. 2020; 18:153Matthews Q, da Silva SJR, Norouzi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115440>
3. **Quadruple negative SARS-CoV-2-PCR: Still COVID-19 pneumonia!** Deutsche Medizinische Wochenschrift 2020; 145:1498-1502Dubbke-Laule A, Gnauck M, Straub R *et al.*

4. **Not all that glitters is COVID! Differential diagnosis of FDG-avid interstitial lung disease in low-prevalence regions.** Eur J Hybrid Imaging 2020; 4:19Papa A, Pozzessere C, Cicone F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103048>
5. **SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment.** Front. Immunol. 2020; 11:570927Khalaf K, Papp N, Chou JT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123144>
6. **Dual-branch combination network (DCN): Towards accurate diagnosis and lesion segmentation of COVID-19 using CT images.** Med. Image Anal. 2020; 67:101836Gao K, Su J, Jiang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129141>

DM-MS-Obesity (24 articles)

1. **Management of glucose profile throughout strict COVID-19 lockdown by patients with type 1 diabetes prone to hypoglycaemia using sensor-augmented pump.** Acta Diabetol 2020;1-6Viñals C, Mesa A, Roca D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125525>
2. **Don't sugar coat the COVID (only the vasculature).** Biomed J 2020; Häfner SJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115641>
3. **Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes.** Diabetes Metab. 2020; Sathish T, Tapp RJ, Cooper ME, Zimmet P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129968>
4. **Independent Impact of Diabetes on the Severity of Coronavirus Disease 2019 in 5,307 Patients in South Korea: A Nationwide Cohort Study.** Diabetes Metab. J. 2020; 44:737-746Moon SJ, Rhee EJ, Jung JH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115212>
5. **Clinical characteristics and short term outcomes after recovery from COVID-19 in patients with and without diabetes in Bangladesh.** Diabetes Metab Syndr 2020; 14:2031-2038Akter F, Mannan A, Mehedi HMH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113469>
6. **Short term follow-up of patients presenting with acute onset diabetes and diabetic ketoacidosis during an episode of COVID-19.** Diabetes Metab Syndr 2020; 14:2039-2041Kuchay MS, Reddy PK, Gagneja S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113470>
7. **Analysis of clinical features and pulmonary CT features of coronavirus disease 2019 (COVID-19) patients with diabetes mellitus.** Endokrynol. Pol. 2020; 71:367-375Yan Y, Yang F, Zhu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125688>
8. **Managing Diabetes During the COVID-19 Pandemic.** Eur Endocrinol 2020; 16:85-87Doupis J, Avramidis K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117436>
9. **Short-term Hydroxychloroquine in COVID-19 Infection in People With or Without Metabolic Syndrome - Clearing Safety Issues and Good Clinical Practice.** Eur Endocrinol 2020; 16:109-112Dutta D, Sharma M, Sharma R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117441>
10. **Challenges in Women with Diabetes During the COVID-19 Pandemic.** Eur Endocrinol 2020; 16:100-108Priya G, Bajaj S, Grewal E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117440>
11. **COVID-19 and diabetes mellitus: Unraveling the hypotheses that worsen the prognosis (Review).** Exp. Ther. Med. 2020; 20:194Albulescu R, Dima SO, Florea

- IR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101484>
12. **The Impact of COVID-19 on Blood Glucose: A Systematic Review and Meta-Analysis.** Front. Endocrinol. (Lausanne) 2020; 11:574541Chen J, Wu C, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123093>
 13. **Prevention and Management of Type 2 Diabetes and Metabolic Syndrome in the Time of COVID-19: Should We Add a Cup of Coffee?** Front Nutr 2020; 7:581680Semiz S, Serdarevic F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123550>
 14. **Diabetes is associated with increased risk for in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis comprising 18,506 patients.** Hormones (Athens) 2020:1-10Palaodimos L, Chamorro-Pareja N, Karamanis D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123973>
 15. **Improved glycemic control amongst people with long-standing diabetes during COVID-19 lockdown: a prospective, observational, nested cohort study.** Int. J. Diabetes Dev. Ctries. 2020:1-6Rastogi A, Hiteshi P, Bhansali A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106739>
 16. **Response to: Is newly diagnosed diabetes a stronger risk factor than pre-existing diabetes for COVID-19 severity?** J. Diabetes 2020; Lippi G, Sanchis-Gomar F, Henry BM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128349>
 17. **Is newly diagnosed diabetes a stronger risk factor than pre-existing diabetes for COVID-19 severity?** J. Diabetes 2020; Sathish T, de Mello GT, Cao Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107708>
 18. **Macrophages in diabetes mellitus (DM) and COVID-19: do they trigger DM?** J Diabetes Metab Disord 2020:1-4Kloc M, Ghobrial RM, Lewicki S, Kubiak JZ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102261>
 19. **The burden of type 2 diabetes pre-and during the COVID-19 pandemic - a review.** J Diabetes Metab Disord 2020:1-9Sciberras J, Camilleri LM, Cuschieri S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102262>
 20. **Management of diabetes during fasting and COVID-19 - Challenges and solutions.** J Family Med Prim Care 2020; 9:3797-3806Ahmed WN, Arun CS, Koshy TG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110770>
 21. **Coronavirus disease 2019 (COVID-19): Insights into the recent trends and the role of the primary care in diabetic patients.** J Family Med Prim Care 2020; 9:3843-3847Marghalani AM, Althumali IM, Yousef LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110777>
 22. **Corona pandemic: Diabetes promotes kidney failure in COVID-19 patients.** MMW-Fortschritte der Medizin 2020; 162:31Fritschka E.
 23. **COVID-19 and Obesity: Is Bariatric Surgery Protective? Retrospective Analysis on 2145 Patients Undergone Bariatric-Metabolic Surgery from High Volume Center in Italy (Lombardy).** Obes. Surg. 2020; Uccelli M, Cesana GC, De Carli SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128218>
 24. **Covid-19: Fat, Obesity, Inflammation, Ethnicity, and Sex Differences.** Pathogens 2020; 9Krams IA, Luoto S, Rantala MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114495>

Education and training and science (47 articles)

1. **Online Liver Imaging Course; Pivoting to Transform Radiology Education During the SARS-CoV-2 Pandemic.** Acad Radiol 2020; Elsayes KM, Marks RM,

- Kamel S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109449>
2. **[Pharmacy students in between pedagogical continuity and field mobilization].** Actual. Pharm. 2020; 59:49-50Napieralski J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100499>
 3. **Virtualising the School During COVID-19 and Beyond in Africa: Infrastructure, Pedagogy, Resources, Assessment, Quality Assurance, Student Support System, Technology, Culture and Best Practices.** Adv Med Educ Pract 2020; 11:755-759Owolabi JO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117046>
 4. **First Special Section on Systems and Control Research Efforts Against COVID-19 and Future Pandemics.** Annu Rev Control 2020; Hernandez-Vargas EA, Giordano G, Sontag E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100889>
 5. **ABA Finding Its Heart During a Pandemic: An Exploration in Social Validity.** Behav Anal Pract 2020:1-10Nicolson AC, Lazo-Pearson JF, Shandy J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101602>
 6. **Diverse Responses of the Biobanks in Indo-Pacific Rim Region During the COVID-19 Pandemic: Case Scenarios from Two Low- and Middle-Income Countries and Two High-Income Countries in the Indo-Pacific Rim Region.** Biopreserv. Biobank. 2020; Yadav BK, Ng W, Fachiroh J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118846>
 7. **Ending COVID-19: progress and gaps in research-highlights of the July 2020 GloPID-R COVID-19 Research Synergies Meetings.** BMC Med 2020; 18:342. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115460>
 8. **Student satisfaction with videoconferencing teaching quality during the COVID-19 pandemic.** BMC Med. Educ. 2020; 20:396Fatani TH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129295>
 9. **Coronavirus Disease 2019 (COVID-19) Disparities: A Call for Equity in Health Outcomes and Clinical Research.** Clin Infect Dis 2020; Linas BP, Cunningham CO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111148>
 10. **Students' self-regulated learning (SRL) profile dataset measured during Covid-19 mitigation in Yogyakarta, Indonesia.** Data Brief 2020; 33:106422Sulisworo D, Fitriawanati M, Maryani I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102667>
 11. **Emerging Standards and the Hybrid Model for Organizing Scientific Events During and After The COVID-19 Pandemic.** Disaster Med Public Health Prep 2020:1-17Hanaei S, Takian A, Majdzadeh R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100253>
 12. **Challenges of remote assessment in higher education in the context of COVID-19: a case study of Middle East College.** Educ Assess Eval Account 2020:1-17Guangul FM, Suhail AH, Khalit MI, Khidhir BA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101539>
 13. **Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium.** Eur. J. Cancer 2020; 141:82-91Rubio-San-Simón A, André N, Cefalo MG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129040>
 14. **Science unites a troubled world: Lessons from the pandemic.** Eur. J. Pharmacol. 2020:173696Booz GW, Zouein FA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130278>
 15. **Impact of COVID-19 on Clinical and Academic Urological Practice: A Survey from European Association of Urology Section of Uro-technology.** Eur Urol

- Open Sci 2020; 21:22-28 Heinze A, Umari P, Basulto-Martínez M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33123688>
16. **Study Protocol for the COVID-19 Pandemic Adjustment Survey (CPAS): A Longitudinal Study of Australian Parents of a Child 0-18 Years.** Front Psychiatry 2020; 11:555750 Westrupp EM, Karantzas G, Macdonald JA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33110413>
 17. **COVID-19 and Distance Learning: Effects on Georgia State University School of Public Health Students.** Front Public Health 2020; 8:576227 Armstrong-Mensah E, Ramsey-White K, Yankey B, Self-Brown S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102425>
 18. **Challenges and needs for social behavioural research and community engagement activities during the COVID-19 pandemic in rural Mozambique.** Glob Public Health 2020;1-5 Magaço A, Munguambe K, Nhacolo A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33125306>
 19. **Are Special Care Dentistry Services Prepared for a Global Disruption in Healthcare? A Call for a Wider Promotion of Dental Conscious Sedation Training.** Healthcare (Basel) 2020; 8:Dziedzic A, Tanasiewicz M, Abed H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33105613>
 20. **Clinical Communication Skills Training in Dental Medical Education: The COVID-19 Pandemic Challenge.** Healthcare (Basel) 2020; 8:Salgado H, Castro-Vale I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113808>
 21. **Academic Crisis During COVID 19: Online Classes, a Panacea for Imminent Doctors.** Indian J Otolaryngol Head Neck Surg 2020;1-5 Shetty S, Shilpa C, Dey D, Kavya S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102186>
 22. **Family Physicians' Knowledge about and Attitudes towards COVID-19 - A Cross-sectional Multicentric Study.** Infect Chemother 2020; Gokdemir O, Pak H, Bakola M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33124215>
 23. **Bibliometric Analysis of Early COVID-19 Research: The Top 50 Cited Papers.** Infect Dis (Auckl) 2020; 13:1178633720962935 El Hawary H, Salimi A, Diab N, Smith L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110348>
 24. **The Impact of the COVID-19 Pandemic on the Quality of Educational Process: A Student Survey.** Int J Environ Res Public Health 2020; 17:Radu MC, Schnakovszky C, Herghelegiu E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114192>
 25. **The influence of the learning health system to address the COVID-19 pandemic: An examination of early literature.** Int. J. Health Plann. Manage. 2020; Douthit BJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103264>
 26. **A database for the epidemic trends and control measures during the first wave of COVID-19 in mainland China.** Int J Infect Dis 2020; Fu H, Wang H, Xi X *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33130212>
 27. **A commentary on "The coronavirus (COVID-19) pandemic: Adaptations in medical education".** Int J Surg 2020; 84:89-90 Naglik L, Ravindran P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33126084>
 28. **A commentary on "The coronavirus (COVID-19) pandemic: Adaptations in medical education"(Commentary).** Int J Surg 2020; Naglik L, Ravindran P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33127586>
 29. **Letter to editor "A redeployment model of surgery residents to COVID-19 diagnostic and treatment zone (CDTZ). A safe and cost-effective strategy in a**

- middle income country. Int J Surg 2020; Rana RE, Khan MR, Lakhani GS, Enam SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130242>
30. **Commentary on "Near-peer OSCE-style joint examination videos improve confidence in the clinical environment".** Int J Surg 2020; 84:94-95 Ravindran P, Naglik L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127589>
 31. **Arts and crafts as an educational strategy and coping mechanism for Republic of Korea and United States parents during the COVID-19 pandemic.** Int Rev Educ 2020;1-21 Choi M, Tessler H, Kao G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110275>
 32. **Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19.** J Am Coll Cardiol 2020; 76:2060-2072 Piazza G, Campia U, Hurwitz S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121712>
 33. **Impact of the COVID-19 Pandemic on Student and Resident Teaching and Training in Surgical Oncology.** J Clin Med 2020; 9 Hau HM, Weitz J, Bork U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114552>
 34. **From Pandemic to Progression: An Educational Framework for the Implementation of Virtual Mental Healthcare for Children and Youth as a Response to COVID-19.** J Contemp Psychother 2020;1-7 Doan BT, Yang YB, Romanchych E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110276>
 35. **Meeting the need: Creation of an online infection prevention course by the Golisano Institute for Developmental Disability Nursing for direct support professionals during COVID-19.** J Intellect Disabil 2020;1744629520962617 Kiss EA, Redlo JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111623>
 36. **Medical Teaching and Assessment in the Era of COVID-19.** J Med Educ Curric Dev 2020; 7:2382120520965255 Monaghan AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117891>
 37. **An opportunity for change in medical education amidst COVID-19: Perspective of a medical student.** J. Pediatr. Rehabil. Med. 2020; Kelly K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104049>
 38. **Virtual Interviews May Fall Short for Pediatric Surgery Fellowships: Lessons Learned From COVID-19/SARS-CoV-2.** J. Surg. Res. 2020; Lewit R, Gosain A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127064>
 39. **Experience of e-learning and online assessment during the COVID-19 pandemic at the College of Medicine, Qassim University.** J Taibah Univ Med Sci 2020; Elzainy A, El Sadik A, Al Abdulmonem W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106752>
 40. **Adaptation of internet-based multiple mini-interviews in a limited-resource medical school during the coronavirus disease 2019 pandemic.** Korean J Med Educ 2020; Yolanda S, Wisnu W, Wahjudi JM, Findyartini A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33108858>
 41. **Resuming cadaver dissection during a pandemic.** Med. Educ. Online 2021; 26:1842661 Bond G, Franchi T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33108248>
 42. **E-learning: Depression, anxiety, and stress symptomatology among Lebanese university students during COVID-19 quarantine.** Nurs. Forum 2020; Fawaz M, Samaha A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125744>
 43. **Exams tested by Covid-19: An opportunity to rethink standardized senior secondary examinations.** Prospects (Paris) 2020;1-15 Cairns R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110277>

44. **Covid-19 pandemic and the prospects of education in South Africa.** Prospects (Paris) 2020;1-12Le Grange L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100404>
45. **Responding to COVID-19 in an Uninsured Hispanic/Latino Community: Testing, Education and Telehealth at a Free Clinic in Providence.** R I Med J (2013) 2020; 103:41-46Barry K, McCarthy M, Melikian G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126788>
46. **Baseline results of a living systematic review for COVID-19 funded research projects.** Wellcome Open Res 2020; 5:209Norton A, Bucher A, Antonio E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117894>
47. **Remote-learning, time-use, and mental health of Ecuadorian high-school students during the COVID-19 quarantine.** World Dev 2021; 138:105225Asanov I, Flores F, McKenzie D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110286>

Elderly (23 articles)

1. **[Accommodation facilities for dependent elderly people facing the pandemic].** Actual. Pharm. 2020; 59:47-48Chagué V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100498>
2. **Comparison of clinical characteristics of COVID-19 between elderly patients and young patients: a study based on a 28-day follow-up.** Aging (Albany NY). 2020; 12Zhang L, Fan T, Yang S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106442>
3. **SARS-CoV-2 infection fatality rate among elderly retired Danish blood donors - A cross-sectional study.** Clin Infect Dis 2020; Pedersen OB, Nissen J, Dinh KM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103182>
4. **Unravelling the modes of transmission of SARS-CoV-2 during a nursing home outbreak: looking beyond the church super-spread event.** Clin Infect Dis 2020; Voeten H, Sikkema RS, Damen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119065>
5. **COVID-19 vaccine race: analysis of age-dependent immune responses against SARS-CoV-2 indicates that more than just one strategy may be needed.** Curr Med Chem 2020; Campillo NE, Jimenez M, Canelles M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109026>
6. **It's time: delivering optimal emergency care of residents of aged care facilities in the era of COVID-19.** Emerg. Med. Australas. 2020; Burkett E, Carpenter CR, Hullick C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33131219>
7. **[Ambivalence, control, support. Caring for the elderly patient at a "good enough" distance].** Evol. Psychiatr. (Paris) 2020; Verdon B, Racin C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106708>
8. **The effects of aging on host resistance and disease tolerance to SARS-CoV-2 infection.** Febs j. 2020; Mok DZL, Chan CYY, Ooi EE, Kuan Rong C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33124149>
9. **The "Elderly" Lesson in a "Stressful" Life: Italian Holistic Approach to Increase COVID-19 Prevention and Awareness.** Front. Endocrinol. (Lausanne). 2020; 11:579401Angelini S, Pinto A, Hrelia P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101211>
10. **Immunesenescence: A Predisposing Risk Factor for the Development of COVID-19?** Front. Immunol. 2020; 11:573662Hazeldine J, Lord JM.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123152>
11. **Consequences for the Elderly After COVID-19 Isolation: FEaR (Frail Elderly amid Restrictions).** *Front. Psychol.* 2020; 11:565052Briguglio M, Giorgino R, Dell'Osso B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117231>
 12. **The Effect of COVID-19 on Loneliness in the Elderly. An Empirical Comparison of Pre-and Peri-Pandemic Loneliness in Community-Dwelling Elderly.** *Front. Psychol.* 2020; 11:585308Heidinger T, Richter L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101154>
 13. **Clinical manifestations and factors associated with mortality from COVID-19 in older adults: Retrospective population-based study with 9807 older Brazilian COVID-19 patients.** *Geriatr Gerontol Int* 2020; de Souza CD, de Arruda Magalhães AJ, Lima AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111433>
 14. **Social Isolation and Psychological Distress During the COVID-19 Pandemic: A Cross-National Analysis.** *Gerontologist* 2020; Kim HH, Jung JH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125065>
 15. **Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19.** *Gerontology* 2020:1-9Díaz Y, Ramos-Suzarte M, Martín Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33105142>
 16. **Dealing with COVID-19 Outbreaks in Long-term Care Homes: A Protocol for Room Moving and Cohorting.** *Infect Control Hosp Epidemiol* 2020:1-4Kain D, McCreight L, Johnstone J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109298>
 17. **Knowledge, Attitude, and Practice of High-Risk Age Groups to Coronavirus Disease-19 Prevention and Control in Korem District, Tigray, Ethiopia: Cross-Sectional Study.** *Infect Drug Resist* 2020; 13:3801-3809Adhena G, Hidru HD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33122925>
 18. **Exploring the N95 and Surgical Mask Supply in U.S. Nursing Homes During COVID-19.** *J. Appl. Gerontol.* 2020:733464820969015Li Y, Fang F, He M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100107>
 19. **Clinical Characteristics and Risk Factors for Mortality in Very Old Patients Hospitalized with COVID-19 in Spain.** *J Gerontol A Biol Sci Med Sci* 2020; Ramos-Rincon JM, Buonaiuto V, Ricci M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103720>
 20. **Cytokine Response in SARS-CoV-2 Infection in the Elderly.** *J Inflamm Res* 2020; 13:737-747Sherwani S, Khan MWA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116752>
 21. **Oculoplastic fellow education during the COVID-19 crisis.** *Orbit* 2020:1-5Homer NA, Epstein A, Somogyi M, Shore JW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121312>
 22. **rRT-PCR Results of a Covid-19 Diagnosed Geriatric Patient.** *SN Compr Clin Med* 2020:1-4Görgülü Ö, Duyan M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103060>
 23. **The Double Burden of the COVID-19 Pandemic and Polypharmacy on Geriatric Population - Public Health Implications.** *Ther. Clin. Risk Manag.* 2020; 16:1007-1022Rahman S, Singh K, Dhingra S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116550>

Epidemiology (112 articles)

1. **Flattening the curve on COVID-19 : South Korea's measures in tackling initial outbreak of coronavirus.** Am. J. Epidemiol. 2020; Lee D, Heo K, Seo Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106843>
2. **Impacts of COVID-19 lockdown on diet patterns among youths in China: the COVID-19 Impact on Lifestyle Change Survey (COINLICS).** Appetite 2020;105015Jia P, Liu L, Xie X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121998>
3. **Global analysis of the COVID-19 pandemic using simple epidemiological models.** Appl Math Model 2020; 90:995-1008Enrique Amaro J, Dudouet J, Nicolás Orce J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110288>
4. **Global analysis of the COVID-19 pandemic using simple epidemiological models.** Appl Math Model 2021; 90:995-1008Enrique Amaro J, Dudouet J, Nicolás Orce J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110288>
5. **When the Best Pandemic Models are the Simplest.** Biology (Basel) 2020; 9Jahedi S, Yorke JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114047>
6. **The development of a quarantine strategy is an important path to a normalized response to COVID-19.** Biosci Trends 2020; Zhu H, Lu H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100292>
7. **Impacts of reopening strategies for COVID-19 epidemic: a modeling study in Piedmont region.** BMC Infect. Dis. 2020; 20:798Pernice S, Castagno P, Marcotulli L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115434>
8. **Comparison of spatiotemporal characteristics of the COVID-19 and SARS outbreaks in mainland China.** BMC Infect. Dis. 2020; 20:805Zhang X, Rao H, Wu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126857>
9. **Estimation of SIR model's parameters of COVID-19 in Algeria.** Bull Natl Res Cent 2020; 44:180Lounis M, Bagal DK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100825>
10. **The role of Force Health Protection in the Canadian Armed Forces' response to the COVID-19 pandemic.** Can. Commun. Dis. Rep. 2020; 46:279-281Edge HM, Carlucci S, Lu D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104085>
11. **High-Density Amplicon Sequencing Identifies Community Spread and Ongoing Evolution of SARS-CoV-2 in the Southern United States.** Cell Rep. 2020:108352McNamara RP, Caro-Vegas C, Landis JT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113345>
12. **Mathematical Perspective of Covid-19 Pandemic: Disease Extinction Criteria in Deterministic and Stochastic Models.** Chaos Solitons Fractals 2020:110381Adak D, Majumder A, Bairagi N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100607>
13. **Fractional Order Model for the Role of Mild Cases in the Transmission of COVID-19.** Chaos Solitons Fractals 2020:110374Baba IA, Nasidi BA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100604>
14. **Dynamics of a stochastic coronavirus (COVID-19) epidemic model with Markovian switching.** Chaos Solitons Fractals 2020; 141:110361Boukanjime B, Caraballo T, El Fatini M, El Khalifi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100608>
15. **Dynamic model of infected population due to spreading of pandemic COVID-19 considering both intra and inter zone mobilization factors with rate of detection.** Chaos Solitons Fractals 2020:110377Ghosh M, Ghosh S, Ghosh S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100606>

16. **Is spread of COVID-19 a chaotic epidemic?** Chaos Solitons Fractals 2020;110376 Jones A, Strigul N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100605>
17. **Forecasting spread of COVID-19 using Google Trends: A hybrid GWO-Deep learning approach.** Chaos Solitons Fractals 2020;110336 Prasanth S, Singh U, Kumar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110297>
18. **Anti-SARS-CoV-2 antibody detection in healthcare workers of two tertiary hospitals in Athens, Greece.** Clin Immunol 2020; 221:108619 Vlachoyiannopoulos P, Alexopoulos H, Apostolidi E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127563>
19. **Anti-SARS-CoV-2 antibody detection in healthcare workers of two tertiary hospitals in Athens, Greece.** Clin Immunol 2020; 221:108619 Vlachoyiannopoulos P, Alexopoulos H, Apostolidi I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127563>
20. **Response to the COVID-19 pandemic among people experiencing homelessness in congregant living settings in San Diego, CA.** Clin Infect Dis 2020; Marquez H, Ramers C, Northrup A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118015>
21. **Dose-response Relation Deduced for Coronaviruses from COVID-19, SARS and MERS Meta-analysis Results and its Application for Infection Risk Assessment of Aerosol Transmission.** Clin Infect Dis 2020; Zhang X, Wang J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119733>
22. **Geolocated Twitter-based population mobility in Victoria, Australia, during the staged COVID-19 restrictions.** Crit Care Resusc 2020; Nguyen T, Gupta S, Raman J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33105920>
23. **Kindergartens Reopening in the Period of Regular Epidemic Prevention and Control, Beneficial or Harmful?** Curr Med Sci 2020; 40:817-821 Dong QQ, Qiu LR, Cheng LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123896>
24. **COVID-19 in Africa: Africa seems safer than Europe.** Deutsches Arzteblatt International 2020; 117:A1970-A1972 Fischer-Fels J.
25. **Transmission of SARS-CoV-2 by children.** Deutsches Arzteblatt International 2020; 117:553-560 Merckx J, Labrecque JA, Kaufman JS.
26. **COVID-19 surge capacity solutions: our experience of converting a concert hall into a temporary hospital for mild and moderate COVID-19 patients.** Disaster Med Public Health Prep 2020;1-10 Sacchetto D, Raviolo M, Beltrando C, Tommasoni N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100254>
27. **Epidemiological analysis of corona virus disease 2019 (COVID-19) in two cities in China based on public data.** Disaster Med Public Health Prep 2020;1-16 Zhou N, Zhang X, Zhang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100249>
28. **Analysis of COVID-19 burden, epidemiology and mitigation strategies in Muslim majority countries.** East Mediterr Health J 2020; 26:1173-1183 Jardine R, Wright J, Samad Z, Bhutta ZA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103744>
29. **COVID-19 and lombardy: TESTing the impact of the first wave of the pandemic.** EBioMedicine 2020; 61:103069 Perico L, Tomasoni S, Peracchi T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130396>
30. **The 'Great Lockdown' and its determinants.** Econ Lett 2020; 197:109628 Ferraresi M, Kotsogiannis C, Rizzo L, Secomandi R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100438>

31. **The Values and Limitations of Mathematical Modeling to COVID-19 in the World: A Follow Up Report.** Emerg Microbes Infect 2020:1-21Tang Y, Tang S, Wang S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121387>
32. **Prognosticating the spread of covid-19 pandemic based on optimal arima estimators.** Endocr. Metab. Immune Disord. Drug Targets 2020; Sandhir V, Kumar V, Kumar V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121426>
33. **Digital contact tracing and exposure notification: ethical guidance for trustworthy pandemic management.** Ethics Inf Technol 2020:1-10Ranisch R, Nijsingh N, Ballantyne A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106749>
34. **Corona pan(dem)ic: gateway to global surveillance.** Ethics Inf Technol 2020:1-10Surber RS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100895>
35. **COVID-19 in LMICs: The Need to Place Stigma Front and Centre to Its Response.** Eur J Dev Res 2020:1-21Roelen K, Ackley C, Boyce P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100598>
36. **Epidemiology of the First Wave of COVID-19 ICU Admissions in South Wales- The Interplay Between Ethnicity and Deprivation.** Front Med (Lausanne) 2020; 7:569714Baumer T, Phillips E, Dhadda A, Szakmany T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117831>
37. **Correlates of Health-Protective Behavior During the Initial Days of the COVID-19 Outbreak in Norway.** Front. Psychol. 2020; 11:564083Zickfeld JH, Schubert TW, Herting AK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123045>
38. **Impact assessment of full and partial stay-at-home orders, face mask usage, and contact tracing: An agent-based simulation study of COVID-19 for an urban region.** Glob Epidemiol 2020:100036Tatapudi H, Das R, Das TK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103108>
39. **Aligning SARS-CoV-2 indicators via an epidemic model: application to hospital admissions and RNA detection in sewage sludge.** Health Care Manag Sci 2020:1-10Kaplan EH, Wang D, Wang M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111195>
40. **Health inequality experienced by the socially disadvantaged populations during the outbreak of COVID-19 in Hong Kong: An interaction with social inequality.** Health Soc Care Community 2020; Siu JY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125773>
41. **Lessons Learned from Japan's Response to the First Wave of COVID-19: A Content Analysis.** Healthcare (Basel) 2020; 8Shimizu K, Negita M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114264>
42. **Time-related changes in sex distribution of COVID-19 incidence proportion in Italy.** Heliyon 2020; 6:e05304Bianconi V, Mannarino MR, Bronzo P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102879>
43. **SARS-CoV 2 (Covid-19) Heterogeneous Mortality Rates across Countries May Be Partly Explained by Life Expectancy, Calorie Intake, and Prevalence of Diabetes.** Hum. Ecol. Interdiscip. J. 2020:1-6Nkhata SG, Ngoma TN, Chilenga PM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100471>
44. **SARS-CoV-2 infection among hospital workers of one of the most severely affected institutions in Madrid, Spain: a surveillance cross-sectional study.** Infect Control Hosp Epidemiol 2020:1-28Pérez-García F, Pérez-Zapata A, Arcos N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118904>
45. **A survey of preparedness against COVID-19 in hospitals in Tokyo, Japan with healthcare personnel with COVID-19 and in-facility transmission.** Infect Control

- Hosp Epidemiol 2020;1-18 Tagashira Y, Takamatsu A, Hasegawa S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33115548>
46. **Knowledge, Attitudes, and Practices Towards COVID-19 Pandemic Among Quarantined Adults in Tigray Region, Ethiopia.** Infect Drug Resist 2020; 13:3727-3737 Haftom M, Petrucka P, Gemechu K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116693>
 47. **Influenza and COVID-19: What does co-existence mean?** Influenza Other Respir Viruses 2020; Chotpitayasunondh T, Fischer TK, Heraud JM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33128444>
 48. **Applying computer simulations in battling with COVID-19, using pre-analyzed molecular and chemical data to face the pandemic.** Inform Med Unlocked 2020; 21:100458 Khazeei Tabari MA, Khoshhal H, Tafazoli A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33102687>
 49. **COVID-19 patients and contacted person awareness about home quarantine instructions.** Int J Clin Pract 2020:e13810 Elgendy MO, Abd Elmawla MN, Abdel Hamied AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128825>
 50. **Risk analysis and hot spots detection of SARS-CoV-2 in Nigeria using demographic and environmental variables: an early assessment of transmission dynamics.** Int. J. Environ. Health Res. 2020:1-12 Ameh Yaro C, Udama Eneche PS, Abu Anyebe D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103470>
 51. **COVID-19 Spread in Saudi Arabia: Modeling, Simulation and Analysis.** Int J Environ Res Public Health 2020; 17 Alrasheed H, Althnain A, Kurdi H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33113936>
 52. **Global to USA County Scale Analysis of Weather, Urban Density, Mobility, Homestay, and Mask Use on COVID-19.** Int J Environ Res Public Health 2020; 17 Jamshidi S, Baniasad M, Niyogi D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114771>
 53. **Knowledge, Attitudes and Practices Towards COVID-19 Amongst Ethnic Minorities in Hong Kong.** Int J Environ Res Public Health 2020; 17 Wong CL, Chen J, Chow KM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121143>
 54. **Fast Response to Superspreading: Uncertainty and Complexity in the Context of COVID-19.** Int J Environ Res Public Health 2020; 17 Zenk L, Steiner G, Pina ECM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121161>
 55. **On single point forecasts for fat-tailed variables.** Int J Forecast 2020; Taleb NN, Bar-Yam Y, Cirillo P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100449>
 56. **Epidemiologic and Clinical Characteristics of COVID-19 Patients from a Quarantine Center in a Developing Community: A Retrospective Study.** Int. J. Gen. Med. 2020; 13:937-944 Khraise WN, Khraise TW, Starling Emerald B, Allouh MZ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116785>
 57. **The influence of the learning health system to address the COVID-19 pandemic: An examination of early literature.** Int. J. Health Plann. Manage. 2020; Douthit BJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103264>
 58. **Adoption of Preventive Behaviour Strategies and Public Perceptions About COVID-19 in Singapore.** Int J Health Policy Manag 2020; Ozdemir S, Ng S, Chaudhry I, Finkelstein EA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33105971>
 59. **Competing or Interactive Effect Between Perceived Response Efficacy of Governmental Social Distancing Behaviors and Personal Freedom on Social Distancing Behaviors in the Chinese Adult General Population in Hong Kong.**

- Int J Health Policy Manag 2020; Yu Y, Lau JTF, Lau MMC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33105967>
60. **COVID19 in the Least Developed Fragile and Conflict-Affected Countries - How Can the Most Vulnerable be Protected?** Int J Infect Dis 2020; Ebrahim SH, Gozzer E, Ahmed Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130196>
 61. **A database for the epidemic trends and control measures during the first wave of COVID-19 in mainland China.** Int J Infect Dis 2020; Fu H, Wang H, Xi X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130212>
 62. **Covid-19 cumulative incidence, intensive care and mortality in Italian regions compared to selected European countries.** Int J Infect Dis 2020; Olivieri A, Palù G, Sebastiani G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130199>
 63. **Public acceptance of Covid-19 lockdown scenarios.** Int. J. Psychol. 2020; Gollwitzer M, Platzer C, Zwarg C, Göritz AS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118180>
 64. **A new rapid screening program based on risk scores for COVID-19 patients.** Intern Emerg Med 2020;1-8Chen R, Xu G, Yang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111164>
 65. **Rapid Report 2: Symptoms of anxiety and depression during the first 12 weeks of the Coronavirus (COVID-19) pandemic in Australia.** Internet Interv 2020; 22:100351Staples L, Nielssen O, Kayrouz R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110762>
 66. **Causal impact of masks, policies, behavior on early covid-19 pandemic in the U.S.** J Econom 2020; Chernozhukov V, Kasahara H, Schrimpf P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100476>
 67. **Panel forecasts of country-level Covid-19 infections.** J Econom 2020; Liu L, Moon HR, Schorfheide F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100475>
 68. **Estimation of Covid-19 prevalence from serology tests: A partial identification approach.** J Econom 2020; Toulis P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100477>
 69. **Quarantine an effective mode for control of the spread of COVID19? A review.** J Family Med Prim Care 2020; 9:3867-3871Patel A, Patel S, Fulzele P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110781>
 70. **Knowledge, attitude, and perception of Indian population toward coronavirus disease (COVID-19).** J Family Med Prim Care 2020; 9:4265-4269Tandon T, Dubey AK, Dubey S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110843>
 71. **Comparative epidemiology between the 2009 H1N1 influenza and COVID-19 pandemics.** J Infect Public Health 2020; da Costa VG, Saivish MV, Santos DER *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121906>
 72. **CoVID-19: Parent and caregiver concerns about reopening New Zealand schools.** J. Paediatr. Child Health 2020; Jeffs E, Lucas N, Walls T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33112012>
 73. **Tackling the COVID-19 pandemic: The Bangladesh perspective.** J Public Health Res 2020; 9:1794Islam MT, Talukder AK, Siddiqui MN, Islam T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117758>
 74. **Mathematical modeling of COVID-19 transmission: the roles of intervention strategies and lockdown.** Math Biosci Eng 2020; 17:5961-5986Bugalia S, Bajiya VP, Tripathi JP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120585>
 75. **The dynamics of COVID-19 spread: evidence from Lebanon.** Math Biosci Eng 2020; 17:5618-5632Deeb OE, Jalloul M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120585>

term=33120569

76. **Dynamics of SARS-CoV-2 infection model with two modes of transmission and immune response.** Math Biosci Eng 2020; 17:5326-5340 Hattaf K, Yousfi N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33120555>
77. **Analyzing the effects of public interventions on reducing public gatherings in China during the COVID-19 epidemic via mobile terminals positioning data.** Math Biosci Eng 2020; 17:4875-4890 Nie L, Guo X, Yi CQ, Wang RJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33120532>
78. **Lifting mobility restrictions and the effect of superspreading events on the short-term dynamics of COVID-19.** Math Biosci Eng 2020; 17:6240-6258 Santana-Cibrian M, Acuña-Zegar MA, Velasco-Hernandez JX.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33120597>
79. **Using a partial differential equation with Google Mobility data to predict COVID-19 in Arizona.** Math Biosci Eng 2020; 17:4891-4904 Wang HY, Yamamoto N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120533>
80. **Differences in how interventions coupled with effective reproduction numbers account for marked variations in COVID-19 epidemic outcomes.** Math Biosci Eng 2020; 17:5085-5098 Xia F, Xiao Y, Liu PY *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33120541>
81. **Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area.** mBio 2020; 11 Long SW, Olsen RJ, Christensen PA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127862>
82. **Successful containment to date of SARS-CoV-2 transmission in the Northern Territory.** Med. J. Aust. 2020; Douglas NM, Meumann EM, Krause VL, Davies J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33111312>
83. **Testing the Accuracy of the ARIMA Models in Forecasting the Spreading of COVID-19 and the Associated Mortality Rate.** Medicina (Kaunas) 2020; 56 Ilie OD, Ciobica A, Doroftei B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121072>
84. **Updated North Cyprus response status for COVID-19 in comparison with similar country sizes. Highlights on the importance of population per square meter.** Multidiscip Respir Med 2020; 15:699 Serakinci N, Savasan A, Rasmussen F.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33117534>
85. **Increasing and declining of COVID-19 cases puzzling the health experts in Pakistan.** New Microbes New Infect 2020; 100791 Shah PT, Xing L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101693>
86. **Epidemiological and Clinical Findings of Short-Term Recurrence of Severe Acute Respiratory Syndrome Coronavirus 2 Ribonucleic Acid Polymerase Chain Reaction Positivity in 1282 Discharged Coronavirus Disease 2019 Cases: A Multicenter, Retrospective, Observational Study.** Open Forum Infect Dis 2020; 7:ofaa432 Chen SL, Xu H, Feng HY *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33123610>
87. **Transmission of SARS-CoV-2 in Public Transportation Vehicles: A Case Study in Hunan Province, China.** Open Forum Infect Dis 2020; 7:ofaa430 Luo K, Lei Z, Hai Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123609>
88. **Spread of Coronavirus 2019 From Wuhan to Rural Villages in the Hubei Province.** Open Forum Infect Dis 2020; 7:ofaa228 You M, Wu Z, Yang Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33117853>

89. **Predictive Accuracy of COVID-19 World Health Organization (WHO) Severity Classification and Comparison with a Bayesian-Method-Based Severity Score (EPI-SCORE).** *Pathogens* 2020; 9de Terwangne C, Laouni J, Jouffe L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114416>
90. **Prevention of SARS-COV-2 coronavirus spread at the Auschwitz-Birkenau State Museum in Poland. The most visited Memorial site in the world during the COVID-19 pandemic.** *Przegl. Epidemiol.* 2020; 74:303-315Wawrzyk A, Rybitwa D, Cywiński P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115219>
91. **No Community Left Behind: A Call for Action During the COVID-19 Pandemic.** *Psychiatr. Serv.* 2020:appips202000261Sullivan SR, Bell KA, Spears AP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106097>
92. **Knowledge, Attitudes and Practices Toward Prevention and Early Detection of COVID-19 and Associated Factors Among Religious Clerics and Traditional Healers in Gondar Town, Northwest Ethiopia: A Community-Based Study.** *Risk Manag. Healthc. Policy* 2020; 13:2239-2250Asmelash D, Fasil A, Tegegne Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117002>
93. **A Country Pandemic Risk Exposure Measurement Model.** *Risk Manag. Healthc. Policy* 2020; 13:2067-2077Grima S, Kizilkaya M, Rupeika-Apoga R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116987>
94. **Evidence-Based Framework and Implementation of China's Strategy in Combating COVID-19.** *Risk Manag. Healthc. Policy* 2020; 13:1989-1998Zhao D, Lin H, Zhang Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116979>
95. **COVID-19 in Shanghai: IPC Policy Exploration in Support of Work Resumption Through System Dynamics Modeling.** *Risk Manag. Healthc. Policy* 2020; 13:1951-1963Zhao J, Jia J, Qian Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116976>
96. **Weaving public health and safety nets to respond the COVID-19 pandemic.** *Saf Sci* 2021; 134:105058Fan D, Li Y, Liu W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110294>
97. **A dynamical model of SARS-CoV-2 based on people flow networks.** *Saf Sci* 2020:105034Lopez V, Čukić M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100582>
98. **A dynamical model of SARS-CoV-2 based on people flow networks.** *Saf Sci* 2021; 134:105034López V, Čukić M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100582>
99. **Emergency department crowding and hospital transformation during COVID-19, a retrospective, descriptive study of a university hospital in Stockholm, Sweden.** *Scand. J. Trauma Resusc. Emerg. Med.* 2020; 28:107Af Ugglas B, Skyttberg N, Wladis A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115521>
100. **Early Detection of Covid-19 in Canadian Provinces and its Anticipatory Measures for a Medical Emergency.** *SN Comput Sci* 2020; 1:349Kamboj VK, Verma C, Gupta A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103121>
101. **Preparing for Outbreaks - Implications for Resilient Water Utility Operations and Services.** *Sustain Cities Soc* 2020:102558Gude VG, Muire PJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101881>
102. **Coronavirus disease (COVID-19) prevention and treatment methods and effective parameters: A systematic literature review.** *Sustain Cities Soc* 2021; 64:102568Rahmani AM, Mirmahaleh SYH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110743>

103. **Characteristics and evaluation of the effectiveness of monitoring and control measures for the first 69 Patients with COVID-19 from 18 January 2020 to 2 March in Wuxi, China.** *Sustain Cities Soc* 2021; 64:102559Shi P, Gao Y, Shen Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101882>
104. **Excess deaths from COVID-19 correlate with age and socio-economic status. A database study in the Stockholm region.** *Ups. J. Med. Sci.* 2020; 125:297-304Strang P, Fürst P, Schultz T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100083>
105. **Sewage surveillance system using urological wastewater: Key to COVID-19 monitoring?** *Urol. Oncol.* 2020; de Jong FC, GeurtsvanKessel CH, Molenkamp R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127302>
106. **Willingness to Accept Trade-Offs Among COVID-19 Cases, Social-Distancing Restrictions, and Economic Impact: A Nationwide US Study.** *Value Health* 2020; 23:1438-1443Reed S, Gonzalez JM, Johnson FR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127014>
107. **SARS-CoV, MERS-CoV, and 2019-nCoV viruses: an overview of origin, evolution, and genetic variations.** *Virusdisease* 2020:1-13Krishnamoorthy S, Swain B, Verma RS, Gunthe SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102628>
108. **The local governance of COVID-19: Disease prevention and social security in rural India.** *World Dev* 2020:105234Dutta A, Fischer HW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106724>
109. **Public Support for Development Aid during the COVID-19 Pandemic.** *World Dev* 2020:105248Kobayashi Y, Heinrich T, Bryant KA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106725>
110. **Why is the Number of COVID-19 Cases Lower Than Expected in Sub-Saharan Africa? A Cross-Sectional Analysis of the Role of Demographic and Geographic Factors.** *World Dev* 2020; 138:105251Nguimkeu P, Tadadjeu S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106726>
111. **Why is the number of COVID-19 cases lower than expected in Sub-Saharan Africa? A cross-sectional analysis of the role of demographic and geographic factors.** *World Dev* 2021; 138:105251Nguimkeu P, Tadadjeu S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106726>
112. **Low incidence of COVID-19 in the West African sub-region: mitigating healthcare delivery system or a matter of time?** *Z Gesundh Wiss* 2020:1-10Bankole TO, Omoyeni OB, Oyeboode AO, Akintunde DO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101839>

Gastro-enterology (9 articles)

1. **Online Liver Imaging Course; Pivoting to Transform Radiology Education During the SARS-CoV-2 Pandemic.** *Acad Radiol* 2020; Elsayes KM, Marks RM, Kamel S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109449>
2. **Aminotransferases disorders associated with venous thromboembolic events in patients infected with COVID-19.** *Ann. Hepatol.* 2020; Hamadé A, Woehl B, Talbot M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130333>
3. **Management of Patients with Liver Transplant and Chronic Liver Diseases During COVID-19 Pandemic: A Brief Review.** *Arch Iran Med* 2020; 23:713-717Taher M, Miroliaee A, Ebrahimi Daryani N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107315>

4. **ESSD Commentary on Dysphagia Management During COVID Pandemia.** Dysphagia 2020:1-4Schindler A, Baijens LWJ, Clave P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33111204>
5. **Elective Gastrointestinal Surgery in COVID Times.** Indian J Surg 2020:1-7Kapoor D, Perwaiz A, Singh A, Chaudhary A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110299>
6. **How do we respond to COVID-19 pandemic with rapid rescue plan for ALF/ACLF patients by living-donor liver transplantation?** J Dig Dis 2020; He K, Qian Y, Xi Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111491>
7. **The Liver in COVID-19-Related Death: Protagonist or Innocent Bystander?** Pathobiology 2020:1-7Schmit G, Lelotte J, Vanhaebost J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33108789>
8. **Trends in interest of COVID-19 on Polish Internet.** Przegl. Epidemiol. 2020; 74:258-275Jarynowski A, Wójta-Kempa M, Belik V.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33112108>
9. **Update on Hepatitis C Epidemiology: Unaware and Untreated Infected Population Could Be the Key to Elimination.** SN Compr Clin Med 2020:1-8Stasi C, Silvestri C, Voller F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103061>

Guidelines (7 articles)

1. **Review and comparison of HVAC operation guidelines in different countries during the COVID-19 pandemic.** Build. Environ. 2020:107368Guo BM, Xu P, Xiao T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071439>
2. **The changing paradigm of an aesthetic practice during the COVID-19 pandemic - An expert consensus.** Dermatol Ther 2020:e14382Kandhari R, Kohli M, Trasi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33090637>
3. **Preventive Measures for COVID-19 in Dental Treatments.** Disaster Med Public Health Prep 2020:1-13Guo J, Xie H, Wu H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33092676>
4. **Guidelines for Resuming Elective Hip and Knee Surgical Activity Following the COVID-19 Pandemic: An Italian Perspective.** HSS J. 2020:1-6D'Ambrosi R, Biazzo A, Masia F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33071683>
5. **An Overview on Guidelines on COVID-19 Virus and Natural and Assisted Reproductive Techniques Pregnancies.** Int J Fertil Steril 2020; 14:264-271Pirjani R, Rabiei M, Abiri A, Moini A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33098398>
6. **Longitudinal Quantitative Analysis of Radiation Oncology Staff Illness in a New York City Center during COVID-19: The Impact of New Guidelines on Operations and Employee Health.** Int J Part Ther 2020; 7:21-27Hasan S, Press RH, Chhabra A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33094132>
7. **Clinical protocols in dental practice: Post-COVID-19.** J Conserv Dent 2019; 22:408-410Hegde MN, Qaiser S, Hegde ND. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33082652>

Imaging (25 articles)

1. **The Role of Imaging in the Management of Suspected or Known COVID-19 Pneumonia. A Multidisciplinary Perspective.** Ann Am Thorac Soc 2020; 17:1358-

- 1365Roshkovan L, Chatterjee N, Galperin-Aizenberg M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33124905>
2. **Chest high-resolution computed tomography is associated to short-time progression to severe disease in patients with COVID-19 pneumonia.** *Clin Imaging* 2020; 70:61-66Cereser L, Da Re J, Zuiani C, Girometti R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33125986>
 3. **COVID-19 detection in radiological text reports integrating entity recognition.** *Comput. Biol. Med.* 2020; 127:104066López-Úbeda P, Díaz-Galiano MC, Martín-Noguerol T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130435>
 4. **Unexpected Ground-Glass Opacities on Abdominopelvic CT of a Patient With a Negative SARS-CoV-2 Antigen Test Result and No Respiratory Symptoms Upon Admission.** *Cureus* 2020; 12:e11044Soler-Luna C, Reynoso-Saldana D, Burgos MI, Gutierrez CH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101790>
 5. **Dual-Energy Computed Tomography of the Lung in COVID-19 Patients: Mismatch of Perfusion Defects and Pulmonary Opacities.** *Diagnostics (Basel)* 2020; 10Afat S, Othman AE, Nikolaou K, Gassenmaier S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33114478>
 6. **Qualitative and quantitative chest CT parameters as predictors of specific mortality in COVID-19 patients.** *Emerg Radiol* 2020; Colombi D, Villani GD, Maffi G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119835>
 7. **Impact of the COVID-19 pandemic on emergency department CT for suspected diverticulitis.** *Emerg Radiol* 2020:1-8Gibson AL, Chen BY, Rosen MP *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33111154>
 8. **Analysis of clinical features and pulmonary CT features of coronavirus disease 2019 (COVID-19) patients with diabetes mellitus.** *Endokrynol. Pol.* 2020; 71:367-375Yan Y, Yang F, Zhu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125688>
 9. **The accuracy of teleradiologists in diagnosing COVID-19 based on a French multicentric emergency cohort.** *Eur Radiol* 2020; Nivet H, Crombé A, Schuster P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123790>
 10. **The Role of the Computed Tomography (CT) Thorax in the Diagnosis of COVID-19 for Patients Presenting with Acute Surgical Emergencies. A Single Institute Experience.** *Indian J Surg* 2020:1-6Majeed T, Ali RS, Solomon J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100739>
 11. **CGNet: A graph-knowledge embedded convolutional neural network for detection of pneumonia.** *Inf. Process. Manag.* 2021; 58:102411Yu X, Wang SH, Zhang YD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100482>
 12. **Characterization of Myocardial Injury in Patients With COVID-19.** *J Am Coll Cardiol* 2020; 76:2043-2055Giustino G, Croft LB, Stefanini GG *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33121710>
 13. **Cardiac Injury in COVID-19-Echoing Prognostication.** *J Am Coll Cardiol* 2020; 76:2056-2059Lavie CJ, Sanchis-Gomar F, Lippi G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33121711>
 14. **CT Volumes from 2,398 Radiology Practices in the United States: A Real-Time Indicator of the Effect of COVID-19 on Routine Care, January to September 2020.** *J Am Coll Radiol* 2020; Davenport MS, Fruscello T, Chatfield M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33129768>
 15. **FLANNEL: Focal Loss Based Neural Network Ensemble for COVID-19 Detection.** *J Am Med Inform Assoc* 2020; Qiao Z, Bae A, Glass LM *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125051>
16. **Bone fractures during the time of coronavirus.** *J. Clin. Pharm. Ther.* 2020; Umeda-Raffa S, Pergolizzi JV, Jr., Raffa RB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104253>
 17. **Use of ultrasonography in COVID-19: Probing for success.** *J Family Med Prim Care* 2020; 9:3863-3866 Kumar S, Kumar A, Goel P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110780>
 18. **Investigating the initial effect of COVID-19 on the functioning of outpatient diagnostic imaging facilities.** *J Med Imaging Radiat Sci* 2020; Maizlin NN, Ohorodnyk P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121887>
 19. **Post-mortem ultrasonography: a safer alternative to autopsies in COVID-19 deaths.** *J Ultrasound* 2020:1-2 Kanchan T, Shrestha R, Krishan K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128737>
 20. **Preoperative computerized tomography screening for COVID-19 pneumonia in asymptomatic patients: experiences from two centers.** *Jpn J Radiol* 2020; Gümüs T, Kabaoglu ZU, Coskun B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33131031>
 21. **Dual-branch combination network (DCN): Towards accurate diagnosis and lesion segmentation of COVID-19 using CT images.** *Med. Image Anal.* 2020; 67:101836 Gao K, Su J, Jiang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129141>
 22. **Lung Ultrasound in Children with Respiratory Tract Infections: Viral, Bacterial or COVID-19? A Narrative Review.** *Open Access Emerg. Med.* 2020; 12:275-285 Kharasch S, Duggan NM, Cohen AR, Shokoohi H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116963>
 23. **MetaCOVID: A Siamese neural network framework with contrastive loss for n-shot diagnosis of COVID-19 patients.** *Pattern Recognit* 2020:107700 Shorfuzzaman M, Hossain MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100403>
 24. **Novel 3D segmentation for reliable volumetric assessment of the nasal airway: a CBCT study.** *Quintessence Int.* 2020:2-12 Mupparapu M, Shi KJ, Lo AD, Setzer FC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118002>
 25. **A topic-based hierarchical publish/subscribe messaging middleware for COVID-19 detection in X-ray image and its metadata.** *Soft comput* 2020:1-11 Eken S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100897>

Immune response (3 articles)

1. **SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination.** *Adv Mater* 2020:e2005637 Huang WC, Zhou S, He X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111375>
2. **Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study.** *Am. J. Med.* 2020; Mahajan S, Srinivasan R, Redlich CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130124>
3. **Innate and adaptive immune responses against coronavirus.** *Biomed. Pharmacother.* 2020; 132:110859 Hosseini A, Hashemi V, Shomali N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120236>

4. **Measuring the Serologic Response to Severe Acute Respiratory Syndrome Coronavirus 2: Methods and Meaning.** *Clin. Lab. Med.* 2020; 40:603-614 Pecora ND, Zand MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121625>
5. **Multisystem Inflammatory Syndrome in Children Temporally Related to COVID-19: A Case Report From Saudi Arabia.** *Cureus* 2020; 12:e10589 Al Ameer HH, AlKadhem SM, Busaleh F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110725>
6. **Perfect storm: a rheumatologist's point of view on COVID-19 infection.** *Curr. Rheumatol. Rev.* 2020; Kobak S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121412>
7. **Covid-19 and Autoimmune Diseases: A Systematic Review of Reported Cases.** *Curr. Rheumatol. Rev.* 2020; Saad MA, Alfshawy M, Nassar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121413>
8. **Delayed acute myocarditis and COVID-19-related multisystem inflammatory syndrome.** *ESC Heart Fail* 2020; Nicol M, Cacoub L, Baudet M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107217>
9. **Immunesenescence: A Predisposing Risk Factor for the Development of COVID-19?** *Front. Immunol.* 2020; 11:573662 Hazeldine J, Lord JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123152>
10. **Longitudinal Analysis of T and B Cell Receptor Repertoire Transcripts Reveal Dynamic Immune Response in COVID-19 Patients.** *Front. Immunol.* 2020; 11:582010 Niu X, Li S, Li P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117392>
11. **ACE2, COVID-19 Infection, Inflammation, and Coagulopathy: Missing Pieces in the Puzzle.** *Front. Physiol.* 2020; 11:574753 Abassi Z, Higazi AAR, Kinaneh S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123031>
12. **Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity.** *Immunity* 2020; Ripberger TJ, Uhrlaub JL, Watanabe M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129373>
13. **Biochemical and immunological aspects of Covid-19 infection and therapeutical intervention of oral low dose cytokine therapy: A systematic review.** *Immunopharmacol. Immunotoxicol.* 2020:1-15 M R, S S, Jose SP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106053>
14. **Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection.** *J. Clin. Invest.* 2020; Files JK, Boppana S, Perez MD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119547>
15. **Low Seroprevalence of SARS-CoV-2 Antibodies during Systematic Antibody Screening and Serum Responses in Patients after COVID-19 in a German Transplant Center.** *J Clin Med* 2020; 9 Choi M, Bachmann F, Naik MG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114149>
16. **Similar Clinical Course and Significance of Circulating Innate and Adaptive Immune Cell Counts in STEMI and COVID-19.** *J Clin Med* 2020; 9 de Dios E, Rios-Navarro C, Perez-Sole N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126723>
17. **COVID-19 in patients with cutaneous immune-mediated diseases in The Netherlands: real-world observational data.** *J Eur Acad Dermatol Venereol* 2020; de Wijs LEM, Joustra MM, Olydam JI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33131098>

18. **A review on exploring evidence-based approach to harnessing the immune system in times of corona virus pandemic: Best of modern and traditional Indian system of medicine.** J Family Med Prim Care 2020; 9:3826-3837 Pathania M, Bhardwaj P, Pathania N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110775>
19. **Lack of detrimental effect of corticosteroids on antibody responses to SARS-CoV-2 and viral clearance in patients hospitalized with COVID-19.** J Infect 2020; Masiá M, Fernández-González M, García JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115658>
20. **Analysis of humoral immune responses in SARS-CoV-2 infected patients.** J Infect Dis 2020; Henss L, Scholz T, von Rhein C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128369>
21. **COVID-19 infection prevalence in pediatric population: Etiology, clinical presentation, and outcome.** J Infect Public Health 2020; Alsohime F, Temsah MH, Al-Nemri AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127335>
22. **Unexpected high frequency of unspecific reactivities by testing pre-epidemic blood specimens from Europe and Africa with SARS-CoV-2 IgG-IgM antibody rapid tests points IgM as Achilles heel.** J Med Virol 2020; Bouassa RM, Péré H, Tonen-Wolyec S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107601>
23. **Maternal SARS-CoV-2 infection associated to systemic inflammatory response and pericardial effusion in the newborn: a Case-Report.** J Pediatric Infect Dis Soc 2020; Lima ARO, Cardoso CC, Bentim PRB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125068>
24. **Anti-SARS-CoV-2 IgG antibody response among Indian COVID-19 patients using β -propiolactone-inactivated, whole virus-based indirect ELISA.** J. Virol. Methods 2020; 287:113996 Kulkarni R, Patil HP, Palkar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126149>
25. **Immunity after COVID-19: Protection or sensitization?** Math. Biosci. 2020:108499 Danchin A, Turinici G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129826>
26. **Dynamics of SARS-CoV-2 infection model with two modes of transmission and immune response.** Math Biosci Eng 2020; 17:5326-5340 Hattaf K, Yousfi N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120555>
27. **Association of Early Nasopharyngeal Immune Markers With COVID-19 Clinical Outcome: Predictive Value of CCL2/MCP-1.** Open Forum Infect Dis 2020; 7:ofaa407 Sierra B, Pérez AB, Aguirre E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123608>
28. **Coagulopathy of Patients with COVID-19 is Associated with Infectious and Inflammatory Markers.** Risk Manag. Healthc. Policy 2020; 13:1965-1975 Long X, Zhang Z, Zou W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116977>
29. **T-cell immunobiology and cytokine storm of COVID-19.** Scand. J. Immunol. 2020:e12989 Luo XH, Zhu Y, Mao J, Du RC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113222>
30. **Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan.** Transfusion 2020; Kubota-Koketsu R, Terada Y, Yunoki M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104267>

31. **Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization.** *Viruses* 2020; 12Ding S, Laumaea A, Benlarbi M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33114742>

Management miscellaneous diseases (93 articles)

1. **[Drawing lessons from the pandemic for a new pharmacy practice].** *Actual. Pharm.* 2020; 59:44-46Mrozovski JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100497>
2. **[Reflections on the health crisis in the pharmacy].** *Actual. Pharm.* 2020; 59:40-43Sicard J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100496>
3. **HIV Prevention and Treatment in the Context of the COVID-19 in the Bronx, New York: Implications for Practice and Research.** *AIDS Rev.* 2020; 22:143-147Patel VV, Beil R, Slawek D, Akiyama MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118533>
4. **Management of Patients with Liver Transplant and Chronic Liver Diseases During COVID-19 Pandemic: A Brief Review.** *Arch Iran Med* 2020; 23:713-717Taher M, Miroliaee A, Ebrahimi Daryani N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33107315>
5. **The State of Orthodontic Practice After the Outbreak of COVID-19 in Southeast Asia: The Current Scenario and Future Recommendations.** *Asia Pac. J. Public Health* 2020;1010539520962919Karobari MI, Marya A, Venugopal A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33106020>
6. **The experience of UK bladder cancer patients during the COVID-19 pandemic: A survey-based snapshot.** *BJU Int* 2020; Spencer-Bowdage S, Russell B, Rigby J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33124729>
7. **Collateral effects of the coronavirus disease 2019 pandemic on lung cancer diagnosis in Korea.** *BMC Cancer* 2020; 20:1040Park JY, Lee YJ, Kim T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33121456>
8. **COVID-19 pandemic and dental hygienists in Italy: a questionnaire survey.** *BMC Health Serv. Res.* 2020; 20:994Bontà G, Campus G, Cagetti MG.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33129340>
9. **Post COVID-19 lockdown: measures and practices for dental institutes.** *BMC Oral Health* 2020; 20:291Al Kawas S, Al-Rawi N, Talaat W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33109185>
10. **Neurorehabilitation in the times of Covid-19: insights from the Spanish Neurorehabilitation Society (SENR).** *Brain Inj.* 2020;1-2Laxe S, Ferri J, Juárez-Belaunde A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104386>
11. **Course of Sars-CoV2 infection in patients with cancer treated with anti-PD-1: a case presentation and review of the literature.** *Cancer Invest.* 2020;1-10Pala L, Conforti F, Cocorocchio E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125301>
12. **Colorectal Surgery in Romania during the COVID-19 Pandemic.** *Chirurgia (Bucur.)* 2020; 115:129-137Tomulescu V, Surlin V, Scripcariu V *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33119486>
13. **SARS-CoV-2 and COVID-19 for the ophthalmologist.** *Clin Exp Ophthalmol* 2020; Brandão-de-Resende C, Diniz-Filho A, de Almeida Brito F, Vasconcelos-Santos DV.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33131139>

14. **Blood Banking and Transfusion Medicine Challenges During the COVID-19 Pandemic.** Clin. Lab. Med. 2020; 40:587-601Ngo A, Masel D, Cahill C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33121624>
15. **Development of a Patient-Centered Framework for Oncology Clinicians to Address Uncertainty in Cancer Care During the COVID-19 Pandemic.** Curr. Treat. Options Oncol. 2020; 21:99Dhawan N, Prommer E, Sinclair CT, Subbiah IM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33119833>
16. **Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic.** Dermatol Ther 2020; Armesto S, González Vela C, Sánchez J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33112014>
17. **Clinical Practice During the COVID-19 Pandemic: A Cross-Sectional Survey of Attending Dermatologists.** Dermatol Ther 2020:e14484Stewart CR, Lipner SR.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33128426>
18. **Medical emergencies during the COVID-19 pandemic - An analysis of emergency department data in Germany.** Deutsches Arzteblatt International 2020; 117:545-552Slagman A, Behringer W, Greiner F *et al.*
19. **Thoughts on the future medical care pattern of paediatrics in China based on the outbreak of COVID-19.** Disaster Med Public Health Prep 2020:1-5Liu H, Wang L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100260>
20. **The Impact of COVID-19 Social Restrictions on Trauma Presentations in South Australia.** Emerg. Med. Australas. 2020; Harris D, Ellis DY, Gorman D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33124718>
21. **Impact of the COVID-19 pandemic on emergency department CT for suspected diverticulitis.** Emerg Radiol 2020:1-8Gibson AL, Chen BY, Rosen MP *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33111154>
22. **A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19.** Eur. J. Cancer 2020; 141:92-104Yekedüz E, Utkan G, Ürün Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130550>
23. **The Role of Dentists in COVID-19 Is Beyond Dentistry: Voluntary Medical Engagements and Future Preparedness.** Front Med (Lausanne) 2020; 7:566Seneviratne CJ, Lau MWJ, Goh BT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117825>
24. **Mapping Evidence of Pharmacy Services for COVID-19 in China.** Front. Pharmacol. 2020; 11:555753Yi ZM, Hu Y, Wang GR, Zhao RS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33117160>
25. **A Syndemic Perspective on the Management of Non-communicable Diseases Amid the COVID-19 Pandemic in Low- and Middle-Income Countries.** Front Public Health 2020; 8:508Yadav UN, Rayamajhee B, Mistry SK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33102414>
26. **[COVID-19 and work environment: legislative developments about the role of the occupational physician in the emergency management and in the SARS-CoV-2-related work accidents notification].** G. Ital. Med. Lav. Ergon. 2020; 42:195-200Garzaro G, Declementi M, Frammartino R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33119980>
27. **[COVID-19 emergency management activities promoted by an university hospital in Northern Italy].** G. Ital. Med. Lav. Ergon. 2020; 42:187-194Lago P, Albano G, Toscani M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119979>

28. **Protecting the vulnerable during COVID-19: Treating and preventing chronic disease disparities.** Gates Open Res 2020; 4:125Mobula LM, Heller DJ, Commodore-Mensah Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117965>
29. **COVID-19 pandemic: How to ensure surgical care services?** Geburtshilfe Frauenheilkd. 2020; 80:964-965.
30. **Organization of outpatient consultations at a hand surgery department in a French university hospital during the COVID-19 lockdown.** Hand Surg Rehabil 2020; Gabriel C, Mathiot A, Boumediane M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130022>
31. **Impact of COVID-19 pandemic, national lockdown, and unlocking on an apex tertiary care ophthalmic institute.** Indian J Ophthalmol 2020; 68:2391-2395Agarwal R, Sharma N, Patil A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120625>
32. **Impact of the COVID-19 lockdown on digital device-related ocular health.** Indian J Ophthalmol 2020; 68:2378-2383Bahkir FA, Grandee SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120622>
33. **Knowledge, attitude and practise toward COVID-19 among patients presenting to five tertiary eye care hospitals in South India - A multicentre questionnaire-based survey.** Indian J Ophthalmol 2020; 68:2385-2390Christy JS, Kaur K, Gurnani B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120624>
34. **Preoperative COVID-19 testing for elective vitreoretinal surgeries: Experience from a major tertiary care institute in South India.** Indian J Ophthalmol 2020; 68:2373-2377Kannan NB, Sen S, Reddy H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120621>
35. **Corneal transplantation and eye banking practices during COVID-19-related lockdown period in India from a network of tertiary eye care centers.** Indian J Ophthalmol 2020; 68:2368-2371Roy A, Das S, Chaurasia S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120619>
36. **Management of Traumatology Patients During the Coronavirus (COVID-19) Pandemic: Experience in a Hub Trauma Hospital in Northern Italy.** Indian J. Orthop. 2020;1-6D'Angelo F, Monestier L, De Falco G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110274>
37. **'POLIDON' Approach-A Novel Solution for the ENT & Skull Base Surgeons in COVID-19 era.** Indian J Otolaryngol Head Neck Surg 2020;1-5Arefin MK, Arafat MS, Talukder DC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102188>
38. **Cochlear Implant Surgery During the Covid Pandemic Lockdown-The KEM Hospital, Pune Experience.** Indian J Otolaryngol Head Neck Surg 2020;1-4Vaid N, Vaze V, Gokhale N, Kothadiya A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102187>
39. **Elective Gastrointestinal Surgery in COVID Times.** Indian J Surg 2020;1-7Kapoor D, Perwaiz A, Singh A, Chaudhary A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110299>
40. **Outcomes of Cancer Surgery During the COVID-19 Pandemic: Preparedness to Practising Continuous Cancer Care.** Indian J Surg Oncol 2020;1-5Ramachandra C, Sugoor P, Karjol U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100778>
41. **Head and Neck Practice in the COVID-19 Pandemics Today: A Rapid Systematic Review.** Int Arch Otorhinolaryngol 2020; 24:e518-e526Hojaij FC,

- Chinelatto LA, Boog GHP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101521>
42. **COVID-19 Infection and Its Influence in Otorhinolaryngology-Head and Neck Surgery.** Int Arch Otorhinolaryngol 2020; 24:e527-e534Parilli-Troconis D, Baptista P, Marcano-Lozada M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123266>
 43. **Symptoms, Management and Healthcare Utilization of COPD Patients During the COVID-19 Epidemic in Beijing.** Int. J. Chron. Obstruct. Pulmon. Dis. 2020; 15:2487-2494Liang Y, Chang C, Chen Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116465>
 44. **The Experience of COPD Patients in Lockdown Due to the COVID-19 Pandemic.** Int. J. Chron. Obstruct. Pulmon. Dis. 2020; 15:2621-2627Pleguezuelos E, Del Carmen A, Moreno E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33122900>
 45. **Supplying synthetic opioids during a pandemic: An early look at North America.** Int. J. Drug Policy 2020:102833Pardo B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127281>
 46. **Impact of COVID-19 on Dental Emergency Services in Cluj-Napoca Metropolitan Area: A Cross-Sectional Study.** Int J Environ Res Public Health 2020; 17Petrescu NB, Aghiorghiesei O, Mesaros AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33105688>
 47. **State of Fragility Fractures Management during the COVID-19 Pandemic.** Int J Environ Res Public Health 2020; 17Tarantino U, Cariati I, Tancredi V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33105834>
 48. **COVID-19 DISEASE IN PEOPLE LIVING WITH HIV: A MULTICENTER CASE-SERIES STUDY.** Int J Infect Dis 2020; Cabello A, Zamarro B, Nistal S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127499>
 49. **A cohort study of 30 day mortality after NON-EMERGENCY surgery in a COVID-19 cold site.** Int J Surg 2020; 84:57-65Kasivisvanathan V, Lindsay J, Rakshani-Moghadam S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33122153>
 50. **Effective management of a firearm injury with multiple intestinal perforation in a COVID 19 positive patient: A rare case report.** Int. J. Surg. Case Rep. 2020; 77:5-8Rohit G, Hariprasad CP, Kumar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110742>
 51. **Effective management of a firearm injury with multiple intestinal perforation in a COVID 19 positive patient: A rare case report.** Int. J. Surg. Case Rep. 2020; 77:5-8Rohita G, Hariprasad CP, Kumar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110742>
 52. **COVID-19 Lockdown and Eye Injury: A Case Series from Jordan.** Int Med Case Rep J 2020; 13:493-501Alqudah AA, Al Dwairi RA, Alqudah NM, Abumurad SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116940>
 53. **Prevalence of coronavirus disease 2019 in rheumatic patients and evaluation of the effect of disease-modifying anti-rheumatic drugs.** Intern Emerg Med 2020:1-5Moradi S, Masoumi M, Mohammadi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128696>
 54. **Practices and attitudes of bariatric surgeons in Israel during the first phase of the COVID-19 pandemic.** Isr J Health Policy Res 2020; 9:59Beglaibter N, Zelekha O, Keinan-Boker L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126921>
 55. **Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: a Biobadaderm cohort analysis.** J Am

- Acad Dermatol 2020; Baniandr s-Rodr guez O, Vilar-Alejo J, Rivera R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33122022>
56. **Analysis of Availability of Online Dermatology Appointments During COVID-19.** J Am Acad Dermatol 2020; Gu L, Xiang L, Lipner S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33127378>
 57. **Exploring the unknown territories in the new normal world of COVID.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S77-s80Bajwa SJS, Gupta R, Wahi A, Goraya SPS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100651>
 58. **Anesthesiologist and COVID-19-current perspective.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S50-s57Kumar S, Palta S, Saroa R, Mitra S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100647>
 59. **Anesthesia for oral surgeries during the COVID-19 pandemic.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S96-s104Myatra SN, Gupta S, Pai PS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100656>
 60. **Regional anesthesia in the coronavirus disease (COVID-19) pandemic: Clinical guidelines by AORA, India.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S109-s115Ponde VC, Diwan S, Gopal TVS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100658>
 61. **Emergency neurological procedures during COVID-19 pandemic: Practical issues.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S104-s109Singh GP, Hrishi AP, Rath GP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100657>
 62. **Approach to skin malignancies in COVID-19 pandemic days.** J Biol Regul Homeost Agents 2020; 34Aslan Kayiran M, Karadag AS, Wollina U.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33111514>
 63. **Adrenal insufficiency at the time of COVID-19: a retrospective study in patients referring to a tertiary centre.** J. Clin. Endocrinol. Metab. 2020; Carosi G, Morelli V, Del Sindaco G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107576>
 64. **Impact of COVID-19 Quarantine on Advanced Hemorrhoidal Disease and the Role of Telemedicine in Patient Management.** J Clin Med 2020; 9Campenn  P, Marra AA, Ferri L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113796>
 65. **Bone fractures during the time of coronavirus.** J. Clin. Pharm. Ther. 2020; Umeda-Raffa S, Pergolizzi JV, Jr., Raffa RB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104253>
 66. **Impact of the COVID-19 pandemic on obstructive sleep apnea: recommendations for symptom management.** J. Clin. Sleep Med. 2020; Rizzo D, Libman E, Baltzan M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100266>
 67. **The effects of the COVID-19 pandemic on patients with narcolepsy.** J. Clin. Sleep Med. 2020; Rodrigues Aguilar AC, Frange C, Huebra L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33124977>
 68. **Medical and socioeconomic challenges of private dermatocosmetology clinics during COVID-19 pandemic: A survey from Turkey.** J Cosmet Dermatol 2020; Esme P, Akoglu G, Erbil H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128425>
 69. **Impact of the COVID-19 Pandemic on Emergency Department Use: Focus on Patients Requiring Urgent Revascularization.** J. Emerg. Med. 2020; Montagnon R, Rouffilange L, Agard G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129611>
 70. **COVID-19, HIV and key populations: cross-cutting issues and the need for population-specific responses.** J Int AIDS Soc 2020; 23:e25632Iversen J, Sabin K, Chang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119183>

71. **A Review of Recommendations for Routine Immunization Services During COVID-19 Pandemic That are Relevant for Nursing Personnel Involved in the Implementation of Immunoprophylaxis.** J Multidiscip Healthc 2020; 13:1099-1105 Bednarek A, Klepacz R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116556>
72. **Comprehensive review of guidelines to practice prosthodontic and implant procedures during COVID-19 pandemic.** J Oral Biol Craniofac Res 2020; 10:768-775 Pruthi G, Parkash H, Bharathi PV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101891>
73. **Comprehensive guidelines to practice prosthodontic procedures and implant treatment during COVID-19 era: A narrative review.** J Oral Biol Craniofac Res 2020; Pruthi G, Parkash H, Vijaya Bharathi P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101891>
74. **COVID-19 microsurgical breast reconstruction national practise survey: A survey of BAPRAS members and proposal of COVID-19 specific perioperative and ERAS pathways.** J. Plast. Reconstr. Aesthet. Surg. 2020; Ali S, Ibrahim N, Warwick J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127350>
75. **Healthcare utilization patterns among persons who use drugs during the COVID-19 pandemic.** J. Subst. Abuse Treat. 2020:108177 Murphy SM, Yoder J, Pathak J, Avery J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109432>
76. **COVID-19 innovations in medication for addiction treatment at a Skid Row syringe exchange.** J. Subst. Abuse Treat. 2020:108181 Tringale R, Subica AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129635>
77. **A critical review of the safety of minimally invasive surgery in the era of COVID-19.** Minim. Invasive Ther. Allied Technol. 2020:1-7 Emile SH, Hamid HKS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107358>
78. **Impact of COVID-19 Pandemic on Neurosurgical Practice in India: A Survey on Personal Protective Equipment Usage, Testing, and Perceptions on Disease Transmission.** Neurol. India 2020; 68:1133-1138 Moorthy RK, Rajshekhar V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109863>
79. **Influence of the CoviD-19 pandemic on the prehospital emergency and tele-emergency care - A comparative cohort study.** Notarzt 2020; 36:271-277 Felzen M, Brockert AK, Beckers S *et al.*
80. **Modeling the Impact of Delaying Bariatric Surgery due to COVID-19: a Decision Analysis.** Obes. Surg. 2020; Shipe ME, Beeghly-Fadiel A, Deppen SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104988>
81. **COVID-19 screening protocols for preoperative assessment of head and neck cancer patients candidate for elective surgery in the midst of the pandemic: A narrative review with comparison between two Italian institutions.** Oral Oncol 2020; 112:105043 Ferrari M, Paderno A, Giannini L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129056>
82. **A székletmikrobiota-transzplantáció technológiájának és minőségirányítási hátterének újragondolása a SARS-CoV-2 vírushátrányítás kapcsán.** Orv. Hetil. 2020; 161:1858-1871 Nagy GG, Tudlik Z, Gergely L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130602>
83. **Coronavirus Disease-19 and Otology/Neurotology.** Otolaryngol. Clin. North Am. 2020; 53:1153-1157 Vivas EX. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127042>
84. **A Comparative Study Looking at Trauma and Orthopaedic Operating Efficiency in the COVID-19 Era.** Perioper Care Oper Room Manag

- 2020;100142Mercer ST, Agarwal R, Dayananda KSS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33106778>
85. **Transition to Home-Based Treatment Plans for Center-Based Cardiac, Pulmonary, and Vascular Rehabilitation during COVID-19.** R I Med J (2013). 2020; 103:30-33Riley H, Stabile L, Wu WC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126784>
 86. **Impact of COVID-19 pandemic on rheumatoid arthritis from a Multi-Centre patient-reported questionnaire survey: influence of gender, rural-urban gap and north-south gradient.** Rheumatol. Int. 2020; Abualfadi E, Ismail F, Shereef RRE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130920>
 87. **Reduced Number of Pediatric Orthopedic Trauma Requiring Operative Treatment during COVID-19 Restrictions: A Nationwide Cohort Study.** Scand. J. Surg. 2020;1457496920968014Raitio A, Ahonen M, Jääskelä M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100133>
 88. **Update on Hepatitis C Epidemiology: Unaware and Untreated Infected Population Could Be the Key to Elimination.** SN Compr Clin Med 2020;1-8Stasi C, Silvestri C, Voller F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103061>
 89. **Managing patient flows in radiation oncology during the COVID-19 pandemic : Reworking existing treatment designs to prevent infections at a German hot spot area University Hospital.** Strahlenther. Onkol. 2020; Akuamoa-Boateng D, Wegen S, Ferdinandus J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123776>
 90. **Emergency Surgery during COVID-19: Lessons Learned.** Surg J (N Y) 2020; 6:e167-e170Bhattacharjee HK, Chaliyadan S, Verma E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33102699>
 91. **Getting Back to work: A framework and pivot plan to resume Elective Surgery and procedures after COVID-19.** Surg Open Sci 2020; Serrano OK, Orlando R, Papasavas P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106786>
 92. **The Double Burden of the COVID-19 Pandemic and Polypharmacy on Geriatric Population - Public Health Implications.** Ther. Clin. Risk Manag. 2020; 16:1007-1022Rahman S, Singh K, Dhingra S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116550>
 93. **Management of urologic cancers during the pandemic and potential impact of treatment deferrals on outcomes.** Urol. Oncol. 2020; Mian BM, Siddiqui S, Ahmad AE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129674>

Management (77 articles)

1. **Not Remembering History, Dooms Us to Repeat It: Using the Lessons of the Global HIV Response to Address COVID-19.** AIDS Behav. 2020;1-3Rotheram-Borus MJ, Tomlinson M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123825>
2. **SARS-CoV-2 and HIV: Epidemiology, Treatment, and Lessons Learned from HIV.** AIDS Rev. 2020; 22:133-142Castel AD, Wilbourn B, Magnus M, Greenberg AE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118529>
3. **A Primary Care Answer to a Pandemic: Keeping a Population of Patients Safe at Home through Chronic Care Management and Remote Patient Monitoring.** Am. J. Lifestyle Med. 2020; 14:595-601Donohue D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33117101>

4. **Combating COVID 19 in a public sector hospital in Pakistan.** Ann Med Surg (Lond) 2020; Ayyaz M, Chima KK, Butt UI *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33106759>
5. **Repercussions of the COVID-19 pandemic on the well-being and training of medical clerks: a pan-Canadian survey.** BMC Med. Educ. 2020; 20:385Abbas M, Dhane M, Beniey M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109168>
6. **Hospitalised COVID-19 patients of the Mount Sinai Health System: a retrospective observational study using the electronic medical records.** BMJ Open 2020; 10:e040441Wang Z, Zheutlin A, Kao YH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33109676>
7. **Perioperative management of patients with suspected or confirmed COVID-19: review and recommendations for perioperative management from a retrospective cohort study.** Br J Anaesth 2020; Zheng H, Hébert HL, Chatziperi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121750>
8. **Nutritional Care in Relation to COVID-19.** Br J Nurs 2020; 29:1096-1103Delaney E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104430>
9. **COVID-19: Topical Agents and Therapeutic Prevention of Nasal Viral Acquisition.** Dermatol Ther 2020; Abdelhadi S, Ruszczak Z, Schwartz RA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33107144>
10. **COVID-19 mortality: Full heparinization.** Deutsches Arzteblatt International 2020; 117:A1873Kiesewetter H.
11. **Visual loss following assisted mechanical ventilation due to SARS-CoV-2 - A case series.** Deutsches Arzteblatt International 2020; 117:561-562Reich M, Pauleikhoff L, Schröter N *et al.*
12. **COVID-19 surge capacity solutions: our experience of converting a concert hall into a temporary hospital for mild and moderate COVID-19 patients.** Disaster Med Public Health Prep 2020;1-10Sacchetto D, Raviolo M, Beltrando C, Tommasoni N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100254>
13. **Stabilizing mast cells by commonly used drugs: a novel therapeutic target to relieve post-COVID syndrome?** Drug Discov Ther 2020; Kazama I.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33116043>
14. **It's time: delivering optimal emergency care of residents of aged care facilities in the era of COVID-19.** Emerg. Med. Australas. 2020; Burkett E, Carpenter CR, Hullick C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33131219>
15. **Relating angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID-19.** ESC Heart Fail 2020; 7:3119-3123Wong MCS, Wong S, Huang J, Yan B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121220>
16. **Conscious prone positioning during non-invasive ventilation in COVID-19 patients: experience from a single centre.** F1000Res 2020; 9:859Burton-Papp HC, Jackson AIR, Beecham R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110499>
17. **Perspective: The Potential Effects of Naringenin in COVID-19.** Front. Immunol. 2020; 11:570919Alberca RW, Teixeira FME, Beserra DR *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101291>
18. **Immune-Boosting, Antioxidant and Anti-inflammatory Food Supplements Targeting Pathogenesis of COVID-19.** Front. Immunol. 2020; 11:570122Mrityunjaya M, Pavithra V, Neelam R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33117359>

19. **Unfractionated Heparin in SARS-CoV-2 Pneumonia: Ischemic Stroke Case Report.** Front. Neurol. 2020; 11:573356Efendizade A, Dmytriw AA, Hewitt K, Davies GA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101181>
20. **Prevention and Management of Type 2 Diabetes and Metabolic Syndrome in the Time of COVID-19: Should We Add a Cup of Coffee?** Front Nutr 2020; 7:581680Semiz S, Serdarevic F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123550>
21. **Association of time to diagnosis with socioeconomic position and geographical accessibility to healthcare among symptomatic COVID-19 patients: A retrospective study in Hong Kong.** Health Place 2020; 66:102465Wu Y, Yan X, Zhao S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130449>
22. **Changes in Antimicrobial Utilization During the COVID-19 Pandemic after Implementation of a Multispecialty Clinical Guidance Team.** Infect Control Hosp Epidemiol 2020:1-28Staub MB, Beaulieu RM, Graves J, Nelson GE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100250>
23. **A survey of preparedness against COVID-19 in hospitals in Tokyo, Japan with healthcare personnel with COVID-19 and in-facility transmission.** Infect Control Hosp Epidemiol 2020:1-18Tagashira Y, Takamatsu A, Hasegawa S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115548>
24. **Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands.** Infect Dis (Lond) 2020:1-9Karami Z, Knoop BT, Dofferhoff ASM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103530>
25. **Analysis of Influencing Factors and Pharmaceutical Care of Patients with COVID-19 in Fangcang Shelter Hospital.** Infect Drug Resist 2020; 13:3443-3450Cheng F, Li Q, Han Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116663>
26. **Flattening the Risk: Pre-Exposure Prophylaxis for COVID-19.** Infect Drug Resist 2020; 13:3689-3694Stricker RB, Fesler MC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116688>
27. **Predictors of Coronavirus Disease 2019 (COVID-19) Prevention Practices Using Health Belief Model Among Employees in Addis Ababa, Ethiopia, 2020.** Infect Drug Resist 2020; 13:3751-3761Tadesse T, Alemu T, Amogne G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33122922>
28. **Prophylactic and Therapeutic Topical Povidone-Iodine in COVID-19: What is the Evidence?** Int Forum Allergy Rhinol 2020; Yan CH, Bleier BS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118690>
29. **Management perspectives from the 2019 Wuhan international workshop on fulminant myocarditis.** Int J Cardiol 2020; Veronese G, Ammirati E, Chen C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33122017>
30. **Assessment of the Consultation Rate with General Practitioners in the Initial Phase of the COVID-19 Pandemic.** Int J Environ Res Public Health 2020; 17Ochal M, Romaszko M, Glińska-Lewczuk K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33105612>
31. **Fast Response to Superspreading: Uncertainty and Complexity in the Context of COVID-19.** Int J Environ Res Public Health 2020; 17Zenk L, Steiner G, Pina ECM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121161>

32. **Filling the gaps in the characterization of the clinical management of COVID-19: 30-day hospital admission and fatality rates in a cohort of 118 150 cases diagnosed in outpatient settings in Spain.** Int J Epidemiol 2020; Prieto-Alhambra D, Balló E, Coma E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118037>
33. **The probiotic Bifidobacterium in the management of Coronavirus: A theoretical basis.** Int. J. Immunopathol. Pharmacol. 2020; 34:2058738420961304Bozkurt HS, Quigley EM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103512>
34. **Effectiveness of non-pharmaceutical interventions on COVID-19 transmission in 190 countries from 23 January to 13 April 2020.** Int J Infect Dis 2020; Bo Y, Guo C, Lin C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129965>
35. **Intensive Care Unit-Acquired Weakness: Not just Another Muscle Atrophying Condition.** Int J Mol Sci 2020; 21Lad H, Saumur TM, Herridge MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33105809>
36. **Beyond the mask: a multidisciplinary reflection on palliating patients with COVID-19 receiving continuous positive airway pressure ventilation.** Int. J. Palliat. Nurs. 2020; 26:336-340Hough A, Dell GD, Blaber M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33108921>
37. **Prevalence of coronavirus disease 2019 in rheumatic patients and evaluation of the effect of disease-modifying anti-rheumatic drugs.** Intern Emerg Med 2020;1-5Moradi S, Masoumi M, Mohammadi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128696>
38. **The Protective Roles of Exercise and Maintenance of Daily Living Routines for Chinese Adolescents During the COVID-19 Quarantine Period.** J. Adolesc. Health 2020; Ren H, He X, Bian X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121902>
39. **Fast tracking intensive care units and operation rooms during the COVID-19 pandemic in resource limited settings.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S7-s14Aggarwal R, Bhatia R, Soni KD, Trikha A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100639>
40. **COVID-2019: Experience of setting up quarantine center.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S14-s18Datta R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100640>
41. **Intensive care management of patients with COVID-19.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S29-s38Trikha A, Singh AK, Khanna P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100643>
42. **Traditional Indian practices: Time to revisit and re-adopt for a healthier lifestyle.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S166-s171Tyagi R, Gupta V, Kumar R, Wander GS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100675>
43. **Management of a COVID-19 Patient during ECMO: Paying Attention to Acquired von Willebrand Syndrome.** J Atheroscler Thromb 2020; Hayakawa M, Takano K, Kayashima M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116032>
44. **Medical management of COVID-19 clinic.** J. Biomed. Res. 2020;1-6Mehta N, Qiao R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100274>
45. **COVID-19: An Australian center's perspective.** J. Card. Surg. 2020; Lim L, Matalanis G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33124709>
46. **ECMO therapy in COVID-19: The Zurich experience.** J. Card. Surg. 2020; Sromicki J, Schmiady M, Maisano F, Mestres CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33124076>

47. **Clinical data of early COVID-19 cases receiving extracorporeal membrane oxygenation in Wuhan, China.** J. Clin. Anesth. 2020; 68:110044Huang S, Xia H, Wu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130357>
48. **Outcomes of COVID-19 Hospitalized Patients Previously Treated with Renin-Angiotensin System Inhibitors.** J Clin Med 2020; 9Cordeanu EM, Jambert L, Severac F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126565>
49. **Knowledge, Attitude, and Practice Towards COVID-19 Among People Living with HIV/AIDS in Kigali, Rwanda.** J. Community Health 2020:1-6Iradukunda PG, Pierre G, Muhozi V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106963>
50. **Community-based palliative care during the COVID 19 pandemic.** J Family Med Prim Care 2020; 9:3169-3175Atreya S, Kumar R, Salins N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102264>
51. **Emergency and primary care collaboration during COVID-19 pandemic: A quick systematic review of reviews.** J Family Med Prim Care 2020; 9:3856-3862Kumar R, Nedungalaparambil NM, Mohanan N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110779>
52. **A review on exploring evidence-based approach to harnessing the immune system in times of corona virus pandemic: Best of modern and traditional Indian system of medicine.** J Family Med Prim Care 2020; 9:3826-3837Pathania M, Bhardwaj P, Pathania N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110775>
53. **Short Term Home Oxygen Therapy for COVID-19 patients: The COVID-HOT algorithm.** J Family Med Prim Care 2020; 9:3209-3219Sardesai I, Grover J, Garg M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102272>
54. **[Assessment model for evaluating the preparedness plan for COVID-19 in a tertiary care hospital].** J Healthc Qual Res 2020; Llorente-Parrado C, Mejon-Berges R, Cossio-Gil Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127345>
55. **Evidence-Based Management of the Critically Ill Adult With SARS-CoV-2 Infection.** J. Intensive Care Med. 2020:885066620969132Chivukula RR, Maley JH, Dudzinski DM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111601>
56. **Lessons from Italian front-line nurses' experiences during the COVID-19 pandemic: a qualitative descriptive study.** J. Nurs. Manag. 2020; Catania G, Zanini M, Hayter M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107657>
57. **An Illumination of the ICN's Core Competencies in Disaster Nursing Version 2.0: Response of advanced practice nurses to COVID-19 outbreak in China.** J. Nurs. Manag. 2020; Mao X, Yang Q, Li X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107099>
58. **Appropriate orthodontic appliances during the COVID-19 pandemic: A scoping review.** J Oral Biol Craniofac Res 2020; 10:782-787Kaur H, Kochhar AS, Gupta H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106770>
59. **Disparities and ethical considerations for children with tracheostomies during the COVID-19 pandemic.** J. Pediatr. Rehabil. Med. 2020; Kana LA, Shuman AG, Helman J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104051>
60. **Melatonin controversies, an update.** J. Pineal Res. 2020:e12702Boutin JA, Jockers R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33108677>
61. **Probiotics in Treatment of Viral Respiratory Infections and Neuroinflammatory Disorders.** Molecules 2020; 25Shahbazi R, Yasavoli-Sharahi H, Alsadi N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33105830>

62. **Building the COVID-19 Collaborative Emergency Network: a case study of COVID-19 outbreak in Hubei Province, China.** Nat Hazards (Dordr) 2020;1-31Liu J, Hao J, Shi Z, Bao HXH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100580>
63. **Management of COVID-19 in an Outpatient Dialysis Program.** Nephrol. Nurs. J. 2020; 47:423-427Noce E, Zorzanello M, Patel D, Kodali R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107714>
64. **The Emerging Role of Vitamin C in the Prevention and Treatment of COVID-19.** Nutrients 2020; 12Carr AC, Rowe S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121019>
65. **A Review of Nutrition Support Guidelines for Individuals with or Recovering from COVID-19 in the Community.** Nutrients 2020; 12Cawood AL, Walters ER, Smith TR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33105731>
66. **"Virtual Interdisciplinary COVID-19 Team": A Hospital Pandemic Preparedness Approach.** Oman Med. J. 2020; 35:e190Balkhair A, Al Jufaili M, Al Wahaibi K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110634>
67. **Fangcang shelter hospitals are a One Health approach for responding to the COVID-19 outbreak in Wuhan, China.** One Health 2020; 10:100167Wang KW, Gao J, Song XX *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117879>
68. **[Reconsidering the technical aspects and quality management background of faecal microbiota transplantation due to the novel coronavirus pandemic].** Orv. Hetil. 2020; 161:1858-1871Nagy GG, Tudlik Z, Gergely L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130602>
69. **A Public-Private Partnership Model to Build a Triage System in Response to a COVID-19 Outbreak in Hanam City, South Korea.** Osong Public Health Res Perspect 2020; 11:339-342Ku SS, Choe YJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117640>
70. **Overview of the possible role of vitamin C in management of COVID-19.** Pharmacol. Rep. 2020;1-12Abobaker A, Alzwi A, Alraied AHA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113146>
71. **Hospital admission rates, length of stay, and in-hospital mortality for common acute care conditions in COVID-19 vs. pre-COVID-19 era.** Public Health 2020; 189:6-11Butt AA, Kartha AB, Masoodi NA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126120>
72. **COVID-19 in Shanghai: IPC Policy Exploration in Support of Work Resumption Through System Dynamics Modeling.** Risk Manag. Healthc. Policy 2020; 13:1951-1963Zhao J, Jia J, Qian Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116976>
73. **Preparing for Outbreaks - Implications for Resilient Water Utility Operations and Services.** Sustain Cities Soc 2020;102558Gude VG, Muire PJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101881>
74. **Coronavirus disease (COVID-19) prevention and treatment methods and effective parameters: A systematic literature review.** Sustain Cities Soc 2021; 64:102568Rahmani AM, Mirmahaleh SYH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110743>
75. **Characteristics and evaluation of the effectiveness of monitoring and control measures for the first 69 Patients with COVID-19 from 18 January 2020 to 2 March in Wuxi, China.** Sustain Cities Soc 2021; 64:102559Shi P, Gao Y, Shen Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101882>

76. **Targeting sedentary behavior as a feasible health strategy during COVID-19.** Transl. Behav. Med. 2020; Zieff G, Bates LC, Kerr ZY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118596>
77. **A multivariate analysis of risk factors associated with death by Covid-19 in the USA, Italy, Spain, and Germany.** Z Gesundh Wiss 2020:1-7Cobre AF, Böger B, Vilhena RO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101840>

Mental – public health (104 articles)

1. **Mental Health Problems of HIV Healthcare Providers During the COVID-19 Pandemic: The Interactive Effects of Stressors and Coping.** AIDS Behav. 2020; Mi T, Yang X, Sun S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128108>
2. **Psychological tolls of COVID-19 on industry employees.** Ann Tour Res 2020:103080Chen CC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100432>
3. **Priority concerns for people with intellectual and developmental disabilities during the COVID-19 pandemic.** BJPsych Open 2020; 6:e128Tromans S, Kinney M, Chester V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118913>
4. **Comparison of Psychological Distress and Demand Induced by COVID-19 during the Lockdown Period in Patients Undergoing Peritoneal Dialysis and Hemodialysis: A Cross-Section Study in a Tertiary Hospital.** Blood Purif. 2020:1-9Xia X, Wu X, Zhou X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113536>
5. **The psychological burden experienced by Chinese citizens during the COVID-19 outbreak: prevalence and determinants.** BMC Public Health 2020; 20:1617Ren Z, Zhou Y, Liu Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109156>
6. **Knowledge, Attitudes, and Practices of Cancer Patients Towards COVID-19: A Cross-Sectional Study in Central Nepal.** Cancer Manag. Res. 2020; 12:10173-10180Sah GS, Shrestha G, Dhakal A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116872>
7. **Telephone based Interventions for Psychological Problems in Hospital Isolated Patients with COVID-19.** Clin Psychopharmacol Neurosci 2020; 18:616-620Kim JW, Stewart R, Kang SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33124594>
8. **The Psychological Impact of COVID-19 Disease is more Severe on Intensive Care Unit Healthcare Providers: A Cross-sectional Study.** Clin Psychopharmacol Neurosci 2020; 18:607-615Saracoglu KT, Simsek T, Kahraman S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33124593>
9. **Prevalence, Psychological Responses and Associated Correlates of Depression, Anxiety and Stress in a Global Population, During the Coronavirus Disease (COVID-19) Pandemic.** Community Ment. Health J. 2020:1-10Shah SMA, Mohammad D, Qureshi MFH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33108569>
10. **Variables protecting mental health in the Spanish population affected by the COVID-19 pandemic.** Curr. Psychol. 2020:1-12Robles-Bello MA, Sánchez-Teruel D, Valencia Naranjo N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106742>
11. **Perfect storm: a rheumatologist's point of view on COVID-19 infection.** Curr. Rheumatol. Rev. 2020; Kobak S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121412>
12. **Sociodemographic and psychological study on performance of students for the COVID-19 aftermath dataset.** Data Brief 2020; 33:106421Fesol SFA, Arshad

- MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102666>
13. **The COVID-ASSESS Dataset - COVID19 related Anxiety and Stresses in pregnancy, post-partum and breastfeeding during lockdown in Italy.** Data Brief 2020;106440 Raval di C, Vannacci A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102644>
 14. **Child protection: When something gets stuck.** Deutsches Arzteblatt International 2020; 117:A1732-A1734.
 15. **Psyche and COVID-19: Commitment to plurality in discourse.** Deutsches Arzteblatt International 2020; 117:A1754 Bechtold A.
 16. **The impact of the COVID-19 pandemic on mental health: early quarantine-related anxiety and its correlates among Jordanians.** East Mediterr Health J 2020; 26:1165-1172 Massad I, Al-Taher R, Massad F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103743>
 17. **Mental health status of health-care professionals working in quarantine and non-quarantine Egyptian hospitals during the COVID-19 pandemic.** East Mediterr Health J 2020; 26:1155-1164 Youssef N, Mostafa A, Ezzat R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103742>
 18. **Digital contact tracing and exposure notification: ethical guidance for trustworthy pandemic management.** Ethics Inf Technol 2020:1-10 Ranisch R, Nijssingh N, Ballantyne A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106749>
 19. **COVID-19: urgency for distancing from domestic violence.** Eur J Psychotraumatol 2020; 11:1800245 Ertan D, El-Hage W, Thierrée S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110483>
 20. **The Design, Implementation, and Acceptability of a Telehealth Comprehensive Recovery Service for People With Complex Psychosis Living in NYC During the COVID-19 Crisis.** Front Psychiatry 2020; 11:581149 Lynch DA, Medalia A, Saperstein A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101093>
 21. **Psychopathological Burden and Quality of Life in Substance Users During the COVID-19 Lockdown Period in Italy.** Front Psychiatry 2020; 11:572245 Martinotti G, Alessi MC, Di Natale C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101086>
 22. **The Influence of Telemedicine Care on the Management of Behavioral and Psychological Symptoms in Dementia (BPSD) Risk Factors Induced or Exacerbated During the COVID-19 Pandemic.** Front Psychiatry 2020; 11:577629 Soares WB, Silvestre IT, Lima AMO, de Almondes KM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101090>
 23. **Interactions Between Socioeconomic Status and Mental Health Outcomes in the Nigerian Context Amid COVID-19 Pandemic: A Comparative Study.** Front. Psychol. 2020; 11:559819 Agberotimi SF, Akinsola OS, Oguntayo R, Olaseni AO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117227>
 24. **Stressors and Resources for Healthcare Professionals During the Covid-19 Pandemic: Lesson Learned From Italy.** Front. Psychol. 2020; 11:2179 Barelli S, Palamenghi L, Graffigna G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117208>
 25. **Wearing Face Masks Strongly Confuses Counterparts in Reading Emotions.** Front. Psychol. 2020; 11:566886 Carbon CC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101135>
 26. **The Effect of COVID-19 on Loneliness in the Elderly. An Empirical Comparison of Pre-and Peri-Pandemic Loneliness in Community-Dwelling Elderly.** Front.

- Psychol. 2020; 11:585308Heidinger T, Richter L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101154>
27. **Parents and Children During the COVID-19 Lockdown: The Influence of Parenting Distress and Parenting Self-Efficacy on Children's Emotional Well-Being.** Front. Psychol. 2020; 11:584645Morelli M, Cattellino E, Baiocco R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33123063>
 28. **Emotional, Behavioral, and Psychological Impact of the COVID-19 Pandemic.** Front. Psychol. 2020; 11:566212Pedrosa AL, Bitencourt L, Fróes ACF *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33117234>
 29. **Pandemic Dreams: Network Analysis of Dream Content During the COVID-19 Lockdown.** Front. Psychol. 2020; 11:573961Pesonen AK, Lipsanen J, Halonen R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117240>
 30. **Stay at Home and Teach: A Comparative Study of Psychosocial Risks Between Spain and Mexico During the Pandemic.** Front. Psychol. 2020; 11:566900Prado-Gascó V, Gómez-Domínguez MT, Soto-Rubio A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101136>
 31. **Psychological Behavior of Frontline Medical Staff in the Use of Preventive Medication for COVID-19: A Cross-Sectional Study.** Front. Psychol. 2020; 11:2104Yu X, Li Y, Tang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101103>
 32. **Relationship Between Psychological Responses and the Appraisal of Risk Communication During the Early Phase of the COVID-19 Pandemic: A Two-Wave Study of Community Residents in China.** Front Public Health 2020; 8:550220Jin Z, Zhao KB, Xia YY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102420>
 33. **Transitioning Between Online Gambling Modalities and Decrease in Total Gambling Activity, but No Indication of Increase in Problematic Online Gambling Intensity During the First Phase of the COVID-19 Outbreak in Sweden: A Time Series Forecast Study.** Front Public Health 2020; 8:554542Lindner P, Forsström D, Jonsson J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33117770>
 34. **The impact of the COVID-19 pandemic on help-seeking behaviors in individuals suffering from eating disorders and their caregivers.** Gen. Hosp. Psychiatry 2020; 67:136-140Richardson C, Patton M, Phillips S, Paslakis G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33129138>
 35. **Social Isolation and Psychological Distress During the COVID-19 Pandemic: A Cross-National Analysis.** Gerontologist 2020; Kim HH, Jung JH.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33125065>
 36. **Challenges and needs for social behavioural research and community engagement activities during the COVID-19 pandemic in rural Mozambique.** Glob Public Health 2020;1-5Magaço A, Munguambe K, Nhacolo A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33125306>
 37. **The psychological typhoon eye effect during the COVID-19 outbreak in China: the role of coping efficacy and perceived threat.** Global Health 2020; 16:105Zhang L, Ma M, Li D, Xin Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109228>
 38. **COVID-19: Racism Is Like That.** Health Equity 2020; 4:443-445Brown EA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33111030>

39. **Triggers of mental health problems among frontline healthcare workers during the COVID-19 pandemic in private care homes and domiciliary care agencies: Lived experiences of care workers in the Midlands region, UK.** Health Soc Care Community 2020; Nyashanu M, Pfende F, Ekpenyong MS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33107131>
40. **Health inequality experienced by the socially disadvantaged populations during the outbreak of COVID-19 in Hong Kong: An interaction with social inequality.** Health Soc Care Community 2020; Siu JY.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33125773>
41. **Insomnia, Perceived Stress, and Family Support among Nursing Staff during the Pandemic Crisis.** Healthcare (Basel) 2020; 8Tselebis A, Lekka D, Sikaras C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114662>
42. **Assessment of the Anxiety Level of Andalusian Podiatrists during the COVID-19 Pandemic: The Increase Phase.** Healthcare (Basel) 2020; 8Vilar-Palomo S, Pabón-Carrasco M, Gonzalez-Elena ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114550>
43. **Global scenario, public health concerns and mitigation strategies to counter current ongoing SARS-CoV-2 / COVID-19 pandemic.** Hum Vaccin Immunother 2020;1-11Barbuddhe SB, Rawool DB, Gaonkar PP *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33121328>
44. **Perceived psychosocial health and its sociodemographic correlates in times of the COVID-19 pandemic: a community-based online study in China.** Infect Dis Poverty 2020; 9:148Wang GY, Tang SF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106187>
45. **Knowledge, Attitude, and Practice of High-Risk Age Groups to Coronavirus Disease-19 Prevention and Control in Korem District, Tigray, Ethiopia: Cross-Sectional Study.** Infect Drug Resist 2020; 13:3801-3809Adhena G, Hidru HD.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33122925>
46. **Development and Psychometric Testing of the Self-Care in COVID-19 (SCOID) Scale, an Instrument for Measuring Self-Care in the COVID-19 Pandemic.** Int J Environ Res Public Health 2020; 17De Maria M, Ferro F, Ausili D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114651>
47. **COVID-19-Related Mental Health Effects in the Workplace: A Narrative Review.** Int J Environ Res Public Health 2020; 17Giorgi G, Lecca LI, Alessio F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33120930>
48. **Personnel Well-Being in the Helsinki University Hospital during the COVID-19 Pandemic-A Prospective Cohort Study.** Int J Environ Res Public Health 2020; 17Haravuori H, Junttila K, Haapa T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126583>
49. **A Renewed Outbreak of the COVID-19 Pandemic: A Longitudinal Study of Distress, Resilience, and Subjective Well-Being.** Int J Environ Res Public Health 2020; 17Kimhi S, Eshel Y, Marciano H, Adini B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33113914>
50. **Psychotherapy by Telephone or Internet in Austria and Germany Which CBT Psychotherapists Rate It more Comparable to Face-to-Face Psychotherapy in Personal Contact and Have more Positive Actual Experiences Compared to Previous Expectations?** Int J Environ Res Public Health 2020; 17Korecka N, Rabenstein R, Pieh C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114136>

51. **Travel Anxiety, Risk Attitude and Travel Intentions towards "Travel Bubble" Destinations in Hong Kong: Effect of the Fear of COVID-19.** *Int J Environ Res Public Health* 2020; 17Luo JM, Lam CF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120949>
52. **What Factors Drive the Satisfaction of Citizens on Governments' Responses to COVID-19?** *Int J Infect Dis* 2020; Chen CWS, Lee S, Dong MC, Taniguchi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115678>
53. **A Large-Scale Survey on Trauma, Burnout, and Posttraumatic Growth among Nurses during the COVID-19 Pandemic.** *Int. J. Ment. Health Nurs.* 2020; Chen R, Sun C, Chen JJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107677>
54. **Anxiety and depression in frontline health care workers during the outbreak of Covid-19.** *Int J Soc Psychiatry* 2020:20764020968119Xing LQ, Xu ML, Sun J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100114>
55. **Rapid report 2: Symptoms of anxiety and depression during the first 12 weeks of the Coronavirus (COVID-19) pandemic in Australia.** *Internet Interv* 2020; 22:100351Staples L, Nielssen O, Kayrouz R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110762>
56. **The Psychological Impacts of COVID-19: A Study of Frontline Physicians and Nurses in the Arab World.** *Ir. J. Psychol. Med.* 2020:1-17Al Mahyijari N, Badahdah AM, Khamis F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109291>
57. **The COVID-19 pandemic and serious psychological consequences in Bangladesh: A population-based nationwide study.** *J. Affect. Disord.* 2020; 279:462-472Mamun MA, Sakib N, Gozal D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120247>
58. **Increased Psychological Distress during COVID-19 and Quarantine in Ireland: A National Survey.** *J Clin Med* 2020; 9Burke T, Berry A, Taylor LK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126707>
59. **Impact of Timely Public Health Measures on Kidney Transplantation in Austria during the SARS-CoV-2 Outbreak-A Nationwide Analysis.** *J Clin Med* 2020; 9Watschinger B, Watschinger C, Reindl-Schwaighofer R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126481>
60. **How the COVID-19 pandemic has changed our lives: A study of psychological correlates across 59 countries.** *J. Clin. Psychol.* 2020; Alzueta E, Perrin P, Baker FC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128795>
61. **From Pandemic to Progression: An Educational Framework for the Implementation of Virtual Mental Healthcare for Children and Youth as a Response to COVID-19.** *J Contemp Psychother* 2020:1-7Doan BT, Yang YB, Romanchych E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110276>
62. **The impact of the COVID-19 pandemic on European police officers: Stress, demands and coping resources.** *J Crim Justice* 2020:101756Frenkel MO, Giessing L, Egger-Lampl S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100418>
63. **Psychological impact of the coronavirus disease 2019 (COVID-19) pandemic on dental students: A nationwide study.** *J. Dent. Educ.* 2020; Hakami Z, Khanagar SB, Vishwanathaiah S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128397>
64. **Changing agendas and priorities of public health associations across the globe following in the era of COVID-19 pandemic-A mini-review.** *J Family Med*

- Prim Care 2020; 9:3838-3842Al-Khateeb BF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110776>
65. **Primary care physician's approach for mental health impact of COVID-19.** J Family Med Prim Care 2020; 9:3189-3194Rohilla J, Tak P, Jhanwar S, Hasan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102268>
 66. **Preparedness, perceived impact and concerns of health care workers in a teaching hospital during coronavirus disease 2019 (COVID-19).** J Family Med Prim Care 2020; 9:4247-4251Saurabh K, Ranjan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110840>
 67. **The prevalence of psychological consequences of COVID-19: A systematic review and meta-analysis of observational studies.** J Health Psychol 2020:1359105320966639Arora T, Grey I, Östlundh L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118376>
 68. **Psychological symptoms of the outbreak of the COVID-19 confinement in Spain.** J Health Psychol 2020:1359105320967086Odriozola-González P, Planchuelo-Gómez Á, Irturia MJ, de Luis-García R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33124471>
 69. **COVID-19: Social Work's Opportunity to Revitalize Advocacy for a Universal, Single-Payer Healthcare System.** J Hum Rights Soc Work 2020:1-7Yingling ME. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110937>
 70. **COVID-19 Outbreak and Its Association with Healthcare Workers' Emotional Stress: a Cross-Sectional Study.** J Korean Med Sci 2020; 35:e372Park C, Hwang JM, Jo S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107230>
 71. **Loneliness, Mental Health, and Substance Use among US Young Adults during COVID-19.** J. Psychoactive Drugs 2020:1-9Horigan VE, Schmidt RD, Feaster DJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111650>
 72. **Effect of COVID-19 on Mental Health Rehabilitation Centers.** J Psychosoc Rehabil Ment Health 2020:1-4Aamir A, Awan S, de Filippis R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106766>
 73. **Rehabilitation During a Pandemic: Psychiatrists as First Responders?** J Psychosoc Rehabil Ment Health 2020:1-2Cave J, Crews M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110740>
 74. **Stay-at-home circumstances do not produce sleep disorders: An international survey during the COVID-19 pandemic.** J. Psychosom. Res. 2020; 139:110282Roitblat Y, Burger J, Leit A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130483>
 75. **Domestic violence challenge and COVID-19 pandemic.** J Public Health Res 2020; 9:1853Nojomi M, Babaee E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117759>
 76. **A commentary on the impact of COVID-19 on engagement of youth with substance use and co-occurring psychiatric disorders.** J. Subst. Abuse Treat. 2020:108175Bagley SM, Hadland SE, Yule AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127195>
 77. **Online digital recovery support services: An overview of the science and their potential to help individuals with substance use disorder during COVID-19 and beyond.** J. Subst. Abuse Treat. 2020:108152Bergman BG, Kelly JF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129636>
 78. **COVID-19-related treatment service disruptions among people with single- and polysubstance use concerns.** J. Subst. Abuse Treat. 2020:108180Mellis AM,

- Potenza MN, Hulsey JN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127196>
79. **COVID-19 and psychiatric illness: rectal foreign bodies (30 stylus batteries) in a young male patient affected by Asperger syndrome.** *J Surg Case Rep* 2020; 2020:rjaa345Lovisetto F, Guala A, Facciotto G, Zonta S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101637>
80. **Role of Emotion in Excessive Use of Twitter During COVID-19 Imposed Lockdown in India.** *J Technol Behav Sci* 2020;1-8Arora A, Chakraborty P, Bhatia MPS, Mittal P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102690>
81. **Risk and Protective Factors for Prospective Changes in Adolescent Mental Health during the COVID-19 Pandemic.** *J. Youth Adolesc.* 2020;1-14Magson NR, Freeman JYA, Rapee RM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33108542>
82. **Mental health of people in Australia in the first month of COVID-19 restrictions: a national survey.** *Med. J. Aust.* 2020; Fisher JR, Tran TD, Hammarberg K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107063>
83. **Mental health and COVID-19: are we really all in this together?** *Med. J. Aust.* 2020; McGorry P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107074>
84. **Mental health of forensic odontologists in Covid-19: An Indian perspective.** *Med. Leg. J.* 2020;25817220965377Johnson A, Parekh U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107772>
85. **Gender-related time course of sleep disturbances and psychological symptoms during the COVID-19 lockdown: A longitudinal study on the Italian population.** *Neurobiol Stress* 2020;100259Salfi F, Lauriola M, Amicucci G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102641>
86. **[Position paper of the Austrian Alzheimer Association (Österreichische Alzheimer Gesellschaft, ÖAG) : Effects of the COVID-19 pandemic in Austria on people with dementia and their care environment-problem areas, recommendations, and strategies].** *Neuropsychiatr.* 2020; Defrancesco M, Banher C, Dal-Bianco P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123943>
87. **E-learning: Depression, anxiety, and stress symptomatology among Lebanese university students during COVID-19 quarantine.** *Nurs. Forum* 2020; Fawaz M, Samaha A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125744>
88. **Health-Related Quality of Life and its Associated Factors in COVID-19 Patients.** *Osong Public Health Res Perspect* 2020; 11:296-302Arab-Zozani M, Hashemi F, Safari H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117634>
89. **Staying on track in turbulent times: Trait self-control and goal pursuit during self-quarantine.** *Pers. Individ. Dif.* 2021; 170:110454Kokkoris MD, Stavrova O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100454>
90. **Self-compassion and life-satisfaction among Chinese self-quarantined residents during COVID-19 pandemic: A moderated mediation model of positive coping and gender.** *Pers. Individ. Dif.* 2021; 170:110457Li A, Wang S, Cai M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100455>
91. **State anxiety levels of nurses providing care to patients with COVID-19 in Turkey.** *Perspect. Psychiatr. Care* 2020; Bahadir-Yilmaz E, Yüksel A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103790>
92. **The effect of coronavirus (COVID-19) outbreak on the mental well-being and mental health of individuals.** *Perspect. Psychiatr. Care* 2020; Sümen A, Adibelli D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103787>

93. **Association between state stay-at-home orders and risk reduction behaviors and mental distress amid the COVID-19 pandemic.** Prev. Med. 2020;106299Liu Y, Mattke S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129909>
94. **Posttraumatic stress disorder symptoms in healthcare workers after the peak of the COVID-19 outbreak: A survey of a large tertiary care hospital in Wuhan.** Psychiatry Res 2020; 294:113541Zhang H, Shi Y, Jing P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128999>
95. **Depression and Coping Among COVID-19-Infected Individuals After 10 Days of Mandatory in-Hospital Quarantine, Irbid, Jordan.** Psychol. Res. Behav. Manag. 2020; 13:823-830Samrah SM, Al-Mistarehi AH, Aleshawi AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116970>
96. **Child Protection: A Guide for Navigating a Disclosure of Sexual Abuse in Rhode Island Amid the COVID-19 Pandemic.** R I Med J (2013) 2020; 103:47-51Manickam S, Slingsby B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126789>
97. **A less objectionable greed? Work-life conflict and unjust pay during a pandemic.** Res Soc Stratif Mobil 2021; 71:100564Schieman S, Narisada A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110284>
98. **[Confined community health: Reflections and experiences from the local public health.].** Rev. Esp. Salud Publica 2020; 94. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33124619>
99. **[COVID-19 in Spain: the psychological impact of the pandemic on nurses].** Rev. Infirm. 2020; 69:33-35Fernández V, Bouchard JP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129475>
100. **Weaving public health and safety nets to respond the COVID-19 pandemic.** Saf Sci 2021; 134:105058Fan D, Li Y, Liu W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110294>
101. **Sleep quality during the COVID-19 pandemic: not one size fits all.** Sleep Med. 2020; 76:86-88Kocevska D, Blanken TF, Van Someren EJW, Rösler L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126035>
102. **Anticipated Effects of the Covid-19 Pandemic on Family Members Affected by Addiction.** Sucht 2020; 66:201-206Bischof G, Velleman R, Bischof A, Orford JJ.
103. **Remote-learning, time-use, and mental health of Ecuadorian high-school students during the COVID-19 quarantine.** World Dev 2021; 138:105225Asanov I, Flores F, McKenzie D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110286>
104. **Public Support for Development Aid during the COVID-19 Pandemic.** World Dev 2020;105248Kobayashi Y, Heinrich T, Bryant KA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106725>

Meta-analyses - systematic reviews (21 articles)

1. **Rheumatic manifestations of COVID-19: a systematic review and meta-analysis.** BMC Rheumatol 2020; 4:65Ciaffi J, Meliconi R, Ruscitti P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123675>
2. **"Impact of Corticosteroids in COVID-19 Outcomes: Systematic Review and Meta-Analysis".** Chest 2020; Cano EJ, Fuentes XF, Campioli CC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129791>
3. **The relationship between severe or dead COVID-19 and asthma: a meta-analysis.** Clin. Exp. Allergy 2020; Wang Y, Ao G, Qi X, Ma M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33131117>

4. **Dose-response Relation Deduced for Coronaviruses from COVID-19, SARS and MERS Meta-analysis Results and its Application for Infection Risk Assessment of Aerosol Transmission.** Clin Infect Dis 2020; Zhang X, Wang J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119733>
5. **Re -Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis.** Clin Microbiol Infect 2020; Vedrines N, Bouthors AT, Gayet S, Lacout A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129929>
6. **Incidence of Myocardial Injury in COVID-19-Infected Patients: A Systematic Review and Meta-Analysis.** Diseases 2020; 8Prasitlumkum N, Chokesuwattanaskul R, Thongprayoon C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120956>
7. **A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19.** Eur. J. Cancer 2020; 141:92-104Yekedüz E, Utkan G, Ürün Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130550>
8. **The Impact of COVID-19 on Blood Glucose: A Systematic Review and Meta-Analysis.** Front. Endocrinol. (Lausanne) 2020; 11:574541Chen J, Wu C, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123093>
9. **Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis.** Front Med (Lausanne) 2020; 7:586221Boregowda U, Perisetti A, Nanjappa A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123544>
10. **Association of Peripheral Lymphocyte and the Subset Levels With the Progression and Mortality of COVID-19: A Systematic Review and Meta-Analysis.** Front Med (Lausanne) 2020; 7:558545Lu Q, Wang Z, Yin Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102499>
11. **Stroke and Novel Coronavirus Infection in Humans: A Systematic Review and Meta-Analysis.** Front. Neurol. 2020; 11:579070Lee KW, Yusof Khan AHK, Ching SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123082>
12. **EXPRESS: Stroke in COVID-19: a systematic review and meta-analysis.** Int. J. Stroke 2020;1747493020972922Nannoni S, de Groot R, Bell S, Markus HS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103610>
13. **Identification of therapeutic drugs against COVID-19 through computational investigation on drug repurposing and structural modification.** J. Biomed. Res. 2020;1-12Yun Y, Song H, Ji Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33122473>
14. **Circulating Levels of Interleukin-6 and Interleukin-10, But Not Tumor Necrosis Factor-Alpha, as Potential Biomarkers of Severity and Mortality for COVID-19: Systematic Review with Meta-analysis.** J. Clin. Immunol. 2020;1-12Udomsinprasert W, Jittikoon J, Sangroongruangsri S, Chaikledkaew U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128665>
15. **The prevalence of psychological consequences of COVID-19: A systematic review and meta-analysis of observational studies.** J Health Psychol 2020;1359105320966639Arora T, Grey I, Östlundh L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118376>
16. **Exploring the experiences of siblings of adults with intellectual/developmental disabilities during the COVID-19 pandemic.** J. Intellect. Disabil. Res. 2020; Redquest BK, Tint A, Ries H, Lunsky Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33124773>

17. **Guillain-Barré syndrome associated with SARS-CoV-2 infection: a systematic review and individual participant data meta-analysis.** J. Peripher. Nerv. Syst. 2020; Hasan I, Saif-Ur-Rahman KM, Hayat S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33112450>
18. **COVID-19 Patients: A Systematic Review and Meta-Analysis of Laboratory Findings, Comorbidities, and Clinical Outcomes Comparing Medical Staff versus the General Population.** Osong Public Health Res Perspect 2020; 11:269-279 Ebrahimi M, Malehi AS, Rahim F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117631>
19. **Psychological impact of isolation due to COVID-19 among young and fit dormitory residents.** Psychol. Med. 2020:1-2 Gosavi TD, Koh JS, Rosman M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100235>
20. **Efficacy and safety of remdesivir in hospitalized Covid-19 patients: Systematic review and meta-analysis including network meta-analysis.** Rev Med Virol 2020:e2187 Elsayah HK, Elsokary MA, Abdallah MS, ElShafie AH.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33128490>
21. **Corticosteroids in COVID-19: Is it Rational? A Systematic Review and Meta-Analysis.** SN Compr Clin Med 2020:1-21 Budhathoki P, Shrestha DB, Rawal E, Khadka S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103063>

Mortality (40 articles)

1. **Dual disorders and suicide during and following the COVID-19 pandemic.** Acta Neuropsychiatr. 2020:1-4 Sher L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106193>
2. **Case Fatality Rates for COVID-19 Patients Requiring Invasive Mechanical Ventilation: A Meta-analysis.** Am J Respir Crit Care Med 2020; Lim ZJ, Subramaniam A, Reddy MP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119402>
3. **A survival analysis of COVID-19 in the Mexican population.** BMC Public Health 2020; 20:1616 Salinas-Escudero G, Carrillo-Vega MF, Granados-García V *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33109136>
4. **Multivariate mortality analyses in COVID-19: Comparing patients with cancer and patients without cancer in Louisiana.** Cancer 2020; Lunski MJ, Burton J, Tawagi K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33112411>
5. **The relationship between severe or dead COVID-19 and asthma: a meta-analysis.** Clin. Exp. Allergy 2020; Wang Y, Ao G, Qi X, Ma M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33131117>
6. **SARS-CoV-2 infection fatality rate among elderly retired Danish blood donors - A cross-sectional study.** Clin Infect Dis 2020; Pedersen OB, Nissen J, Dinh KM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103182>
7. **COVID-19 mortality: Full heparinization.** Deutsches Arzteblatt International 2020; 117:A1873 Kiesewetter H.
8. **COVID-19 lethality: Lethality instead of mortality.** Deutsches Arzteblatt International 2020; 117:A1930 Runne U.
9. **Predictors of mortality in patients with COVID-19 - a systematic review.** Eur J Integr Med 2020:101226 Mehraeen E, Karimi A, Barzegary A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101547>

10. **Predictors of mortality in patients with COVID-19-a systematic review.** Eur J Integr Med 2020; 40:101226 Mehraeen E, Karimi A, Barzegary A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101547>
11. **COVID-19 Lethality in Sub-Saharan Africa and Helminth Immune Modulation.** Front. Immunol. 2020; 11:574910 Fonte L, Acosta A, Sarmiento ME *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33117371>
12. **Individual-Level Fatality Prediction of COVID-19 Patients Using AI Methods.** Front Public Health 2020; 8:587937 Li Y, Horowitz MA, Liu J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33102426>
13. **Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: results of the ACE-CoV study.** Fundam. Clin. Pharmacol. 2020; Lafaurie M, Martin-Blondel G, Delobel P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111329>
14. **Clinical manifestations and factors associated with mortality from COVID-19 in older adults: Retrospective population-based study with 9807 older Brazilian COVID-19 patients.** Geriatr Gerontol Int 2020; de Souza CD, de Arruda Magalhães AJ, Lima AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111433>
15. **Hematologic predictors of mortality in hospitalized patients with COVID-19: a comparative study.** Hematology 2020; 25:383-388 Mousavi SA, Rad S, Rostami T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33124971>
16. **Diabetes is associated with increased risk for in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis comprising 18,506 patients.** Hormones (Athens) 2020; 1-10 Palaiodimos L, Chamorro-Pareja N, Karamanis D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123973>
17. **SARS-CoV 2 (Covid-19) Heterogeneous Mortality Rates across Countries May Be Partly Explained by Life Expectancy, Calorie Intake, and Prevalence of Diabetes.** Hum. Ecol. Interdiscip. J. 2020; 1-6 Nkhata SG, Ngoma TN, Chilenga PM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100471>
18. **Filling the gaps in the characterization of the clinical management of COVID-19: 30-day hospital admission and fatality rates in a cohort of 118 150 cases diagnosed in outpatient settings in Spain.** Int J Epidemiol 2020; Prieto-Alhambra D, Balló E, Coma E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118037>
19. **Health Care Worker Infections and Deaths due to COVID-9: A Survey from 37 Nations and a Call for WHO to Post National Data on their Website.** Int J Infect Dis 2020; Erdem H, Lucey DR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130210>
20. **Covid-19 cumulative incidence, intensive care and mortality in Italian regions compared to selected European countries.** Int J Infect Dis 2020; Olivieri A, Palù G, Sebastiani G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130199>
21. **A cohort study of 30 day mortality after NON-EMERGENCY surgery in a COVID-19 cold site.** Int J Surg 2020; 84:57-65 Kasivisvanathan V, Lindsay J, Rakshani-Moghadam S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33122153>
22. **An unexplained death after routine cardiac surgery: how long have we dealt with coronavirus disease 2019?** Interact. Cardiovasc. Thorac. Surg. 2020; Varela Barca L, Torralba Cloquell I, Herrero Cereceda J, Sáez de Ibarra JI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130891>
23. **Identification of county-level health factors associated with COVID-19 mortality in the United States.** J. Biomed. Res. 2020; 1-9 Pan W, Miyazaki Y,

- Tsumura H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109778>
24. **Subgroup comparison of COVID-19 case and mortality with associated factors in Mississippi: findings from analysis of the first four months of public data.** J. Biomed. Res. 2020;1-12Zhang L, McLeod ST, Vargas R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100275>
 25. **Circulating Levels of Interleukin-6 and Interleukin-10, But Not Tumor Necrosis Factor-Alpha, as Potential Biomarkers of Severity and Mortality for COVID-19: Systematic Review with Meta-analysis.** J. Clin. Immunol. 2020;1-12Udomsinprasert W, Jittikoon J, Sangroongruangsri S, Chaikledkaew U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128665>
 26. **Inhaled Corticosteroids and COVID-19 Risk and Mortality: A Nationwide Cohort Study.** J Clin Med 2020; 9Choi JC, Jung SY, Yoon UA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114246>
 27. **The Role of COVID-19 in the Death of SARS-CoV-2-Positive Patients: A Study Based on Death Certificates.** J Clin Med 2020; 9Grippo F, Navarra S, Orsi C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121176>
 28. **It's X-Related: Biological Bases of Increased COVID-19 Morbidity and Mortality in Men.** J Endocr Soc 2020; 4:bvaa133Angelides PK, Jindal I, Karaviti L, Geffner ME. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117953>
 29. **Community-based palliative care during the COVID 19 pandemic.** J Family Med Prim Care 2020; 9:3169-3175Atreya S, Kumar R, Salins N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102264>
 30. **Clinical Characteristics and Risk Factors for Mortality in Very Old Patients Hospitalized with COVID-19 in Spain.** J Gerontol A Biol Sci Med Sci 2020; Ramos-Rincon JM, Buonaiuto V, Ricci M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103720>
 31. **Case report: a fatal combination of hemophagocytic lymphohistiocytosis with extensive pulmonary microvascular damage in COVID-19 pneumonia.** J. Hematop. 2020;1-5von der Thüsen JH, van Bommel J, Kros JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110452>
 32. **An Ecologic Study of Disparities in COVID-19 Incidence and Case Fatality in Oakland County, MI, USA, During a State-Mandated Shutdown.** J Racial Ethn Health Disparities 2020;1-8Akanbi MO, Rivera AS, Akanbi FO, Shoyinka A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33124003>
 33. **Testing the Accuracy of the ARIMA Models in Forecasting the Spreading of COVID-19 and the Associated Mortality Rate.** Medicina (Kaunas) 2020; 56Ilie OD, Ciobica A, Doroftei B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121072>
 34. **More than Pneumonia: Distinctive Features of SARS-Cov-2 Infection. From Autopsy Findings to Clinical Implications: A Systematic Review.** Microorganisms 2020; 8D'Errico S, Zanon M, Montanaro M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114061>
 35. **Geospatial Distribution and Predictors of Mortality in Hospitalized Patients With COVID-19: A Cohort Study.** Open Forum Infect Dis 2020; 7:ofaa436. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117852>
 36. **The Liver in COVID-19-Related Death: Protagonist or Innocent Bystander?** Pathobiology 2020;1-7Schmit G, Lelotte J, Vanhaebost J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33108789>
 37. **Hospital admission rates, length of stay, and in-hospital mortality for common acute care conditions in COVID-19 vs. pre-COVID-19 era.** Public Health 2020;

- 189:6-11 Butt AA, Kartha AB, Masoodi NA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33126120>
38. **Risk factors for mortality among hospitalized patients with COVID-19. An overview in Mexican population.** Tuberc Respir Dis (Seoul) 2020; Cortés-Tellés A, López-Romero S, Mancilla-Ceballos R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121231>
39. **Excess deaths from COVID-19 correlate with age and socio-economic status. A database study in the Stockholm region.** Ups. J. Med. Sci. 2020; 125:297-304 Strang P, Fürst P, Schultz T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100083>
40. **A multivariate analysis of risk factors associated with death by Covid-19 in the USA, Italy, Spain, and Germany.** Z Gesundh Wiss 2020:1-7 Cobre AF, Böger B, Vilhena RO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101840>

Online – IT – Apps (68 articles)

1. **[Development of an information website on the proper use of medicines during the pandemic].** Actual. Pharm. 2020; 59:34-39.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100495>
2. **[Covigie, a platform for caregivers and care team coordinators].** Actual. Pharm. 2020; 59:54-56 Piraux A, Mosnier A, Barthelmé T.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100500>
3. **Virtualising the School During COVID-19 and Beyond in Africa: Infrastructure, Pedagogy, Resources, Assessment, Quality Assurance, Student Support System, Technology, Culture and Best Practices.** Adv Med Educ Pract 2020; 11:755-759 Owolabi JO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117046>
4. **Artificial intelligence in medicine and the disclosure of risks.** AI Soc 2020:1-9 Kiener M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110296>
5. **Telemedicine, Patient Satisfaction, and Chronic Rhinosinusitis Care in the Era of COVID-19.** Am J Rhinol Allergy 2020:1945892420970460 Morisada MV, Hwang J, Gill AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115249>
6. **Comparing Chinese and US practitioners' attitudes towards teletherapy during the COVID-19 pandemic.** Asia Pac Psychiatry 2020:e12441 Wang X, Gordon RM, Snyder EW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33108828>
7. **Wearable electrochemical biosensors in North America.** Biosens. Bioelectron. 2020; 172:112750 Min J, Sempionatto JR, Teymourian H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33129072>
8. **Student satisfaction with videoconferencing teaching quality during the COVID-19 pandemic.** BMC Med. Educ. 2020; 20:396 Fatani TH.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33129295>
9. **Forecasting spread of COVID-19 using Google Trends: A hybrid GWO-Deep learning approach.** Chaos Solitons Fractals 2020:110336 Prasanth S, Singh U, Kumar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110297>
10. **Hybrid Telehealth Medical Retina Clinic Due to Provider Exposure and Quarantine During COVID-19 Pandemic.** Clin. Ophthalmol. 2020; 14:3421-3426 Aweidah H, Safadi K, Jotkowitz A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116394>
11. **Telephone based Interventions for Psychological Problems in Hospital Isolated Patients with COVID-19.** Clin Psychopharmacol Neurosci 2020; 18:616-

- 620Kim JW, Stewart R, Kang SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33124594>
12. **"Show this thread": policing, disruption and mobilisation through Twitter. An analysis of UK law enforcement tweeting practices during the Covid-19 pandemic.** *Crime Sci* 2020; 9:20Nikolovska M, Johnson SD, Ekblom P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106764>
 13. **Online portal-based system for improving patient-generated photographs for teledermatology.** *Dermatol Ther* 2020; Su MY, Trefrey BL, Smith GP, Das S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107093>
 14. **Digital contact tracing and exposure notification: ethical guidance for trustworthy pandemic management.** *Ethics Inf Technol* 2020:1-10Ranisch R, Nijssingh N, Ballantyne A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106749>
 15. **The accuracy of teleradiologists in diagnosing COVID-19 based on a French multicentric emergency cohort.** *Eur Radiol* 2020; Nivet H, Crombé A, Schuster P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123790>
 16. **Telemedicine in Oncology: Delivering on an Overdue Promise in the COVID-19 Era.** *Front. Oncol.* 2020; 10:578888West HJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102236>
 17. **The Design, Implementation, and Acceptability of a Telehealth Comprehensive Recovery Service for People With Complex Psychosis Living in NYC During the COVID-19 Crisis.** *Front Psychiatry* 2020; 11:581149Lynch DA, Medalia A, Saperstein A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101093>
 18. **The Influence of Telemedicine Care on the Management of Behavioral and Psychological Symptoms in Dementia (BPSD) Risk Factors Induced or Exacerbated During the COVID-19 Pandemic.** *Front Psychiatry* 2020; 11:577629Soares WB, Silvestre IT, Lima AMO, de Almondes KM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101090>
 19. **Understanding Knowledgeable Workers' Behavior Toward COVID-19 Information Sharing Through WhatsApp in Pakistan.** *Front. Psychol.* 2020; 11:572526Islam T, Mahmood K, Sadiq M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117239>
 20. **Use of Data Mining to Determine Usage Patterns of an Online Evaluation Platform During the COVID-19 Pandemic.** *Front. Psychol.* 2020; 11:588843Reigal RE, Pastrana-Brincones JL, González-Ruiz SL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101157>
 21. **COVID-19 and Distance Learning: Effects on Georgia State University School of Public Health Students.** *Front Public Health* 2020; 8:576227Armstrong-Mensah E, Ramsey-White K, Yankey B, Self-Brown S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102425>
 22. **Rapidly scaling video visits during COVID-19: The ethos of virtual care at Yale Medicine.** *Healthc (Amst)* 2020; 8:100482Hoffman PE, London YR, Weerakoon TS, DeLucia NL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129179>
 23. **Digital triage: Novel strategies for population health management in response to the COVID-19 pandemic.** *Healthc (Amst)* 2020; 8:100493Lai L, Wittbold KA, Dadabhoy FZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129176>
 24. **The reality of virtual care: Implications for cancer care beyond the pandemic.** *Healthc (Amst)* 2020; 8:100480Rodin D, Lovas M, Berlin A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129178>

25. **Impact of the COVID-19 lockdown on digital device-related ocular health.** Indian J Ophthalmol 2020; 68:2378-2383Bahkir FA, Grandee SS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33120622>
26. **Applying computer simulations in battling with COVID-19, using pre-analyzed molecular and chemical data to face the pandemic.** Inform Med Unlocked 2020; 21:100458Khazeei Tabari MA, Khoshhal H, Tafazoli A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33102687>
27. **Psychotherapy by Telephone or Internet in Austria and Germany Which CBT Psychotherapists Rate It more Comparable to Face-to-Face Psychotherapy in Personal Contact and Have more Positive Actual Experiences Compared to Previous Expectations?** Int J Environ Res Public Health 2020; 17Korecka N, Rabenstein R, Pieh C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114136>
28. **Test@Work Texts: Mobile Phone Messaging to Increase Awareness of HIV and HIV Testing in UK Construction Employees during the COVID-19 Pandemic.** Int J Environ Res Public Health 2020; 17Middleton M, Somerset S, Evans C, Blake H.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33114546>
29. **Analysis of Availability of Online Dermatology Appointments During COVID-19.** J Am Acad Dermatol 2020; Gu L, Xiang L, Lipner S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33127378>
30. **Virtual Care Expansion in the Veterans Health Administration During the COVID-19 Pandemic: Clinical Services and Patient Characteristics Associated with Utilization.** J Am Med Inform Assoc 2020; Ferguson JM, Jacobs J, Yefimova M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125032>
31. **FLANNEL: Focal Loss Based Neural Network Ensemble for COVID-19 Detection.** J Am Med Inform Assoc 2020; Qiao Z, Bae A, Glass LM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33125051>
32. **Impact of COVID-19 Quarantine on Advanced Hemorrhoidal Disease and the Role of Telemedicine in Patient Management.** J Clin Med 2020; 9Campennì P, Marra AA, Ferri L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113796>
33. **Development, Implementation, and Results from a COVID-19 Messaging Campaign to Promote Health Care Seeking Behaviors Among Community Clinic Patients.** J. Community Health 2020; Mayfield CA, Sparling A, Hardeman G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128160>
34. **Around the world in 60 days: an exploratory study of impact of COVID-19 on online global news sentiment.** J Comput Soc Sci 2020:1-34Chakraborty A, Bose S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102926>
35. **Bots and online hate during the COVID-19 pandemic: case studies in the United States and the Philippines.** J Comput Soc Sci 2020:1-24Uyheng J, Carley KM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102925>
36. **From Pandemic to Progression: An Educational Framework for the Implementation of Virtual Mental Healthcare for Children and Youth as a Response to COVID-19.** J Contemp Psychother 2020:1-7Doan BT, Yang YB, Romanchych E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110276>
37. **COVID-19 pandemic: usefulness of telemedicine in management of arrhythmias in elderly people.** J Geriatr Cardiol 2020; 17:593-596Mattioli AV, Cossarizza A, Boriani G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117426>
38. **Meeting the need: Creation of an online infection prevention course by the Golisano Institute for Developmental Disability Nursing for direct support**

- professionals during COVID-19.** *J Intellect Disabil* 2020:1744629520962617Kiss EA, Redlo JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111623>
39. **Remote operation for non-fluoroscopic navigation of complex tachycardias.** *J. Interv. Card. Electrophysiol.* 2020:1-6García-Bolao I, Moñino D, Marsal R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125607>
 40. **The rise of 3D Printing entangled with smart computer aided design during COVID-19 era.** *J Manuf Syst* 2020; Nazir A, Azhar A, Nazir U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106722>
 41. **A deep learning model and machine learning methods for the classification of potential coronavirus treatments on a single human cell.** *J Nanopart Res* 2020; 22:313Khalifa NEM, Taha MHN, Manogaran G, Loey M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100894>
 42. **Systematic review of telemedicine in spine surgery.** *J. Neurosurg. Spine* 2020:1-10Kolcun JPG, Ryu WHA, Traynelis VC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126219>
 43. **A Descriptive Study of the Implementation of Remote Occupational Rehabilitation Services Due to the COVID-19 Pandemic Within a Workers' Compensation Context.** *J Occup Rehabil* 2020:1-10Gross DP, Asante A, Pawluk J, Niemeläinen R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118130>
 44. **Video visits and access to care in pediatric rehabilitation therapies in the time of a pandemic.** *J. Pediatr. Rehabil. Med.* 2020; Nulle J, Nelson VS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104052>
 45. **Telemedicine for pediatric physiatry: How social distancing can bring physicians and families closer together.** *J. Pediatr. Rehabil. Med.* 2020; Sukhov R, Asante A, Ilizarov G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104050>
 46. **Experience of e-learning and online assessment during the COVID-19 pandemic at the College of Medicine, Qassim University.** *J Taibah Univ Med Sci* 2020; Elzainy A, El Sadik A, Al Abdulmonem W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106752>
 47. **Role of Emotion in Excessive Use of Twitter During COVID-19 Imposed Lockdown in India.** *J Technol Behav Sci* 2020:1-8Arora A, Chakraborty P, Bhatia MPS, Mittal P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102690>
 48. **Impact of a large-scale telemedicine network on emergency visits and hospital admissions during the coronavirus disease 2019 pandemic in Brazil: Data from the UNIMED-BH system.** *J Telemed Telecare* 2020:1357633x20969529Nascimento BR, Brant LC, Castro ACT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100183>
 49. **Adaptation of internet-based multiple mini-interviews in a limited-resource medical school during the coronavirus disease 2019 pandemic.** *Korean J Med Educ* 2020; Yolanda S, Wisnu W, Wahjudi JM, Findyartini A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33108858>
 50. **Review on 3D printing: Fight against COVID-19.** *Mater. Chem. Phys.* 2020; 258:123943Oladapo BI, Ismail SO, Afolalu TD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106717>
 51. **Review on 3D printing: Fight against COVID-19.** *Mater. Chem. Phys.* 2021; 258:123943Oladapo BI, Ismail SO, Afolalu TD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106717>
 52. **Potential of Graphene-based Materials to Combat COVID-19: Properties, Perspectives and Prospects.** *Mater Today Chem* 2020:100385Srivastava AK,

- Dwivedi N, Dhand C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106780>
53. **Mathematical modeling of COVID-19 transmission: the roles of intervention strategies and lockdown.** Math Biosci Eng 2020; 17:5961-5986 Bugalia S, Bajiya VP, Tripathi JP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120585>
 54. **Using a partial differential equation with Google Mobility data to predict COVID-19 in Arizona.** Math Biosci Eng 2020; 17:4891-4904 Wang HY, Yamamoto N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120533>
 55. **Can AI help in the fight against COVID-19?** Med. J. Aust. 2020; Scott IA, Coiera EW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111999>
 56. **Examining the Emergency Medical Treatment and Active Labor Act: impact on telemedicine for neurotrauma.** Neurosurg. Focus 2020; 49:E8 Shah S, Yang GL, Le DT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130613>
 57. **Telemedicine in Otorhinolaryngological Practice during COVID-19 Pandemic.** Niger. Med. J. 2020; 61:111-113 Ibekwe TS, Fasunla AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100459>
 58. **Influence of the Covid-19 pandemic on the prehospital emergency and tele-emergency care - A comparative cohort study.** Notarzt 2020; 36:271-277 Felzen M, Brockert AK, Beckers S *et al.*
 59. **E-learning: Depression, anxiety, and stress symptomatology among Lebanese university students during COVID-19 quarantine.** Nurs. Forum 2020; Fawaz M, Samaha A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125744>
 60. **An "Infodemic": Leveraging High-Volume Twitter Data to Understand Early Public Sentiment for the Coronavirus Disease 2019 Outbreak.** Open Forum Infect Dis 2020; 7:ofaa258 Medford RJ, Saleh SN, Sumarsono A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117854>
 61. **Automatic ID Consultation for Inpatients With COVID-19: Point, Counterpoint, and a Single-Center Experience.** Open Forum Infect Dis 2020; 7:ofaa318 Nguyen CT, Olson G, Pho MT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117849>
 62. **MetaCOVID: A Siamese neural network framework with contrastive loss for n-shot diagnosis of COVID-19 patients.** Pattern Recognit 2020; 107700 Shorfuzzaman M, Hossain MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100403>
 63. **Telemedicine in pediatric rheumatology: this is the time for the community to embrace a new way of clinical practice.** Pediatr. Rheumatol. Online J. 2020; 18:85 Sheno S, Hayward K, Curran ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129319>
 64. **Benefits and shortcomings of utilizing telemedicine during the COVID-19 pandemic.** Proc. (Bayl. Univ. Med. Cent.) 2020; 33:699-700 Burroughs M, Urits I, Viswanath O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100576>
 65. **Ad hoc teams and telemedicine during COVID-19.** Proc. (Bayl. Univ. Med. Cent.) 2020; 33:696-698 White BAA, Johnson J, Arroliga AC, Couchman G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100575>
 66. **Responding to COVID-19 in an Uninsured Hispanic/Latino Community: Testing, Education and Telehealth at a Free Clinic in Providence.** R I Med J (2013) 2020; 103:41-46 Barry K, McCarthy M, Melikian G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126788>
 67. **A Case Study on the Development of a Data Privacy Management Solution Based on Patient Information.** Sensors (Basel) 2020; 20 Verri Lucca A, Augusto Silva L, Luchtenberg R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114053>

68. **Remote-learning, time-use, and mental health of Ecuadorian high-school students during the COVID-19 quarantine.** World Dev 2021; 138:105225Asanov I, Flores F, McKenzie D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110286>

Other – Miscellaneous (79 articles)

1. **Air-pollutant mass concentration changes during COVID-19 pandemic in Shanghai, China.** Air Qual Atmos Health 2020:1-10Niu Z, Hu T, Kong L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101538>
2. **São Paulo's atmospheric pollution reduction and its social isolation effect, Brazil.** Air Qual Atmos Health 2020:1-10Rosse VP, Pereira JN, Boari A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110453>
3. **The intersection of viral illnesses: A seasonal influenza epidemic amidst the COVID-19 pandemic.** Ann Med Surg (Lond) 2020; 60:41-43Ehrlich H, Boneva D, Elkbuli A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101672>
4. **National tourism strategies during the Covid-19 pandemic.** Ann Tour Res 2020:103076Kreiner NC, Ram Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100431>
5. **Impact analysis of COVID-19 responses on energy grid dynamics in Europe.** Appl Energy 2021; 281:116045Werth A, Gravino P, Prevedello G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110287>
6. **A preliminary simulation study about the impact of COVID-19 crisis on energy demand of a building mix at a district in Sweden.** Appl Energy 2020; 280:115954Zhang X, Pellegrino F, Shen J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100481>
7. **Changes of air quality and its associated health and economic burden in 31 provincial capital cities in China during COVID-19 pandemic.** Atmos Res 2021; 249:105328Nie D, Shen F, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100451>
8. **In recovery mode: manufacturers try to bounce back after COVID-19 disruptions.** Bus Econ 2020:1-13Moutray C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100353>
9. **Calling an Audible: COVID-19 and Competitive Sports.** Circ Cardiovasc Qual Outcomes 2020; Nallamotheu BK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125277>
10. **An Exploratory Assessment of a Multidimensional Healthcare and Economic Data on COVID-19 in Nigeria.** Data Brief 2020:106424Ogundepo E, Folorunso S, Adekanmbi O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102643>
11. **Hospital financing during the corona pandemic: Uncertainties remain.** Deutsches Arzteblatt International 2020; 117:A1539-A1539.
12. **Energy access and pandemic-resilient livelihoods: The role of solar energy safety nets.** Energy Res Soc Sci 2021; 71:101805Zaman R, van Vliet O, Posch A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106771>
13. **Improvement in ambient-air-quality reduced temperature during the COVID-19 lockdown period in India.** Environ Dev Sustain 2020:1-28Pal SC, Chowdhuri I, Saha A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110388>
14. **Assessing correlations between short-term exposure to atmospheric pollutants and COVID-19 spread in all Italian territorial areas.** Environ Pollut

- 2020; 268:115714 Accarino G, Lorenzetti S, Aloisio G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33120339>
15. **Links between air pollution and COVID-19 in England.** Environ Pollut 2020; 268:115859 Travaglio M, Yu Y, Popovic R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33120349>
 16. **Associations between air pollution and COVID-19 epidemic during quarantine period in China.** Environ Pollut 2020; 268:115897 Zhang X, Tang M, Guo F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33126032>
 17. **COVID-19 and climatic factors: A global analysis.** Environ. Res. 2020:110355 Islam N, Bukhari Q, Jameel Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33127399>
 18. **Nexus planning as a pathway towards sustainable environmental and human health post Covid-19.** Environ. Res. 2020:110376 Nhamo L, Ndelela B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33115599>
 19. **Are meteorological factors enhancing COVID-19 transmission in Bangladesh? Novel findings from a compound Poisson generalized linear modeling approach.** Environ. Sci. Pollut. Res. Int. 2020; Islam A, Hasanuzzaman M, Shammi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118070>
 20. **Effects of the COVID-19 lockdown on criteria air pollutants in the city of Daegu, the epicenter of South Korea's outbreak.** Environ. Sci. Pollut. Res. Int. 2020:1-9 Vuong QT, Thang PQ, Park MK, Choi SD.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33113059>
 21. **Unprecedented but not Unpredictable: Effects of the COVID-19 Crisis on Commodity-Dependent Countries.** Eur J Dev Res 2020:1-20 Tröster B, Küblböck K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100597>
 22. **COVID-19 and Global Poverty: Are LDCs Being Left Behind?** Eur J Dev Res 2020:1-23 Valensisi G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100600>
 23. **Are Bitcoin and Ethereum safe-havens for stocks during the COVID-19 pandemic?** Financ Res Lett 2020:101798 Dwita Mariana C, Ekaputra IA, Husodo ZA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100925>
 24. **Covid-19 pandemic and tail-dependency networks of financial assets.** Financ Res Lett 2020:101800 Le TH, Do HX, Nguyen DK, Sensoy A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100926>
 25. **The impact of operating flexibility on firms' performance during the COVID-19 outbreak: Evidence from China.** Financ Res Lett 2020:101808 Liu H, Yi X, Yin L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100927>
 26. **Navigating the wildfire-pandemic interface: Public perceptions of COVID-19 and the 2020 wildfire season in Arizona.** Fire (Basel) 2020; 3 Edgeley CM, Burnett JT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111035>
 27. **The Potential Intermediate Hosts for SARS-CoV-2.** Front. Microbiol. 2020; 11:580137 Zhao J, Cui W, Tian BP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101254>
 28. **Impact of COVID-19 on Online Gambling - A General Population Survey During the Pandemic.** Front. Psychol. 2020; 11:568543 Håkansson A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101137>
 29. **Between Conspiracy Beliefs, Ingroup Bias, and System Justification: How People Use Defense Strategies to Cope With the Threat of COVID-19.** Front. Psychol. 2020; 11:578586 Jutzi CA, Willardt R, Schmid PC, Jonas E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101147>

30. **Behavioral Change Towards Reduced Intensity Physical Activity Is Disproportionately Prevalent Among Adults With Serious Health Issues or Self-Perception of High Risk During the UK COVID-19 Lockdown.** Front Public Health 2020; 8:575091 Rogers NT, Waterlow NR, Brindle H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33102424>
31. **"It's Pure Panic": The Portrayal of Residential Care in American Newspapers During COVID-19.** Gerontologist 2020; Allen LD, Ayalon L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33104191>
32. **Multi-dimensional effects of the COVID-19 pandemic considering the WHO's ecological approach.** Glob Public Health 2020:1-13 Tabari P, Amini M, Khoshnood K, Arya N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125297>
33. **Med-Tech Industry Entry Strategy Analysis under COVID-19 Impact.** Healthcare (Basel) 2020; 8 Fang IC, Chen PT, Chiu HH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33113863>
34. **Estimating Earnings Losses of Migrant Workers Due to COVID-19.** Indian J Labour Econ 2020:1-19 Abella MI, Sasikumar SK.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33106736>
35. **Manufactured Maladies: Lives and Livelihoods of Migrant Workers During COVID-19 Lockdown in India.** Indian J Labour Econ 2020:1-29 Adhikari A, Goregaonkar N, Narayanan R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106737>
36. **Labour Migrants During the Pandemic: A Comparative Perspective.** Indian J Labour Econ 2020:1-16 de Haan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100735>
37. **Understanding challenges for recovery homes during COVID-19.** Int. J. Drug Policy 2020:102986 Polcin DL, Mahoney E, Wittman F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33127280>
38. **The Determinants of Conspiracy Beliefs Related to the COVID-19 Pandemic in a Nationally Representative Sample of Internet Users.** Int J Environ Res Public Health 2020; 17 Duplaga M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114542>
39. **Gender Effect on Political Leaders' Nonverbal Communicative Structure during the COVID-19 Crisis.** Int J Environ Res Public Health 2020; 17 Grebelsky-Lichtman T, Katz R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114350>
40. **Travel Anxiety, Risk Attitude and Travel Intentions towards "Travel Bubble" Destinations in Hong Kong: Effect of the Fear of COVID-19.** Int J Environ Res Public Health 2020; 17 Luo JM, Lam CF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120949>
41. **Investigation of the Importance of Climatic Factors in COVID-19 Worldwide Intensity.** Int J Environ Res Public Health 2020; 17 Tzampoglou P, Loukidis D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33105818>
42. **Managing relationships in the Tourism Supply Chain to overcome epidemic outbreaks: The case of COVID-19 and the hospitality industry in Spain.** Int J Hosp Manag 2021; 92:102733 González-Torres T, Rodríguez-Sánchez JL, Pelechano-Barahona E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106721>
43. **Crisis standards of care in a pandemic: navigating the ethical, clinical, psychological and policy-making maelstrom.** Int. J. Qual. Health Care 2020; Hertelendy AJ, Ciottone GR, Mitchell CL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128564>

44. **Digging our own grave: A Marxian consideration of formal education as a destructive enterprise.** Int Rev Educ 2020:1-17Bainbridge A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100374>
45. **Reply to the letter.** J. Anesth. 2020; Hirata N, Yamakage M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33128605>
46. **Energy trilemma based prioritization of waste-to-energy technologies: Implications for post-COVID-19 green economic recovery in Pakistan.** J Clean Prod 2020:124729Ali Shah SA, Longsheng C, Solangi YA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100603>
47. **The effect of the Covid-19 on sharing economy activities.** J Clean Prod 2020:124782Hossain M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106734>
48. **Around the world in 60 days: an exploratory study of impact of COVID-19 on online global news sentiment.** J Comput Soc Sci 2020:1-34Chakraborty A, Bose S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102926>
49. **Bots and online hate during the COVID-19 pandemic: case studies in the United States and the Philippines.** J Comput Soc Sci 2020:1-24Uyheng J, Carley KM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102925>
50. **The boy's painting (Spain): Thanking health workers during COVID-19 pandemic.** J Family Med Prim Care 2020; 9:3176-3177Noguina EK.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33102265>
51. **Clinical impact of COVID-19 on people with substance use disorders.** J Public Health (Oxf) 2020; Vallecillo G, Perelló R, Güerri R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33103716>
52. **An Ecologic Study of Disparities in COVID-19 Incidence and Case Fatality in Oakland County, MI, USA, During a State-Mandated Shutdown.** J Racial Ethn Health Disparities 2020:1-8Akanbi MO, Rivera AS, Akanbi FO, Shoyinka A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33124003>
53. **Relationships between changes in self-reported physical activity, sedentary behaviour and health during the coronavirus (COVID-19) pandemic in France and Switzerland.** J. Sports Sci. 2020:1-6Cheval B, Sivaramakrishnan H, Maltagliati S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118469>
54. **JUE Insight: How Much does COVID-19 Increase with Mobility? Evidence from New York and Four Other U.S. Cities.** J Urban Econ 2020:103292Glaeser EL, Gorbach C, Redding SJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106711>
55. **COVID-19 Policy-Making in a Country Divided: Catholic Social Teaching as a Path to Unity.** Linacre Q 2020; 87:407-424McGovern TW, Flood AT, Carson PJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100389>
56. **Covid-19 and the healthcare professionals of the future.** Med. Leg. J. 2020:25817220965375Duignan K, Bradbury C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33107775>
57. **Self-care strategies in response to nurses' moral injury during COVID-19 pandemic.** Nurs. Ethics 2020:969733020961825Hossain F, Clatty A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33124492>
58. **Dietary Behaviors in the Post-Lockdown Period and Its Effects on Dietary Diversity: The Second Stage of a Nutrition Survey in a Longitudinal Chinese Study in the COVID-19 Era.** Nutrients 2020; 12Zhang J, Zhao A, Ke Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33114499>
59. **Air Evacuation of Passengers with Potential SARS-CoV-2 Infection Under the Guidelines for Appropriate Infection Control and Prevention.** Osong Public

- [Health Res Perspect](#) 2020; 11:334-338 Kim JG, Lee SH, Kim H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33117639>
60. **The impact of COVID-19 pandemic on malaria elimination.** [Parasite Epidemiol Control](#) 2020:e00187Zawawi A, Alghanmi M, Alsaady I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33102823>
 61. **Patient Satisfaction and Associated Factors During COVID-19 Pandemic in North Shoa Health Care Facilities.** [Patient Prefer Adherence](#) 2020; 14:1923-1934 Deriba BS, Geleta TA, Beyane RS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116436>
 62. **Moral foundations underlying behavioral compliance during the COVID-19 pandemic.** [Pers. Individ. Dif.](#) 2020:110463 Chan EY.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33106715>
 63. **Analyses the effects of COVID-19 outbreak on human sexual behaviour using ordinary least-squares based multivariate logistic regression.** [Qual Quant](#) 2020:1-21 Mahanty C, Kumar R, Mishra BK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100406>
 64. **[COVID-19, neoliberalism and health systems in 30 european countries: relationship to deceases.].** [Rev. Esp. Salud Publica](#) 2020; 94 Barrera-Algarín E, Estepa-Maestre F, Sarasola-Sánchez-Serrano JL, Vallejo-Andrada A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33111713>
 65. **Economics at the FCC 2019-2020: Spectrum Policy, Universal Service, Inmate Calling Services, and Telehealth.** [Rev Ind Organ](#) 2020:1-32 Baker A, Brogan P, Carare O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110292>
 66. **Oil spill + COVID-19: A disastrous year for Brazilian seagrass conservation.** [Sci Total Environ](#) 2020:142872 Magalhães KM, Barros KVS, Lima MCS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33127134>
 67. **How air quality and COVID-19 transmission change under different lockdown scenarios? A case from Dhaka city, Bangladesh.** [Sci Total Environ](#) 2020:143161 Rahman MS, Azad MAK, Hasanuzzaman M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33129520>
 68. **Recommendation on Gambling Advertising during the Corona Pandemic.** [Sucht](#) 2020; 66:217-222 Hayer T, Füchtenschnieder I, Hardeling A *et al.*
 69. **Preparing for outbreaks - Implications for resilient water utility operations and services.** [Sustain Cities Soc](#) 2021; 64:102558 Gude VG, Muire PJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101881>
 70. **Redesigning Supply Chains using Blockchain-Enabled Circular Economy and COVID-19 Experiences.** [Sustain Prod Consum](#) 2021; 27:10-22 Nandi S, Sarkis J, Hervani AA, Helms MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102671>
 71. **The impact of human capital efficiency on Latin American mutual funds during Covid-19 outbreak.** [Swiss J Econ Stat](#) 2020; 156:16 Mirza N, Hasnaoui JA, Naqvi B, Rizvi SKA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102259>
 72. **Impact of COVID-19 in the attendance of blood donors and production on a Brazilian Blood Centres.** [Transfus. Med.](#) 2020; Silva-Malta MCF, Rodrigues DOW, Chaves DG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118220>
 73. **Willingness to Accept Trade-Offs Among COVID-19 Cases, Social-Distancing Restrictions, and Economic Impact: A Nationwide US Study.** [Value Health](#) 2020; 23:1438-1443 Reed S, Gonzalez JM, Johnson FR.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33127014>

74. **Costing the COVID-19 Pandemic: An Exploratory Economic Evaluation of Hypothetical Suppression Policy in the United Kingdom.** Value Health 2020; 23:1432-1437 Zala D, Mosweu I, Critchlow S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33127013>
75. **The local governance of COVID-19: Disease prevention and social security in rural India.** World Dev 2021; 138:105234 Dutta A, Fischer HW.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33106724>
76. **COVID-19 response needs to broaden financial inclusion to curb the rise in poverty.** World Dev 2020:105229 Gutiérrez-Romero R, Ahamed M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33110285>
77. **COVID-19 response needs to broaden financial inclusion to curb the rise in poverty.** World Dev 2021; 138:105229 Gutiérrez-Romero R, Ahamed M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33110285>
78. **In spite of COVID-19, 15 doctors receive "Phytotherapy for Doctors" certificate.** Zeitschrift für Phytotherapie 2020; 41:197 Beer AM.
79. **"But all are pungent and flatulent...". Historical sidelight on garlic, onions and nasturtiums in the era of SARS-CoV-2 and Covid-19.** Zeitschrift für Phytotherapie 2020; 41:165-169 Niedenthal T.

Pathology (84 articles)

1. **The doctors' lot.** Cancer Cytopathol 2020; Gutmann EJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33125190>
2. **Global impact of the COVID-19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries.** Cancer Cytopathol 2020; Vigliar E, Cepurnaite R, Alcaraz-Mateos E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33108683>
3. **Acute respiratory syndrome in COVID-19: Autopsies show some pathophysiological differences to influenza.** Deutsches Arzteblatt International 2020; 117:A1746 Siegmund-Schultze N.
4. **Post-mortem ultrasonography: a safer alternative to autopsies in COVID-19 deaths.** J Ultrasound 2020:1-2 Kanchan T, Shrestha R, Krishan K.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33128737>

Protection (44 articles)

1. **Face masks use during the COVID-19 pandemic: Differences in attitudes and practices between medical and non-medical students. A survey of 2256 students in Poland.** Adv Clin Exp Med 2020; 29:1201-1203 Matusiak Ł, Szepietowska M, Krajewski P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125197>
2. **How Effective Is the Filtration of 'KN95' Filtering Facepiece Respirators During the COVID-19 Pandemic?** Ann Work Expo Health 2020; Brochot C, Saidi MN, Bahloul A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125464>
3. **Contamination of SARS-CoV-2 in patient surroundings and on personal protective equipment in a non-ICU isolation ward for COVID-19 patients with prolonged PCR positive status.** Antimicrob Resist Infect Control 2020; 9:167 Wei L, Huang W, Lu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121538>

4. **Coronavirus Disease 2019 Transmission: Blood Viremia and Aerosol Generation from Spinal Surgery. Is There an Increased Risk to the Surgical Team?** Asian Spine J 2020; 14:702-709 Shah S, Gadiya A, Patel MS, Shafafy M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33108836>
5. **Optical Biosensors for Virus Detection: Prospects for COVID-19.** Chembiochem 2020; Maddali H, Miles CE, Kohn J, O'Carroll DM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119960>
6. **SARS-CoV-2 and Health Care Worker Protection in Low-Risk Settings: a Review of Modes of Transmission and a Novel Airborne Model Involving Inhalable Particles.** Clin. Microbiol. Rev. 2020; 34 Zhang XS, Duchaine C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115724>
7. **Corona pandemic: Recommendations on occupational safety.** Deutsches Arzteblatt International 2020; 117:A1764 Kahl K.
8. **Assessing correlations between short-term exposure to atmospheric pollutants and COVID-19 spread in all Italian territorial areas.** Environ Pollut 2020; 268:115714 Accarino G, Lorenzetti S, Aloisio G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120339>
9. **The microscope drape method to reduce aerosolisation during endoscopic sinus and skull base surgery in the COVID era. How i do it.** Eur Arch Otorhinolaryngol 2020;1-4 Tsagkovits A, Ioannidis D, Rokade A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33112982>
10. **[Ambivalence, control, support. Caring for the elderly patient at a "good enough" distance].** Evol. Psychiatr. (Paris) 2020; Verdon B, Racin C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106708>
11. **Preclinical validation of occupational and environmental safety of an isolation system for non-invasive ventilation in COVID-19 and other aerosol-transmitted infections.** Expert Rev. Med. Devices 2020; Quadros CA, Leal M, Baptista-Sobrinho CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103939>
12. **COVID-19 in healthcare workers: lessons from SARS and MERS epidemics and perspectives for chemoprophylaxis and vaccines.** Expert Rev Vaccines 2020; Labetoulle R, Detoc M, Gagnaire J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107353>
13. **A COVID-19 Outbreak in a Rheumatology Department Upon the Early Days of the Pandemic.** Front Med (Lausanne) 2020; 7:576162 Romão VC, Oliveira-Ramos F, Cruz-Machado AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102507>
14. **Safe Slit-lamp Shield: Maintaining a balance between ergonomics and safety.** Indian J Ophthalmol 2020; 68:2486-2489 Khadia A, Nachiappan S, Kalita IR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120649>
15. **Corneal transplantation and eye banking practices during COVID-19-related lockdown period in India from a network of tertiary eye care centers.** Indian J Ophthalmol 2020; 68:2368-2371 Roy A, Das S, Chaurasia S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120619>
16. **Indoor transmission of SARS-CoV-2.** Indoor Air 2020; Qian H, Miao T, Liu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33131151>
17. **COVID-19 patients and contacted person awareness about home quarantine instructions.** Int J Clin Pract 2020:e13810 Elgendy MO, Abd Elmawla MN, Abdel Hamied AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128825>
18. **Adoption of Preventive Behaviour Strategies and Public Perceptions About COVID-19 in Singapore.** Int J Health Policy Manag 2020; Ozdemir S, Ng S,

- Chaudhry I, Finkelstein EA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33105971>
19. **Health Care Worker Infections and Deaths due to COVID-9: A Survey from 37 Nations and a Call for WHO to Post National Data on their Website.** Int J Infect Dis 2020; Erdem H, Lucey DR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130210>
 20. **Residual SARS-CoV-2 RNA in nasal swabs of convalescent COVID-19: is prolonged quarantine always justified?** Int J Infect Dis 2020; Piralla A, Ricchi M, Cusi MG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130202>
 21. **Lessons learned from first case of Cesarean delivery in a COVID-19 positive parturient in Greek region.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S121-s124 Batistaki C, Galarioti V, Vasiliadou S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100660>
 22. **Safety tent for enhanced personal protection from aerosol-generating procedures while handling the COVID-19 patient airway.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S157-s160 Bidkar P, Goneppanavar U, Kaur J, Ramamoorthy SV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100673>
 23. **Practical approach for safe anesthesia in a COVID-19 patient scheduled for emergency laparotomy.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S57-s61 Goneppanavar U, Desai S, Kaur J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100648>
 24. **Negative pressure aerosol containment box: An innovation to reduce COVID-19 infection risk in healthcare workers.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S144-s147 Gupta V, Sahani A, Mohan B, Wander GS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100667>
 25. **What a pediatric anesthesiologist should know about COVID-19.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S85-s91 Jain A, Bhardwaj N, Yaddanapudi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100654>
 26. **The aerosol box.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S141-s143 Maniar A, Jagannathan B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100666>
 27. **Preventing exposure to COVID-19 in the operation theatre and intensive care unit.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S127-s133 Setlur R, Jaiswal A, Jahan N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100662>
 28. **Exploring the N95 and Surgical Mask Supply in U.S. Nursing Homes During COVID-19.** J. Appl. Gerontol. 2020:733464820969015 Li Y, Fang F, He M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100107>
 29. **Causal impact of masks, policies, behavior on early covid-19 pandemic in the U.S.** J Econom 2020; Chernozhukov V, Kasahara H, Schrimpf P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100476>
 30. **The Use of Facemasks During the COVID-19 Pandemic by the Brazilian Population.** J Multidiscip Healthc 2020; 13:1169-1178 Cotrin P, Bahls AC, da Silva DO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116562>
 31. **Povidone-iodine solution as SARS-CoV-2 prophylaxis for procedures of the upper aerodigestive tract a theoretical framework.** J. Otolaryngol. Head Neck Surg. 2020; 49:77 Naqvi SHS, Citardi MJ, Cattano D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109269>
 32. **Post-mortem ultrasonography: a safer alternative to autopsies in COVID-19 deaths.** J Ultrasound 2020:1-2 Kanchan T, Shrestha R, Krishan K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128737>

33. **Communication Chaos from Discrepancies in Personal Protective Equipment and Preoperative Guidelines.** Laryngoscope 2020; Wang N, Xu MJ, House AE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128391>
34. **More than Pneumonia: Distinctive Features of SARS-Cov-2 Infection. From Autopsy Findings to Clinical Implications: A Systematic Review.** Microorganisms 2020; 8D'Errico S, Zanon M, Montanaro M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114061>
35. **Handwashing and Detergent Treatment Greatly Reduce SARS-CoV-2 Viral Load on Halloween Candy Handled by COVID-19 Patients.** mSystems 2020; 5Salido RA, Morgan SC, Rojas MI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127739>
36. **WHO Knew. How the World Health Organization (WHO) Became a Dangerous Interloper on Workplace Health and Safety and COVID-19.** New Solut. 2020; 30:237-248O'Neill R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121368>
37. **Transmission of SARS-CoV-2 in Public Transportation Vehicles: A Case Study in Hunan Province, China.** Open Forum Infect Dis 2020; 7:ofaa430Luo K, Lei Z, Hai Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123609>
38. **Aerosol transmission for SARS-CoV-2 in the dental practice. A review by SIdP Covid 19 task-force.** Oral Dis 2020; Marco C, Mario R, Luigi B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33124127>
39. **Air Evacuation of Passengers with Potential SARS-CoV-2 Infection Under the Guidelines for Appropriate Infection Control and Prevention.** Osong Public Health Res Perspect 2020; 11:334-338Kim JG, Lee SH, Kim H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117639>
40. **Facile Approaches of Polymeric Face Masks Reuse and Reinforcements for Micro-Aerosol Droplets and Viruses Filtration: A Review.** Polymers (Basel) 2020; 12Wibisono Y, Fadila CR, Saiful S, Bilad MR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126730>
41. **Airborne transmission of SARS-CoV-2 via aerosols.** Rev Med Virol 2020:e2184Comber L, E OM, Drummond L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33105071>
42. **Emergency department crowding and hospital transformation during COVID-19, a retrospective, descriptive study of a university hospital in Stockholm, Sweden.** Scand. J. Trauma Resusc. Emerg. Med. 2020; 28:107Af Ugglas B, Skyttberg N, Wladis A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115521>
43. **Examining the impact of lockdown (due to COVID-19) on ambient aerosols (PM(2.5)): A study on Indo-Gangetic Plain (IGP) Cities, India.** Stoch. Environ. Res. Risk Assess. 2020:1-17Das M, Das A, Sarkar R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100900>
44. **Dried SARS-CoV-2 virus maintains infectivity to Vero E6 cells for up to 48 h.** Vet. Microbiol. 2020; 251:108907Jang H, Ross TM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129043>

Pulmonary disease (21 articles)

1. **COVID-19 and Interstitial Lung Disease: Keep Them Separate.** Am J Respir Crit Care Med 2020; Podolanczuk AJ, Richeldi L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113338>

2. **Phase 1 trial for treatment of COVID-19 patients with pulmonary fibrosis using hESC-IMRCs.** Cell Prolif. 2020:e12944Wu J, Zhou X, Tan Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33107132>
3. **Journal Club-Severe Acute Respiratory Syndrome Coronavirus-2: Impact on COPD Patients.** Chronic Obstr Pulm Dis 2020; 7:413-419Balkissoon R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33108113>
4. **The relationship between severe or dead COVID-19 and asthma: a meta-analysis.** Clin. Exp. Allergy 2020; Wang Y, Ao G, Qi X, Ma M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33131117>
5. **Acute respiratory syndrome in COVID-19: Autopsies show some pathophysiological differences to influenza.** Deutsches Arzteblatt International 2020; 117:A1746Siegmund-Schultze N.
6. **Novel insight from the first lung transplant of a COVID-19 patient.** Eur. J. Clin. Invest. 2020:e13443Chen XJ, Li K, Xu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33131070>
7. **Not all that glitters is COVID! Differential diagnosis of FDG-avid interstitial lung disease in low-prevalence regions.** Eur J Hybrid Imaging 2020; 4:19Papa A, Pozzessere C, Cicone F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103048>
8. **A Suggested Approach for Management of Pediatric Asthma During the COVID-19 Pandemic.** Front Pediatr 2020; 8:563093Ding B, Lu Y.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33102407>
9. **A Nomogram-Based Prediction for Severe Pneumonia in Patients with Coronavirus Disease 2019 (COVID-19).** Infect Drug Resist 2020; 13:3575-3582Zhang Y, Wu L, Yang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116677>
10. **The Experience of COPD Patients in Lockdown Due to the COVID-19 Pandemic.** Int. J. Chron. Obstruct. Pulmon. Dis. 2020; 15:2621-2627Pleguezuelos E, Del Carmen A, Moreno E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33122900>
11. **The pulmonary circuit dynamics in COVID-19!** J. Anesth. 2020:1Magoon R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33128606>
12. **Asthma and COVID-19: In Defense of Evidence-Based SABA.** J. Asthma Allergy 2020; 13:505-508Amirav I, Newhouse MT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116658>
13. **Discharge may not be the end of treatment: pay attention to pulmonary fibrosis caused by severe COVID-19.** J Med Virol 2020; Zhang C, Wu Z, Li JW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107641>
14. **Association between high-dose steroid therapy, respiratory function, and time to discharge in patients with COVID-19: Cohort study.** Med Clin (Barc) 2020; Rodríguez-Molinero A, Pérez-López C, Gálvez-Barrón C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33129511>
15. **More than Pneumonia: Distinctive Features of SARS-Cov-2 Infection. From Autopsy Findings to Clinical Implications: A Systematic Review.** Microorganisms 2020; 8D'Errico S, Zanon M, Montanaro M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33114061>
16. **Changes in quality of life and dyspnoea after hospitalization in COVID-19 patients discharged at home.** Multidiscip Respir Med 2020; 15:713Santus P, Tursi F, Croce G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117535>

17. **[Clinical analysis of early damage in multiple extra-pulmonary organs in COVID-19].** Nan Fang Yi Ke Da Xue Xue Bao 2020; 40:1518-1524 Fan J, Zhang Y, Pan Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118517>
18. **Lung Ultrasound in Children with Respiratory Tract Infections: Viral, Bacterial or COVID-19? A Narrative Review.** Open Access Emerg. Med. 2020; 12:275-285 Kharasch S, Duggan NM, Cohen AR, Shokoohi H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116963>
19. **Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae.** Respir. Med. 2020; 174:106197 Daher A, Balfanz P, Cornelissen C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120193>
20. **Are there pulmonary sequelae in patients recovering from COVID-19?** Respir Res 2020; 21:286 Rogliani P, Calzetta L, Coppola A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126869>
21. **Are patients with asthma and COPD preferred targets of COVID-19?** Tuberc Respir Dis (Seoul) 2020; Bouazza B, Hadj-Said D, Pescatore KA, Chahed R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099990>

Renal disease (16 articles)

1. **The COVID-19 nephrology compendium: AKI, CKD, ESKD and transplantation.** BMC Nephrol. 2020; 21:449 Kant S, Menez SP, Hanouneh M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109103>
2. **COVID-19 Status, Symptom Burden, and Characteristics of Dialysis Patients Residing in Areas of Community Transmission: Research Letter.** Can J Kidney Health Dis 2020; 7:2054358120964178 Gale J, Clark DA, Bohm C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117550>
3. **Outcomes of Patients on Maintenance Dialysis Hospitalized with COVID-19.** Clin J Am Soc Nephrol 2020; Chan L, Jaladanki SK, Somani S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127607>
4. **Complement and protection from tissue injury in COVID-19.** Clin Kidney J 2020; 13:734-738 Ortiz A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123353>
5. **Temporal changes in complement activation in haemodialysis patients with COVID-19 as a predictor of disease progression.** Clin Kidney J 2020; 13:889-896 Predecki M, Clarke C, Medjeral-Thomas N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123364>
6. **Clinical outcomes of dialysis patients with COVID-19 in the initial phase of the COVID-19 outbreak in Wuhan, China.** Int. Urol. Nephrol. 2020; Zeng X, Huang X, Xu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123844>
7. **Detection of SARS-CoV-2 Antibodies in Kidney Transplant Recipients.** J Am Soc Nephrol 2020; Predecki M, Clarke C, Gleeson S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33122285>
8. **COVID-19-Associated Acute Kidney Injury: Learning from the First Wave.** J Am Soc Nephrol 2020; Wald R, Bagshaw SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115918>
9. **Renal infarction in COVID-19 patient.** J Nephrol 2020; Ammous A, Ghaffar MA, El-Charabaty E, El-Sayegh S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119839>
10. **Coronavirus-2019 Disease (COVID-19) in Children.** Medeni Med J 2020; 35:242-252 Ovali F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110677>

11. **Corona pandemic: Diabetes promotes kidney failure in COVID-19 patients.** MMW-Fortschritte der Medizin 2020; 162:31 Fritschka E.
12. **Management of COVID-19 in an Outpatient Dialysis Program.** Nephrol. Nurs. J. 2020; 47:423-427 Noce E, Zorzanello M, Patel D, Kodali R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33107714>
13. **COVID-19 and Acute Kidney Injury.** Nephrol. Nurs. J. 2020; 47:481-482 Robbins KC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107721>
14. **COVID-19 and kidney.** Nieren- und Hochdruckkrankheiten 2020; 49:427 Alscher MD.
15. **COVID-19- A dvantages and challenges of home dialysis.** Nieren- und Hochdruckkrankheiten 2020; 49:437-441 Schrick S, Kimmel M.
16. **It's complicated: A case report on a COVID-19-positive HIV patient presenting with rhabdomyolysis and acute kidney injury.** SAGE Open Med Case Rep 2020; 8:2050313x20965423 Foster A, Khan Z, Siddiqui A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33117541>

Reviews (54 articles)

1. **Roadmap to the Bioanalytical Testing of COVID-19: From Sample Collection to Disease Surveillance.** ACS Sens 2020; Hosseini A, Pandey R, Osman E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33124797>
2. **Loss of smell in COVID-19 patients: a critical review with emphasis on the use of olfactory tests.** Acta Otorhinolaryngol. Ital. 2020; 40:241-247 Marchese-Ragona R, Restivo DA, De Corso E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100334>
3. **What Sepsis Researchers Can Learn From COVID-19.** Am J Respir Crit Care Med 2020; Schinkel M, Virk HS, Nanayakkara PWB *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33125253>
4. **Management of Patients with Liver Transplant and Chronic Liver Diseases During COVID-19 Pandemic: A Brief Review.** Arch Iran Med 2020; 23:713-717 Taher M, Miroliaee A, Ebrahimi Daryani N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33107315>
5. **COVID-19 diagnosis -A review of current methods.** Biosens. Bioelectron. 2020; 172:112752 Yüce M, Filiztekin E, Özkaya KG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126180>
6. **Course of Sars-CoV2 infection in patients with cancer treated with anti-PD-1: a case presentation and review of the literature.** Cancer Invest. 2020:1-10 Pala L, Conforti F, Cocorocchio E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125301>
7. **Journal Club-Severe Acute Respiratory Syndrome Coronavirus-2: Impact on COPD Patients.** Chronic Obstr Pulm Dis 2020; 7:413-419 Balkissoon R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33108113>
8. **Emerging treatment strategies for COVID-19 infection.** Clin. Exp. Med. 2020; Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33128197>
9. **Complement and protection from tissue injury in COVID-19.** Clin Kidney J 2020; 13:734-738 Ortiz A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123353>
10. **Covid-19 and Autoimmune Diseases: A Systematic Review of Reported Cases.** Curr. Rheumatol. Rev. 2020; Saad MA, Alfshawy M, Nassar M *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121413>
11. **Probable positive effects of the photobiomodulation as an adjunctive treatment in COVID-19: A systematic review.** Cytokine 2020; 137:155312Nejatifard M, Asefi S, Jamali R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33128927>
 12. **Monocyte HLA-DR measurement by flow cytometry in COVID-19 patients: an interim review.** Cytometry A 2020; Benlyamani I, Venet F, Coudereau R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33125816>
 13. **Recurrence of SARS-CoV-2 viral RNA in recovered COVID-19 patients: a narrative review.** Eur J Clin Microbiol Infect Dis 2020:1-13Dao TL, Hoang VT, Gautret P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113040>
 14. **Predictors of mortality in patients with COVID-19 - a systematic review.** Eur J Integr Med 2020:101226Mehraeen E, Karimi A, Barzegary A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101547>
 15. **COVID-19 and diabetes mellitus: Unraveling the hypotheses that worsen the prognosis (Review).** Exp. Ther. Med. 2020; 20:194Albulescu R, Dima SO, Florea IR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101484>
 16. **From Influenza Virus to Novel Corona Virus (SARS-CoV-2)-The Contribution of Obesity.** Front. Endocrinol. (Lausanne) 2020; 11:556962Bhattacharya I, Ghayor C, Pérez Dominguez A, Weber FE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123087>
 17. **Increased Plasma Heparanase Activity in COVID-19 Patients.** Front. Immunol. 2020; 11:575047Buijsers B, Yanginlar C, de Nooijer A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33123154>
 18. **Acute Ischemic Stroke in COVID-19: A Case-Based Systematic Review.** Front. Neurol. 2020; 11:1031Wijeratne T, Sales C, Karimi L, Crewther SG.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101164>
 19. **COVID-19 in Human, Animal, and Environment: A Review.** Front Vet Sci 2020; 7:578Swelum AA, Shafi ME, Albaqami NM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33102545>
 20. **Efficacy of Lopinavir/Ritonavir Compared With Standard Care for Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review.** Infect Disord Drug Targets 2020; Hariyanto TI, Kristine E, Jillian Hardi C, Kurniawan A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33121422>
 21. **Head and Neck Practice in the COVID-19 Pandemics Today: A Rapid Systematic Review.** Int Arch Otorhinolaryngol 2020; 24:e518-e526Hojaij FC, Chinelatto LA, Boog GHP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101521>
 22. **A historical insight into an announced tragedy: COVID-19 pandemic.** Int J Clin Pract 2020:e13808Bestetti RB, Freitas TS, Montes-Neto CE.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33128855>
 23. **What a pediatric anesthesiologist should know about COVID-19.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S85-s91Jain A, Bhardwaj N, Yaddanapudi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100654>
 24. **Therapeutic status of hydroxychloroquine in COVID-19: A review.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S160-s165Kaur K, Kaushal S, Kaushal IG.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100674>
 25. **A Comprehensive Review of Neurologic Manifestations of COVID-19 and Management of Pre-existing Neurologic Disorders in Children.** J. Child Neurol.

- 2020:883073820968995Kim Y, Walser SA, Asghar SJ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33112694>
26. **COVID-19 and Adverse Pregnancy Outcome: A Systematic Review of 104 Cases.** J Clin Med 2020; 9Abou Ghayda R, Li H, Lee KH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33114779>
 27. **The burden of type 2 diabetes pre-and during the COVID-19 pandemic - a review.** J Diabetes Metab Disord 2020:1-9Sciberras J, Camilleri LM, Cuschieri S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33102262>
 28. **Changing agendas and priorities of public health associations across the globe following in the era of COVID-19 pandemic-A mini-review.** J Family Med Prim Care 2020; 9:3838-3842Al-Khateeb BF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110776>
 29. **A review on exploring evidence-based approach to harnessing the immune system in times of corona virus pandemic: Best of modern and traditional Indian system of medicine.** J Family Med Prim Care 2020; 9:3826-3837Pathania M, Bhardwaj P, Pathania N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110775>
 30. **Derivation and Internal Validation of a Model to Predict the Probability of Severe Acute Respiratory Syndrome Coronavirus-2 Infection in Community People.** J Gen Intern Med 2020:1-8van Walraven C, Manuel DG, Desjardins M, Forster AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107007>
 31. **Neurological manifestations of patients infected with the SARS-CoV-2: a systematic review of the literature.** J. Neurol. 2020:1-10Cagnazzo F, Arquizan C, Derraz I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125542>
 32. **Systematic review of telemedicine in spine surgery.** J. Neurosurg. Spine 2020:1-10Kolcun JPG, Ryu WHA, Traynelis VC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126219>
 33. **Appropriate orthodontic appliances during the COVID-19 pandemic: A scoping review.** J Oral Biol Craniofac Res 2020; 10:782-787Kaur H, Kochhar AS, Gupta H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106770>
 34. **Comprehensive review of guidelines to practice prosthodontic and implant procedures during COVID-19 pandemic.** J Oral Biol Craniofac Res 2020; 10:768-775Pruthi G, Parkash H, Bharathi PV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101891>
 35. **Comprehensive guidelines to practice prosthodontic procedures and implant treatment during COVID-19 era: A narrative review.** J Oral Biol Craniofac Res 2020; Pruthi G, Parkash H, Vijaya Bharathi P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101891>
 36. **Melatonin controversies, an update.** J. Pineal Res. 2020:e12702Boutin JA, Jockers R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33108677>
 37. **Is there a role for the ACE2 receptor in SARS-CoV-2 interactions with platelets?** J Thromb Haemost 2020; Campbell RA, Boilard E, Rondina MT.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33119197>
 38. **Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis.** Life Sci 2020:118663Shrestha DB, Budhathoki P, Syed NI *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33121991>
 39. **A critical review of the safety of minimally invasive surgery in the era of COVID-19.** Minim. Invasive Ther. Allied Technol. 2020:1-7Emile SH, Hamid HKS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33107358>

40. **A Review of Nutrition Support Guidelines for Individuals with or Recovering from COVID-19 in the Community.** Nutrients 2020; 12:Cawood AL, Walters ER, Smith TR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33105731>
41. **Lung Ultrasound in Children with Respiratory Tract Infections: Viral, Bacterial or COVID-19? A Narrative Review.** Open Access Emerg. Med. 2020; 12:275-285Kharasch S, Duggan NM, Cohen AR, Shokoohi H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116963>
42. **COVID-19 screening protocols for preoperative assessment of head and neck cancer patients candidate for elective surgery in the midst of the pandemic: A narrative review with comparison between two Italian institutions.** Oral Oncol 2020; 112:105043Ferrari M, Paderno A, Giannini L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129056>
43. **The actual threat of COVID-19.** Pol Merkur Lekarski 2020; 48:354-360Płusa T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130799>
44. **Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review.** Protein J 2020;1-13Suhail S, Zajac J, Fossum C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106987>
45. **The influence of vaccination against tuberculosis with the Bacillus-Calmette-Guérin(BCG) vaccine on COVID-19 incidence and mortality - review of the literature.** Przegl. Epidemiol. 2020; 74:290-302Ręka G, Korzeniowska A, Pieciewicz-Szczęśna H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115218>
46. **Effects of COVID-19 pandemic on out-of-hospital cardiac arrests: A systematic review.** Resuscitation 2020; Scquizzato T, Landoni G, Paoli A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130157>
47. **Current Options in the Treatment of COVID-19: A Review.** Risk Manag. Healthc. Policy 2020; 13:1999-2010Teimury A, Mahmoodi Khaledi E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116980>
48. **Systematic review of EEG findings in 617 patients diagnosed with COVID-19.** Seizure 2020; Antony AR, Haneef Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121875>
49. **Coronavirus disease (COVID-19) prevention and treatment methods and effective parameters: A systematic literature review.** Sustain Cities Soc 2021; 64:102568Rahmani AM, Mirmahaleh SYH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110743>
50. **The Current Recommended Drugs and Strategies for the Treatment of Coronavirus Disease (COVID-19).** Ther. Clin. Risk Manag. 2020; 16:933-946Sheikhpour M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116543>
51. **Ozone therapy in COVID-19: A narrative review.** Virus Res. 2020; 291:198207Cattel F, Giordano S, Bertiond C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115670>
52. **SARS-CoV, MERS-CoV, and 2019-nCoV viruses: an overview of origin, evolution, and genetic variations.** Virusdisease 2020:1-13Krishnamoorthy S, Swain B, Verma RS, Gunthe SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102628>
53. **Baseline results of a living systematic review for COVID-19 funded research projects.** Wellcome Open Res 2020; 5:209Norton A, Bucher A, Antonio E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117894>
54. **Profile of SARS-CoV-2.** Wien. Klin. Wochenschr. 2020:1-10Heinz FX, Stiasny K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125580>

Risk factors (70 articles)

1. **Targeting Crucial Host Factors of SARS-CoV-2.** *ACS Infect Dis* 2020; Tharappel AM, Samrat SK, Li Z, Li H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33112126>
2. **Short telomeres increase the risk of severe COVID-19.** *Aging (Albany NY)* 2020; 12Froidure A, Mahieu M, Hoton D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104521>
3. **The Risk and Impact of COVID-19 Pandemic on Immunosuppressed Patients: Cancer, HIV, and Solid Organ Transplant Recipients.** *AIDS Rev.* 2020; 22:151-157Mohammed AH, Blebil A, Dujaili J, Rasool-Hassan BA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118527>
4. **Angiotensin-converting enzyme 2 (ACE2) expression in COPD and IPF fibroblasts- the forgotten cell in COVID-19.** *Am J Physiol Lung Cell Mol Physiol* 2020; Aloufi N, Traboulsi H, Ding J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33112187>
5. **Role of vitamin D in pathogenesis and severity of COVID-19 infection.** *Arch. Physiol. Biochem.* 2020;1-7Honardoost M, Ghavideldarestani M, Khamseh ME. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125298>
6. **Cognitive profile following COVID-19 infection: Clinical predictors leading to neuropsychological impairment.** *Brain Behav Immun Health* 2020; 9:100163Almeria M, Cejudo JC, Sotoca J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111132>
7. **Multivariate mortality analyses in COVID-19: Comparing patients with cancer and patients without cancer in Louisiana.** *Cancer* 2020; Lunski MJ, Burton J, Tawagi K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33112411>
8. **Smoking Cessation Amid the Coronavirus 2019 Pandemic: Making Every Contact Count.** *Chronic Obstr Pulm Dis* 2020; 7:300-302Shahzad Hasan S, Kow CS, Ahmadi K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33108112>
9. **SARS-CoV-2 and Health Care Worker Protection in Low-Risk Settings: a Review of Modes of Transmission and a Novel Airborne Model Involving Inhalable Particles.** *Clin. Microbiol. Rev.* 2020; 34Zhang XS, Duchaine C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115724>
10. **Association of bioelectric impedance analysis body composition and disease severity in COVID-19 hospital ward and ICU patients: The BIAC-19 study.** *Clin. Nutr.* 2020; Moonen H, van Zanten FJL, Driessen L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129597>
11. **The Interferon-induced transmembrane protein 3 gene (IFITM3) rs12252 C variant is associated with COVID-19.** *Cytokine* 2020; 137:155354Gómez J, Albaiceta GM, Cuesta-Llavona E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113474>
12. **Triglyceride to High-Density Lipoprotein Cholesterol Ratio is an Important Determinant of Cardiovascular Risk and Poor Prognosis in Coronavirus Disease-19: A Retrospective Case Series Study.** *Diabetes Metab. Syndr. Obes.* 2020; 13:3925-3936Zhang B, Dong C, Li S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33122929>
13. **Testosterone in COVID-19 - Foe, Friend or Fatal Victim?** *Eur Endocrinol* 2020; 16:88-91Kalra S, Bhattacharya S, Kalhan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117437>

14. **Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOV-19).** *Eur. J. Cancer* 2020; 141:62-81 Lièvre A, Turpin A, Ray-Coquard I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33129039>
15. **Predictors of mortality in patients with COVID-19 - a systematic review.** *Eur J Integr Med* 2020;101226 Mehraeen E, Karimi A, Barzegary A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101547>
16. **Predictors of mortality in patients with COVID-19-a systematic review.** *Eur J Integr Med* 2020; 40:101226 Mehraeen E, Karimi A, Barzegary A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101547>
17. **Possible association of vitamin D status with lung involvement and outcome in patients with COVID-19: a retrospective study.** *Eur. J. Nutr.* 2020;1-9 Abrishami A, Dalili N, Mohammadi Torbati P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123774>
18. **COVID-19 and diabetes mellitus: Unraveling the hypotheses that worsen the prognosis (Review).** *Exp. Ther. Med.* 2020; 20:194 Albulescu R, Dima SO, Florea IR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101484>
19. **The effects of aging on host resistance and disease tolerance to SARS-CoV-2 infection.** *Febs j.* 2020; Mok DZL, Chan CYY, Ooi EE, Kuan Rong C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33124149>
20. **Within-Host Diversity of SARS-CoV-2 in COVID-19 Patients With Variable Disease Severities.** *Front Cell Infect Microbiol* 2020; 10:575613 Al Khatib HA, Benslimane FM, Elbashir IE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123498>
21. **Immunesenescence: A Predisposing Risk Factor for the Development of COVID-19?** *Front. Immunol.* 2020; 11:573662 Hazeldine J, Lord JM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33123152>
22. **ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19.** *Front. Immunol.* 2020; 11:576745 Zipeto D, Palmeira JDF, Argañaraz GA, Argañaraz ER. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117379>
23. **Prognostic Factors for COVID-19 Pneumonia Progression to Severe Symptoms Based on Earlier Clinical Features: A Retrospective Analysis.** *Front Med (Lausanne)* 2020; 7:557453 Huang H, Cai S, Li Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33123541>
24. **Association of Peripheral Lymphocyte and the Subset Levels With the Progression and Mortality of COVID-19: A Systematic Review and Meta-Analysis.** *Front Med (Lausanne)* 2020; 7:558545 Lu Q, Wang Z, Yin Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33102499>
25. **COVID-19 Genetic and Environmental Risk Factors: A Look at the Evidence.** *Front. Pharmacol.* 2020; 11:579415 Abdelzaher H, Saleh BM, Ismail HA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33117174>
26. **Individual-Level Fatality Prediction of COVID-19 Patients Using AI Methods.** *Front Public Health* 2020; 8:587937 Li Y, Horowitz MA, Liu J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33102426>
27. **Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: results of the ACE-CoV study.** *Fundam. Clin. Pharmacol.* 2020; Lafaurie M,

- Martin-Blondel G, Delobel P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111329>
28. **Hematologic predictors of mortality in hospitalized patients with COVID-19: a comparative study.** *Hematology* 2020; 25:383-388 Mousavi SA, Rad S, Rostami T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33124971>
 29. **Diabetes is associated with increased risk for in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis comprising 18,506 patients.** *Hormones (Athens)* 2020:1-10 Palaiodimos L, Chamorro-Pareja N, Karamanis D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123973>
 30. **A Nomogram-Based Prediction for Severe Pneumonia in Patients with Coronavirus Disease 2019 (COVID-19).** *Infect Drug Resist* 2020; 13:3575-3582 Zhang Y, Wu L, Yang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116677>
 31. **Asymptomatic hypoxia in COVID-19 is associated with poor outcome.** *Int J Infect Dis* 2020; Brouqui P, Amrane S, Million M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130200>
 32. **Risk factors for mortality in adult COVID-19 patients; frailty predicts fatal outcome in older patients.** *Int J Infect Dis* 2020; Tehrani S, Killander A, Åstrand P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130213>
 33. **SARS-CoV-2/Renin-Angiotensin System: Deciphering the Clues for a Couple with Potentially Harmful Effects on Skeletal Muscle.** *Int J Mol Sci* 2020; 21 Gonzalez A, Orozco-Aguilar J, Achiardi O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114359>
 34. **A new rapid screening program based on risk scores for COVID-19 patients.** *Intern Emerg Med* 2020:1-8 Chen R, Xu G, Yang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111164>
 35. **Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19.** *J Am Coll Cardiol* 2020; Alvarez-Garcia J, Lee S, Gupta A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129663>
 36. **Troponin and Other Biomarker Levels and Outcomes Among Patients Hospitalized with COVID-19: Derivation and Validation of the HA(2)T(2) COVID-19 Mortality Risk Score.** *J Am Heart Assoc* 2020:e018477 Manocha KK, Kirzner J, Ying X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121304>
 37. **Development of a preoperative Early Warning Scoring System to identify highly suspect COVID-19 patients.** *J. Anaesthesiol. Clin. Pharmacol.* 2020; 36:S62-s74 Ali Z, Goneppanavar U, Dongare PA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100649>
 38. **Identification of county-level health factors associated with COVID-19 mortality in the United States.** *J. Biomed. Res.* 2020:1-9 Pan W, Miyazaki Y, Tsumura H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109778>
 39. **Circulating Levels of Interleukin-6 and Interleukin-10, But Not Tumor Necrosis Factor-Alpha, as Potential Biomarkers of Severity and Mortality for COVID-19: Systematic Review with Meta-analysis.** *J. Clin. Immunol.* 2020:1-12 Udomsinprasert W, Jittikoon J, Sangroongruangsri S, Chaikledkaew U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128665>
 40. **Mean platelet volume/platelet count ratio predicts severe pneumonia of COVID-19.** *J. Clin. Lab. Anal.* 2020:e23607 Zhong Q, Peng J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128497>

41. **Inhaled Corticosteroids and COVID-19 Risk and Mortality: A Nationwide Cohort Study.** J Clin Med 2020; 9Choi JC, Jung SY, Yoon UA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33114246>
42. **The Role of COVID-19 in the Death of SARS-CoV-2-Positive Patients: A Study Based on Death Certificates.** J Clin Med 2020; 9Grippo F, Navarra S, Orsi C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33121176>
43. **Coagulation Parameters: An Efficient Measure for Predicting the Prognosis and Clinical Management of Patients with COVID-19.** J Clin Med 2020;
9Quintana-Díaz M, Andrés-Esteban EM, Ramírez-Cervantes KL *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33126706>
44. **Covid-19-Associated Coagulopathy: Biomarkers of Thrombin Generation and Fibrinolysis Leading the Outcome.** J Clin Med 2020; 9Ranucci M, Sitzia C, Baryshnikova E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126772>
45. **Response to: Is newly diagnosed diabetes a stronger risk factor than pre-existing diabetes for COVID-19 severity?** J. Diabetes 2020; Lippi G, Sanchis-Gomar F, Henry BM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128349>
46. **Is newly diagnosed diabetes a stronger risk factor than pre-existing diabetes for COVID-19 severity?** J. Diabetes 2020; Sathish T, de Mello GT, Cao Y.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33107708>
47. **It's X-Related: Biological Bases of Increased COVID-19 Morbidity and Mortality in Men.** J Endocr Soc 2020; 4:bvaa133Angelides PK, Jindal I, Karaviti L, Geffner ME. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117953>
48. **Derivation and Internal Validation of a Model to Predict the Probability of Severe Acute Respiratory Syndrome Coronavirus-2 Infection in Community People.** J Gen Intern Med 2020;1-8van Walraven C, Manuel DG, Desjardins M, Forster AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107007>
49. **Clinical Characteristics and Risk Factors for Mortality in Very Old Patients Hospitalized with COVID-19 in Spain.** J Gerontol A Biol Sci Med Sci 2020; Ramos-Rincon JM, Buonaiuto V, Ricci M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103720>
50. **The COVID-19 Own Risk Appraisal Scale (CORAS): Development and validation in two samples from the United Kingdom.** J Health Psychol 2020;1359105320967429Jaspal R, Fino E, Breakwell GM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33111594>
51. **Case report: a fatal combination of hemophagocytic lymphohistiocytosis with extensive pulmonary microvascular damage in COVID-19 pneumonia.** J. Hematop. 2020;1-5von der Thüsen JH, van Bommel J, Kros JM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33110452>
52. **MuLBSTA score is a useful tool for predicting COVID-19 disease behavior.** J Infect Chemother 2020; Iijima Y, Okamoto T, Shirai T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33129694>
53. **Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study.** J Transl Med 2020; 18:406Zhang J, Hao Y, Ou W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33121497>
54. **Risk and Protective Factors for Prospective Changes in Adolescent Mental Health during the COVID-19 Pandemic.** J. Youth Adolesc. 2020;1-14Magson NR, Freeman JYA, Rapee RM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33108542>

55. **The impact of oxidative stress damage induced by the environmental stressors on COVID-19.** Life Sci 2020;118653Bakadia BM, Boni BOO, Ahmed AAQ, Yang G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115606>
56. **[Risk stratification of emergencies during the COVID-19 pandemic within the emergency department].** Med Klin Intensivmed Notfmed 2020;1-9Wieckenberg M, Meier V, Pfeiffer S, Blaschke S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33112980>
57. **Mutations Observed in the SARS-CoV-2 Spike Glycoprotein and Their Effects in the Interaction of Virus with ACE-2 Receptor.** Medeni Med J 2020; 35:253-260Durmaz B, Abdulmajed O, Durmaz R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110678>
58. **IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19.** Mol. Med. 2020; 26:97Chen Y, Wang J, Liu C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121429>
59. **Geospatial Distribution and Predictors of Mortality in Hospitalized Patients With COVID-19: A Cohort Study.** Open Forum Infect Dis 2020; 7:ofaa436. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117852>
60. **Upper Respiratory Tract Viral Ribonucleic Acid Load at Hospital Admission Is Associated With Coronavirus Disease 2019 Disease Severity.** Open Forum Infect Dis 2020; 7:ofaa282Guo X, Jie Y, Ye Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117856>
61. **The Liver in COVID-19-Related Death: Protagonist or Innocent Bystander?** Pathobiology 2020;1-7Schmit G, Lelotte J, Vanhaebost J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33108789>
62. **Covid-19: Fat, Obesity, Inflammation, Ethnicity, and Sex Differences.** Pathogens 2020; 9Krams IA, Luoto S, Rantala MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114495>
63. **Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review.** Protein J 2020;1-13Suhail S, Zajac J, Fossum C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106987>
64. **Prediction of survival odds in COVID-19 by zinc, age and selenoprotein P as composite biomarker.** Redox Biol 2020; 38:101764Heller RA, Sun Q, Hackler J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126054>
65. **[CURB-65 as a predictor of 30-day mortality in patients hospitalized with COVID-19 in Ecuador: COVID-EC StudyAbstract].** Rev Clin Esp 2020; Carriel J, Muñoz-Jaramillo R, Bolaños-Ladinez O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110273>
66. **Are patients with asthma and COPD preferred targets of COVID-19?** Tuberc Respir Dis (Seoul) 2020; Bouazza B, Hadj-Said D, Pescatore KA, Chahed R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33099990>
67. **Risk factors for mortality among hospitalized patients with COVID-19. An overview in Mexican population.** Tuberc Respir Dis (Seoul) 2020; Cortés-Tellés A, López-Romero S, Mancilla-Ceballos R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121231>
68. **Shorter incubation period is associated with severe disease progression in patients with COVID-19.** Virulence 2020; 11:1443-1452Lai C, Yu R, Wang M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33108255>
69. **Lack of association between ABO blood groups and susceptibility to SARS-CoV-2 infection.** Vox Sang 2020; Levi JE, Telles PR, Scrivani H, Campana G.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33103769>

70. **A multivariate analysis of risk factors associated with death by Covid-19 in the USA, Italy, Spain, and Germany.** *Z Gesundh Wiss* 2020;1-7Cobre AF, Böger B, Vilhena RO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101840>

Safety (11 articles)

1. **Side chain similarity comparisons for integrated drug repositioning and potential toxicity assessments in epidemic response scenarios: The case for COVID-19.** *Comput Struct Biotechnol J* 2020; 18:2931-2944Ab Ghani NS, Emrizal R, Makmur H, Firdaus-Raih M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101604>
2. **To Anticoagulate or Not: Acute Stroke in a COVID-19 Patient With Gastrointestinal Bleed.** *Cureus* 2020; 12:e10554George J, Kirkland Z, Lattanzio N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101801>
3. **Evidence and the main adverse effects regarding drug therapies in the war against COVID-19.** *Curr Med Chem* 2020; Mora-Ramírez M, Melgoza-Hernández P, Toledo-Ramírez SE, Aranguré JMM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106134>
4. **BRACE-CORONA trial - COVID-19: No severe course in patients undergoing RAS inhibition.** *Deutsches Arzteblatt International* 2020; 117:A1816Eckert N.
5. **Effectiveness of steroid treatment for SARS-CoV-2 pneumonia with COP-like reaction: a case report.** *Disaster Med Public Health Prep* 2020;1-13Kim T, Son E, Jeon D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100248>
6. **Paracetamol-Induced Glutathione Consumption: Is There a Link With Severe COVID-19 Illness?** *Front. Pharmacol.* 2020; 11:579944Sestili P, Fimognari C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117175>
7. **Inhaled Corticosteroids and COVID-19 Risk and Mortality: A Nationwide Cohort Study.** *J Clin Med* 2020; 9Choi JC, Jung SY, Yoon UA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114246>
8. **Lack of detrimental effect of corticosteroids on antibody responses to SARS-CoV-2 and viral clearance in patients hospitalized with COVID-19.** *J Infect* 2020; Masiá M, Fernández-González M, García JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115658>
9. **Coinfection of Tuberculosis Pneumonia and COVID-19 in a Patient Vaccinated with Bacille Calmette-Guérin (BCG): Case Report.** *SN Compr Clin Med* 2020;1-4Luciani M, Bentivegna E, Spuntarelli V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103062>
10. **Tocilizumab and liver injury in patients with COVID-19.** *Therap. Adv. Gastroenterol.* 2020; 13:1756284820959183Serviddio G, Villani R, Stallone G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101458>
11. **[Pharmacokinetic changes related to acute infection. Examples from the SARS-CoV-2 pandemic].** *Therapie* 2020; Chavant A, Gautier-Veyret E, Chhun S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129512>

Treatment options (126 articles)

1. **Profiling SARS-CoV-2 Main Protease (M(PRO)) Binding to Repurposed Drugs Using Molecular Dynamics Simulations in Classical and Neural Network-**

- Trained Force Fields.** *ACS Comb Sci* 2020; Gupta A, Zhou HX.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33119257>
2. **Hypoxia, HIF-1 α , and COVID-19: from pathogenic factors to potential therapeutic targets.** *Acta Pharmacol. Sin.* 2020;1-8Serebrovska ZO, Chong EY, Serebrovska TV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110240>
 3. **Identification of SARS-CoV-2 entry inhibitors among already approved drugs.** *Acta Pharmacol. Sin.* 2020; Yang L, Pei RJ, Li H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33116249>
 4. **[Development of an information website on the proper use of medicines during the pandemic].** *Actual. Pharm.* 2020; 59:34-39.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100495>
 5. **Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19.** *Adv Ther* 2020:1-10Lasky JA, Fuloria J, Morrison ME *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33108622>
 6. **Anti-inflammatory substances from onions could be an option for treatment of COVID-19-a hypothesis.** *Allergo J Int* 2020:1-2Dorsch W, Ring J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33101838>
 7. **The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro.** *Biochem. Pharmacol.* 2020:114302Song J, Zhang L, Xu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121927>
 8. **Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm.** *Biomaterials* 2020; 267:120389Lee YY, Park HH, Park W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130319>
 9. **Potential of natural astaxanthin in alleviating the risk of cytokine storm in COVID-19.** *Biomed. Pharmacother.* 2020; 132:110886Talukdar J, Bhadra B, Dattaroy T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113418>
 10. **An overview of potential therapeutic agents to treat COVID-19.** *Biosci Trends* 2020; Dong X, Tian Z, Shen C, Zhao C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100290>
 11. **Challenges of drug development during the COVID-19 pandemic: key considerations for clinical trial designs.** *Br. J. Clin. Pharmacol.* 2020; Shi J, Xiao Y, Zhang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119136>
 12. **Unfractionated heparin inhibits live wild-type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations.** *Br. J. Pharmacol.* 2020; Tree JA, Turnbull JE, Buttigieg KR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125711>
 13. **Early Initiation of Extracorporeal Blood Purification Using the AN69ST (oXiris®) Hemofilter as a Treatment Modality for COVID-19 Patients: a Single-Centre Case Series.** *Braz J Cardiovasc Surg* 2020; Ugurov P, Popevski D, Gramosli T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113325>
 14. **No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19.** *Braz. J. Microbiol.* 2020:1-5Faíco-Filho KS, Conte DD, de Souza Luna LK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111169>
 15. **First case of COVID-19 infused with hESC derived immunity- and matrix-regulatory cells.** *Cell Prolif.* 2020:e12943Wu J, Hu Z, Wang L *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107123>
16. **"Impact of Corticosteroids in COVID-19 Outcomes: Systematic Review and Meta-Analysis".** *Chest* 2020; Cano EJ, Fuentes XF, Campioli CC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33129791>
 17. **Hypothesis: What is the Best We Can Do with Hydroxychloroquine for COVID-19?** *Clin. Epidemiol.* 2020; 12:1139-1144 Wang S, Mulier S, Jonscher C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33116907>
 18. **Emerging treatment strategies for COVID-19 infection.** *Clin. Exp. Med.* 2020; Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33128197>
 19. **Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19.** *Clin Infect Dis* 2020; Malsy J, Veletzky L, Heide J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103195>
 20. **Response to the COVID-19 pandemic among people experiencing homelessness in congregant living settings in San Diego, CA.** *Clin Infect Dis* 2020; Marquez H, Ramers C, Northrup A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33118015>
 21. **Re -Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis.** *Clin Microbiol Infect* 2020; Vedrines N, Bouthors AT, Gayet S, Lacout A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33129929>
 22. **Side chain similarity comparisons for integrated drug repositioning and potential toxicity assessments in epidemic response scenarios: The case for COVID-19.** *Comput Struct Biotechnol J* 2020; 18:2931-2944 Ab Ghani NS, Emrizal R, Makmur H, Firdaus-Raih M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101604>
 23. **Side chain similarity comparisons for integrated drug repositioning and potential toxicity assessments in epidemic response scenarios: the case for COVID-19.** *Comput Struct Biotechnol J* 2020; Syatila Ab Ghani N, Emrizal R, Makmur H, Firdaus-Raih M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101604>
 24. **Evidence and the main adverse effects regarding drug therapies in the war against COVID-19.** *Curr Med Chem* 2020; Mora-Ramírez M, Melgoza-Hernández P, Toledo-Ramírez SE, Aranguré JMM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106134>
 25. **Natural Products in Mitigation of SARS CoV Infections.** *Curr Med Chem* 2020; Sharma V, Sharma A, Bharate SB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109028>
 26. **The Binding of Remdesivir to SARS-CoV-2 RNA-Dependent RNA polymerase May Pave The Way Towards the Design of Potential Drugs for COVID-19 Treatment.** *Curr. Pharm. Biotechnol.* 2020; Agoni C, Soliman MES.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33109039>
 27. **Ayurveda and Allopathic Therapeutic Strategies in Coronavirus Pandemic Treatment 2020.** *Curr Pharmacol Rep* 2020:1-10 Talwar S, Sood S, Kumar J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33106765>
 28. **Immunomodulatory Therapies for COVID-19 in Solid Organ Transplant Recipients.** *Curr Transplant Rep* 2020:1-11 Fernández-Ruiz M, Aguado JM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33110739>
 29. **Antivirals for COVID-19 in Solid Organ Transplant Recipients.** *Curr Transplant Rep* 2020:1-11 Laracy JC, Verna EC, Pereira MR.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101837>
30. **Probable positive effects of the photobiomodulation as an adjunctive treatment in COVID-19: A systematic review.** Cytokine 2020; 137:155312Nejatifard M, Asefi S, Jamali R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33128927>
 31. **Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients.** Data Brief 2020:106445Zanon D, Musazzi UM, Manca A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33110933>
 32. **BRACE-CORONA trial - COVID-19: No severe course in patients undergoing RAS inhibition.** Deutsches Arzteblatt International 2020; 117:A1816Eckert N.
 33. **Effectiveness of steroid treatment for SARS-CoV-2 pneumonia with COP-like reaction: a case report.** Disaster Med Public Health Prep 2020:1-13Kim T, Son E, Jeon D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100248>
 34. **Is amiloride a promising cardiovascular medication to persist in the COVID-19 crisis?** Drug Discov Ther 2020; Adil MS, Narayanan SP, Somanath PR.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33116037>
 35. **Herbal approach for the management of COVID-19: an overview.** Drug Metab Pers Ther 2020; Fatima S, Haider N, Alam MA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33128525>
 36. **Short-term Hydroxychloroquine in COVID-19 Infection in People With or Without Metabolic Syndrome - Clearing Safety Issues and Good Clinical Practice.** Eur Endocrinol 2020; 16:109-112Dutta D, Sharma M, Sharma R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33117441>
 37. **Repurposing anticancer drugs for the management of COVID-19.** Eur. J. Cancer 2020; 141:40-61El Bairi K, Trapani D, Petrillo A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33125946>
 38. **Delayed hospital admission and high-dose corticosteroids potentially prolong SARS-CoV-2 RNA detection duration of patients with COVID-19.** Eur J Clin Microbiol Infect Dis 2020:1-8Hu Z, Li S, Yang A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33123934>
 39. **Does hydroxychloroquine reduce mortality for COVID-19?** Eur J Intern Med 2020; Gallus S, Clavenna A, Lugo A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127218>
 40. **Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial.** Eur. J. Pharm. Sci. 2020:105631Lou Y, Liu L, Yao H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33115675>
 41. **COVID-19 and antimalarials. Have we been doing it wrong all along?** Eur. J. Pharmacol. 2020:173694Andrei CC, Laurentiu CG, Fazel NS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33130275>
 42. **In silico identification of strong binders of the SARS-CoV-2 receptor-binding domain.** Eur. J. Pharmacol. 2020:173701Behloul N, Baha S, Guo Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33130279>
 43. **Unravelling high-affinity binding compounds towards transmembrane protease serine 2 enzyme in treating SARS-CoV-2 infection using molecular modelling and docking studies.** Eur. J. Pharmacol. 2020:173688M P, Reddy GJ, Hema K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130280>
 44. **Prospects of plasmapheresis for patients with severe COVID-19.** Eur. J. Transl. Myol. 2020; 30:9165Gilmutdinova IR, Yakovlev MY, Eremin PS, Fesun AD.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117508>
45. **Co-aerosolized Pulmonary Surfactant and Ambroxol for COVID-19 ARDS Intervention: What Are We Waiting for?** *Front Bioeng Biotechnol* 2020; 8:577172Kumar P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102461>
 46. **Mesenchymal Stem Cells and Their Extracellular Vesicles: A Potential Game Changer for the COVID-19 Crisis.** *Front Cell Dev Biol* 2020; 8:587866Kassem DH, Kamal MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102489>
 47. **Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?-Lessons Learned From Cancer.** *Front. Immunol.* 2020; 11:588724Barbieri A, Robinson N, Palma G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117402>
 48. **SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment.** *Front. Immunol.* 2020; 11:570927Khalaf K, Papp N, Chou JT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123144>
 49. **The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19.** *Front. Immunol.* 2020; 11:595739Schreiber G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117408>
 50. **Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis.** *Front Med (Lausanne)* 2020; 7:586221Boregowda U, Perisetti A, Nanjappa A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123544>
 51. **Would Repurposing Minocycline Alleviate Neurologic Manifestations of COVID-19?** *Front. Neurosci.* 2020; 14:577780Oliveira AC, Richards EM, Karas MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117121>
 52. **Paracetamol-Induced Glutathione Consumption: Is There a Link With Severe COVID-19 Illness?** *Front. Pharmacol.* 2020; 11:579944Sestili P, Fimognari C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117175>
 53. **Anti-SARS-CoV Natural Products With the Potential to Inhibit SARS-CoV-2 (COVID-19).** *Front. Pharmacol.* 2020; 11:561334Verma S, Twilley D, Esmear T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101023>
 54. **The Important Role of Volatile Components From a Traditional Chinese Medicine Dayuan-Yin Against the COVID-19 Pandemic.** *Front. Pharmacol.* 2020; 11:583651Zhang XR, Li TN, Ren YY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101037>
 55. **Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19.** *Gerontology* 2020:1-9Díaz Y, Ramos-Suzarte M, Martín Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33105142>
 56. **Biochemical and immunological aspects of Covid-19 infection and therapeutical intervention of oral low dose cytokine therapy: A systematic review.** *Immunopharmacol. Immunotoxicol.* 2020:1-15M R, S S, Jose SP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106053>
 57. **Efficacy of Lopinavir/Ritonavir Compared With Standard Care for Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review.** *Infect Disord Drug Targets* 2020; Hariyanto TI, Kristine E, Jillian Hardi C, Kurniawan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121422>
 58. **A connectivity map-based drug repurposing study and integrative analysis of transcriptomic profiling of SARS-CoV-2 infection.** *Infect Genet Evol* 2020:104610Mousavi SZ, Rahmanian M, Sami A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130005>

59. **Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients.** *Int Immunopharmacol* 2020; 89:107088Valizadeh H, Abdolmohammadi-Vahid S, Danshina S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33129099>
60. **COVID-19 outpatients - early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study.** *Int J Antimicrob Agents* 2020;106214Derwand R, Scholz M, Zelenko V.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33122096>
61. **Why we should be more careful using hydroxychloroquine in influenza season?** *Int J Infect Dis* 2020; Çelik HG, Keske Ş, Şener Ü *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33130195>
62. **Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study.** *Int J Infect Dis* 2020; Choi MJ, Kang M, Shin SY *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33127507>
63. **Compassionate Use of Tocilizumab in Severe SARS-CoV2 Pneumonia.** *Int J Infect Dis* 2020; Hernández-Mora MG, Cabello Úbeda A, Pérez LP *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33115682>
64. **Interleukin-6: Molecule in the Intersection of Cancer, Ageing and COVID-19.** *Int J Mol Sci* 2020; 21Brábek J, Jakubek M, Vellieux F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33114676>
65. **Ebselen, a new candidate therapeutic against SARS-CoV-2.** *Int J Surg* 2020; 84:53-56Haritha CV, Sharun K, Jose B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120196>
66. **Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience.** *Intern Emerg Med* 2020; Tascini C, Sermann G, Pagotto A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33131033>
67. **Therapeutic status of hydroxychloroquine in COVID-19: A review.** *J Anaesthesiol. Clin. Pharmacol.* 2020; 36:S160-s165Kaur K, Kaushal S, Kaushal IG.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100674>
68. **Identification of therapeutic drugs against COVID-19 through computational investigation on drug repurposing and structural modification.** *J. Biomed. Res.* 2020;1-12Yun Y, Song H, Ji Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33122473>
69. **Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-α with in-vitro effective drug ivermectin.** *J Biomol Struct Dyn* 2020;1-10Sen Gupta PS, Biswal S, Panda SK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33111618>
70. **Uncaria tomentosa (cat's claw): a promising herbal medicine against SARS-CoV-2/ACE-2 junction and SARS-CoV-2 spike protein based on molecular modeling.** *J Biomol Struct Dyn* 2020;1-17Yepes-Pérez AF, Herrera-Calderon O, Quintero-Saumeth J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118480>
71. **Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically ill patients with COVID-19.** *J. Clin. Pharm. Ther.* 2020; Kocayigit H, Özmen Süner K, Tomak Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33128482>
72. **Supervised molecular dynamics for exploring the druggability of the SARS-CoV-2 spike protein.** *J. Comput. Aided Mol. Des.* 2020; Deganutti G, Prischi F, Reynolds CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103220>

73. **Biological response modifier glucan through balancing of blood glucose may have a prophylactic potential in COVID-19 patients.** J Diabetes Metab Disord 2020;1-4Ikewaki N, Iwasaki M, Abraham SJK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102263>
74. **Lack of detrimental effect of corticosteroids on antibody responses to SARS-CoV-2 and viral clearance in patients hospitalized with COVID-19.** J Infect 2020; Masiá M, Fernández-González M, García JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115658>
75. **Neutralizing Antibody Responses in COVID-19 Convalescent Sera.** J Infect Dis 2020; Lee WT, Girardin RC, Dupuis li AP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104179>
76. **Computational studies reveal mechanism by which quinone derivatives can inhibit SARS-CoV-2. Study of embelin and two therapeutic compounds of interest, methyl prednisolone and dexamethasone.** J Infect Public Health 2020; Caruso F, Rossi M, Pedersen JZ, Incerpi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109497>
77. **Inflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy.** J Inflamm Res 2020; 13:673-680Shibabaw T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116747>
78. **Corticosteroids for COVID-19 patients requiring oxygen support? Yes, but not for everyone: Effect of corticosteroids on mortality and Intensive Care Unit admission in patients with COVID-19 according to patients' oxygen requirements.** J Med Virol 2020; Tortajada C, Colomer E, Andreu-Ballester JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33107607>
79. **Synthesis, anti-bacterial evaluation, DFT study and molecular docking as a potential 3-chymotrypsin-like protease (3CLpro) of SARS-CoV-2 inhibitors of a novel Schiff bases.** J. Mol. Struct. 2020:129454Al-Janabi ASM, Elzupir AO, Yousef TA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100378>
80. **Identification of alkaloids from Justicia adhatoda as potent SARS CoV-2 main protease inhibitors: An in silico perspective.** J. Mol. Struct. 2020:129489Ghosh R, Chakraborty A, Biswas A, Chowdhuri S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100380>
81. **Molecular Basis of SARS-CoV-2 Infection and Rational Design of Potential Antiviral Agents: Modeling and Simulation Approaches.** J. Proteome Res. 2020; Francés-Monerris A, Hognon C, Miclot T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119313>
82. **Noncoding RNAs implication in cardiovascular diseases in the COVID-19 era.** J Transl Med 2020; 18:408Greco S, Madè A, Gaetano C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129318>
83. **The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection.** JACC Basic Transl Sci 2020; Beddingfield BJ, Iwanaga N, Chapagain PP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102950>
84. **Treatment adherence during the COVID-19 pandemic and the impact of confinement on disease activity and emotional status: a survey in 644 rheumatic patients.** Joint Bone Spine 2020:105085López-Medina C, Ladehesa-Pineda L, Gómez-García I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127460>
85. **Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis.** Life Sci 2020:118663Shrestha DB, Budhathoki P, Syed NI *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121991>
86. **Association between high-dose steroid therapy, respiratory function, and time to discharge in patients with COVID-19: Cohort study.** Med Clin (Barc) 2020; Rodríguez-Molinero A, Pérez-López C, Gálvez-Barrón C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129511>
 87. **Ac2-26 mimetic peptide of annexin A1 to treat severe COVID-19: A hypothesis.** Med. Hypotheses 2020; 145:110352 Bonavita AG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129009>
 88. **A multiple therapy hypothesis for treatment of COVID-19 patients.** Med. Hypotheses 2020; 145:110353 Oscar TP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129008>
 89. **Perspectives for the use of N-acetylcysteine as a candidate drug to treat COVID-19.** Mini Rev. Med. Chem. 2020; Luo P, Liu Y, Liu D, Li J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109047>
 90. **Antibody binding epitope Mapping (AbMap) of hundred antibodies in a single run.** Mol. Cell. Proteomics 2020; Qi H, Ma M, Hu C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109704>
 91. **Bioactive Natural Antivirals: An Updated Review of the Available Plants and Isolated Molecules.** Molecules 2020; 25 Mohan S, Elhassan Taha MM, Makeen HA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33105694>
 92. **Potential of Ficus microcarpa metabolites against SARS-CoV-2 main protease supported by docking studies.** Nat Prod Res 2020;1-5 Hassan HA, Abdelmohsen UR, Aly OM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121282>
 93. **Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience.** Open Forum Infect Dis 2020; 7:ofaa319 Kalligeros M, Tashima KT, Mylona EK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117850>
 94. **Covid-19: Fat, Obesity, Inflammation, Ethnicity, and Sex Differences.** Pathogens 2020; 9 Krams IA, Luoto S, Rantala MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114495>
 95. **A Proline-Based Tectons and Supramolecular Synthons for Drug Design 2.0: A Case Study of ACEI.** Pharmaceutics (Basel) 2020; 13 Bojarska J, Remko M, Breza M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114370>
 96. **Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing.** Pharmaceutics 2020; 12 Sahakijpijarn S, Moon C, Koleng JJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33105618>
 97. **Nucleotide analogues as inhibitors of SARS-CoV Polymerase.** Pharmacol Res Perspect 2020; 8:e00674 Ju J, Li X, Kumar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33124786>
 98. **Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine.** Pharmacogenomics Pers. Med. 2020; 13:531-542 Babayeva M, Loewy Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33122936>
 99. **Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease.** Pharmacogenomics Pers. Med. 2020; 13:463-484 Cafiero C, Re A, Micera A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116761>
 100. **Potential SARS-CoV-2 interactions with proteins involved in trophoblast functions - An in-silico study.** Placenta 2020; 103:141-151 Seethy AA, Singh S,

- Mukherjee I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126048>
101. **The dynamic treatment of SARS-CoV-2 disease.** Proc. (Bayl. Univ. Med. Cent.) 2020; 33:572-579 Sandkovsky U, Colley P, Sam T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100531>
 102. **Prediction of survival odds in COVID-19 by zinc, age and selenoprotein P as composite biomarker.** Redox Biol 2020; 38:101764 Heller RA, Sun Q, Hackler J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126054>
 103. **Efficacy and safety of remdesivir in hospitalized Covid-19 patients: Systematic review and meta-analysis including network meta-analysis.** Rev Med Virol 2020:e2187 Elsayah HK, Elsokary MA, Abdallah MS, ElShafie AH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128490>
 104. **Current Options in the Treatment of COVID-19: A Review.** Risk Manag. Healthc. Policy 2020; 13:1999-2010 Teimury A, Mahmoodi Khaledi E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116980>
 105. **Life-threatening COVID-19 presenting as stroke with antiphospholipid antibodies and low ADAMTS-13 activity, and the role of therapeutic plasma exchange: A case series.** SAGE Open Med Case Rep 2020; 8:2050313x20964089 Alharthy A, Faqihi F, Balhamar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101686>
 106. **Exploring RdRp-remdesivir interactions to screen RdRp inhibitors for the management of novel coronavirus 2019-nCoV.** SAR QSAR Environ. Res. 2020; 31:857-867 Singh PK, Pathania S, Rawal RK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100032>
 107. **Computational selection of flavonoid compounds as inhibitors against SARS-CoV-2 main protease, RNA-dependent RNA polymerase and spike proteins: A molecular docking study.** Saudi J. Biol. Sci. 2020; Ragavan Rameshkumar M, Indu P, Arunagirinathan N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110386>
 108. **Corticosteroids in COVID-19: Is it Rational? A Systematic Review and Meta-Analysis.** SN Compr Clin Med 2020;1-21 Budhathoki P, Shrestha DB, Rawal E, Khadka S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103063>
 109. **DFT calculations towards the geometry optimization, electronic structure, infrared spectroscopy and UV-vis analyses of Favipiravir adsorption on the first-row transition metals doped fullerenes; a new strategy for COVID-19 therapy.** Spectrochim. Acta. A Mol. Biomol. Spectrosc. 2020; 247:119082 Rad AS, Ardjmand M, Esfahani MR, Khodashenas B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33120121>
 110. **Mesenchymal stem cell treatment in a critically ill COVID-19 patient: a case report.** Stem Cell Investig 2020; 7:17 Zengin R, Beyaz O, Koc ES *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110915>
 111. **The Current Recommended Drugs and Strategies for the Treatment of Coronavirus Disease (COVID-19).** Ther. Clin. Risk Manag. 2020; 16:933-946 Sheikhpour M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116543>
 112. **Tocilizumab and liver injury in patients with COVID-19.** Therap. Adv. Gastroenterol. 2020; 13:1756284820959183 Serviddio G, Villani R, Stallone G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101458>
 113. **Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan.** Transfusion 2020;

- Kubota-Koketsu R, Terada Y, Yunoki M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104267>
114. **An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled trial.** *Trials* 2020; 21:880Alavi Darazam I, Hatami F, Rabiei MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106183>
 115. **A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:904Bosaeed M, Mahmoud E, Hussein M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129363>
 116. **Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.** *Trials* 2020; 21:883Chowdhury FR, Hoque A, Chowdhury FUH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106167>
 117. **Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:897Emadi A, Chua JV, Talwani R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115543>
 118. **Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:902Ghati N, Roy A, Bhatnagar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126910>
 119. **Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.** *Trials* 2020; 21:886Hassaniyazad M, Bazram A, Hassanipour S, Fathalipour M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109246>
 120. **The efficacy of Siddha Medicine, Kabasura Kudineer (KSK) compared to Vitamin C & Zinc (CZ) supplementation in the management of asymptomatic COVID-19 cases: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:892Natarajan S, Anbarasi C, Sathiyarajeswaran P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109252>
 121. **Assessment of boron-containing compounds and oleoylethanolamide supplementation on the recovery trend in patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial.** *Trials* 2020; 21:890Tutunchi H, Mobasseri M, Pourmoradian S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109244>
 122. **Evaluation of the efficacy and safety of Melatonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial.** *Trials* 2020; 21:882Ziaei A, Davoodian P, Dadvand H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106171>
 123. **Cost-Effectiveness of Antiviral Treatments for Pandemics and Outbreaks of Respiratory Illnesses, Including COVID-19: A Systematic Review of Published Economic Evaluations.** *Value Health* 2020; 23:1409-1422Dawoud DM, Soliman KY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127010>
 124. **Coronavirus Disease 2019: Considerations for Health Technology Assessment From the National Centre for Pharmacoeconomics Review Group.** *Value Health*

- 2020; 23:1423-1426 Leahy J, Hickey C, McConnell D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33127011>
125. **Ozone therapy in COVID-19: A narrative review.** *Virus Res.* 2020; 291:198207 Cattel F, Giordano S, Bertiond C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33115670>
126. **A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam.** *Wellcome Open Res* 2020; 5:141 Kestelyn E, Dung NTP, Lam Minh Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33110944>

Trials (25 articles)

1. **A single-centre, prospective cohort study of COVID-19 patients admitted to ICU for mechanical ventilatory support.** *Acta Anaesthesiol. Scand.* 2020; Søvik S, Bådstøløkken PM, Sørensen V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128800>
2. **Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19.** *Adv Ther* 2020:1-10 Lasky JA, Fuloria J, Morrison ME *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33108622>
3. **Hospitalised COVID-19 patients of the Mount Sinai Health System: a retrospective observational study using the electronic medical records.** *BMJ Open* 2020; 10:e040441 Wang Z, Zheutlin A, Kao YH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33109676>
4. **No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19.** *Braz. J. Microbiol.* 2020:1-5 Faíco-Filho KS, Conte DD, de Souza Luna LK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33111169>
5. **Phase 1 trial for treatment of COVID-19 patients with pulmonary fibrosis using hESC-IMRCs.** *Cell Prolif.* 2020:e12944 Wu J, Zhou X, Tan Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33107132>
6. **A Snapshot of the Response from UK-based Clinical Trials of Investigational Medicinal Products to COVID-19.** *Cureus* 2020; 12:e10613 Neumann S, Henderson E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123427>
7. **COVID-19 Vaccines on Clinical Trials and their Mode of Action for Immunity against the Virus.** *Curr. Pharm. Des.* 2020; Tavakol S, Alavijeh MS, Seifalian AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100195>
8. **BRACE-CORONA trial - COVID-19: No severe course in patients undergoing RAS inhibition.** *Deutsches Arzteblatt International* 2020; 117:A1816 Eckert N.
9. **Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial.** *Eur. J. Pharm. Sci.* 2020:105631 Lou Y, Liu L, Yao H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33115675>
10. **COVID-19 outpatients - early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study.** *Int J Antimicrob Agents* 2020:106214 Derwand R, Scholz M, Zelenko V.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33122096>
11. **Improved glycemic control amongst people with long-standing diabetes during COVID-19 lockdown: a prospective, observational, nested cohort study.**

- Int. J. Diabetes Dev. Ctries. 2020;1-6Rastogi A, Hiteshi P, Bhansali A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33106739>
12. **Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study.** Int J Infect Dis 2020; Choi MJ, Kang M, Shin SY *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33127507>
 13. **Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience.** Open Forum Infect Dis 2020; 7:ofaa319Kalligeros M, Tashima KT, Mylona EK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33117850>
 14. **Novel 3D segmentation for reliable volumetric assessment of the nasal airway: a CBCT study.** Quintessence Int. 2020;2-12Mupparapu M, Shi KJ, Lo AD, Setzer FC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33118002>
 15. **Vaccine- and natural infection-induced mechanisms that could modulate vaccine safety.** Toxicol Rep 2020; 7:1448-1458Kostoff RN, Kanduc D, Porter AL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33110761>
 16. **A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.** Trials 2020; 21:904Bosaeed M, Mahmoud E, Hussein M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33129363>
 17. **Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.** Trials 2020; 21:883Chowdhury FR, Hoque A, Chowdhury FUH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106167>
 18. **Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.** Trials 2020; 21:897Emadi A, Chua JV, Talwani R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33115543>
 19. **Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection: A structured summary of a study protocol for a randomised controlled trial.** Trials 2020; 21:902Ghati N, Roy A, Bhatnagar S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33126910>
 20. **Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.** Trials 2020; 21:886Hassaniazad M, Bazram A, Hassanipour S, Fathalipour M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33109246>
 21. **BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomised controlled trial.** Trials 2020; 21:881Junqueira-Kipnis AP, Dos Anjos LRB, Barbosa LCS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106170>
 22. **The efficacy of Siddha Medicine, Kabasura Kudineer (KSK) compared to Vitamin C & Zinc (CZ) supplementation in the management of asymptomatic COVID-19 cases: A structured summary of a study protocol for a randomised controlled trial.** Trials 2020; 21:892Natarajan S, Anbarasi C, Sathiyarajeswaran P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109252>
 23. **Assessment of boron-containing compounds and oleoylethanolamide supplementation on the recovery trend in patients with COVID-19: A**

- structured summary of a study protocol for a randomized controlled trial.** *Trials* 2020; 21:890Tutunchi H, Mobasser M, Pourmoradian S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33109244>
24. **Evaluation of the efficacy and safety of Melatonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial.** *Trials* 2020; 21:882Ziaei A, Davoodian P, Dadvand H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33106171>
25. **A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam.** *Wellcome Open Res* 2020; 5:141Kestelyn E, Dung NTP, Lam Minh Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33110944>

Vaccines (23 articles)

1. **SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination.** *Adv Mater* 2020:e2005637Huang WC, Zhou S, He X *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33111375>
2. **The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.** *Cells* 2020; 9Papageorgiou AC, Mohsin I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33105869>
3. **Bioethical Implications in Vaccine Development, a COVID-19 Challenge.** *Cureus* 2020; 12:e10530Ospina Henao S, Marín Mora A, Chan Solano F, Ávila-Aguero ML. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33101792>
4. **COVID-19 vaccine race: analysis of age-dependent immune responses against SARS-CoV-2 indicates that more than just one strategy may be needed.** *Curr Med Chem* 2020; Campillo NE, Jimenez M, Canelles M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33109026>
5. **COVID-19 Vaccines on Clinical Trials and their Mode of Action for Immunity against the Virus.** *Curr. Pharm. Des.* 2020; Tavakol S, Alavijeh MS, Seifalian AM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100195>
6. **Survey data for COVID-19 vaccine preference analysis in the United Arab Emirates.** *Data Brief* 2020; 33:106446Muqattash R, Niankara I, Traoret RI.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33106773>
7. **COVID-19 vaccine development: Faster, but safe.** *Deutsches Arzteblatt International* 2020; 117:A1810-A1813Wagner R, Hildt E, Grabski E *et al.*
8. **Public Perceptions of COVID-19 in Australia: Perceived Risk, Knowledge, Health-Protective Behaviors, and Vaccine Intentions.** *Front. Psychol.* 2020; 11:551004Faasse K, Newby J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117223>
9. **Assessing COVID-19 vaccine literacy: a preliminary online survey.** *Hum Vaccin Immunother* 2020:1-9Biasio LR, Bonaccorsi G, Lorini C, Pecorelli S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33118868>
10. **The estimated impact of decreased childhood vaccination due to COVID-19 using a dynamic transmission model of mumps in Japan.** *Hum Vaccin Immunother* 2020:1-4Kitano T, Aoki H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121326>
11. **SARS-CoV-2 vaccine candidates in rapid development.** *Hum Vaccin Immunother* 2020:1-10Li L, Guo P, Zhang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121319>

12. **Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies.** *Immunobiology* 2020; 225:152008 Varghese PM, Tsolaki AG, Yasmin H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33130519>
13. **A Review of Recommendations for Routine Immunization Services During COVID-19 Pandemic That are Relevant for Nursing Personnel Involved in the Implementation of Immunoprophylaxis.** *J Multidiscip Healthc* 2020; 13:1099-1105 Bednarek A, Klepacz R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116556>
14. **Predictors of Non-Adherence to Public Health Instructions During the COVID-19 Pandemic in the Democratic Republic of the Congo.** *J Multidiscip Healthc* 2020; 13:1215-1221 Kabamba Nzaji M, Ngoie Mwamba G, Mbidi Miema J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116566>
15. **Intention to Vaccinate Against the Novel 2019 Coronavirus Disease: The Role of Health Locus of Control and Religiosity.** *J Relig Health* 2020:1-16 Olagoke AA, Olagoke OO, Hughes AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33125543>
16. **IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19.** *Mol. Med.* 2020; 26:97 Chen Y, Wang J, Liu C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33121429>
17. **Is there a role for childhood vaccination against COVID-19?** *Pediatr. Allergy Immunol.* 2020; Eberhardt CS, Siegrist CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33113210>
18. **Protecting the Herd: Why Pharmacists Matter in Mass Vaccination.** *Pharmacy (Basel)* 2020; 8 Lee L, Peterson GM, Naunton M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114654>
19. **The influence of vaccination against tuberculosis with the Bacillus-Calmette-Guérin (BCG) vaccine on COVID-19 incidence and mortality - review of the literature.** *Przegl. Epidemiol.* 2020; 74:290-302 Ręka G, Korzeniowska A, Pieciewicz-Szczęśna H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33115218>
20. **Transforming vaccine development.** *Semin. Immunol.* 2020:101413 Black S, Bloom DE, Kaslow DC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33127296>
21. **Coinfection of Tuberculosis Pneumonia and COVID-19 in a Patient Vaccinated with Bacille Calmette-Guérin (BCG): Case Report.** *SN Compr Clin Med* 2020:1-4 Luciani M, Bentivegna E, Spuntarelli V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33103062>
22. **BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:881 Junqueira-Kipnis AP, Dos Anjos LRB, Barbosa LCS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106170>
23. **Parents' and guardians' views on the acceptability of a future COVID-19 vaccine: A multi-methods study in England.** *Vaccine* 2020; Bell S, Clarke R, Mounier-Jack S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33109389>

Women – pregnancy (27 articles)

1. **Single-cell expression profiles of ACE2 and TMPRSS2 reveals potential vertical transmission and fetus infection of SARS-CoV-2.** *Aging (Albany NY)* 2020; 12 Lü M, Qiu L, Jia G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33104520>
2. **The Impact of Perinatal SARS-CoV2 Infection During the Peripartum Period.** *Am J Obstet Gynecol MFM* 2020:100267 Janssen O, Thompson M, Milburn S *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33103098>

3. **Vaginal delivery in SARS-CoV-2-infected pregnant women in Israel: a multicenter prospective analysis.** Arch. Gynecol. Obstet. 2020; Rottenstreich A, Tsur A, Braverman N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33123808>
4. **Clinical care of pregnant and postpartum women with COVID-19: Living recommendations from the National COVID-19 Clinical Evidence Taskforce.** Aust N Z J Obstet Gynaecol 2020; Vogel JP, Tendal B, Giles M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33119139>
5. **The COVID-19 Pandemic Can Impact Perinatal Mental Health and the Health of the Offspring.** Behav Sci (Basel) 2020; 10Caparros-Gonzalez RA, Ganho-Ávila A, Torre-Luque A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33114124>
6. **COVID-19: a potential driver of immune-mediated breast cancer recurrence?** Breast Cancer Res. 2020; 22:117Francescangeli F, De Angelis ML, Zeuner A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33126915>
7. **The COVID-ASSESS Dataset - COVID19 related Anxiety and Stress in pregnancy, post-partum and breastfeeding during lockdown in Italy.** Data Brief 2020:106440Ravaldi C, Vannacci A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102644>
8. **Novel Coronavirus SARS-CoV-2 (COVID-19) and Pregnancy: A hypothetical view.** Endocr. Metab. Immune Disord. Drug Targets 2020; Ahmed R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100211>
9. **Challenges in Women with Diabetes During the COVID-19 Pandemic.** Eur Endocrinol 2020; 16:100-108Priya G, Bajaj S, Grewal E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117440>
10. **Blood Test Results of Pregnant COVID-19 Patients: An Updated Case-Control Study.** Front Cell Infect Microbiol 2020; 10:560899Sun G, Zhang Y, Liao Q, Cheng Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33117727>
11. **Understanding Gender-Bias in Critically Ill Patients With COVID-19.** Front Med (Lausanne) 2020; 7:564117Chamekh M, Casimir G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102501>
12. **Undergoing active treatment for gynecologic cancer during COVID-19: A qualitative study of the impact on healthcare and social support.** Gynecol Oncol Rep 2020; 34:100659H KM, Brooks JV, Spoozak L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33106774>
13. **Time-related changes in sex distribution of COVID-19 incidence proportion in Italy.** Heliyon 2020; 6:e05304Bianconi V, Mannarino MR, Bronzo P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33102879>
14. **The effect of the COVID-19 pandemic on maternal health due to delay in seeking health care: Experience from a tertiary center.** Int J Gynaecol Obstet 2020; Goyal M, Singh P, Singh K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128794>
15. **Updated experience of a tertiary pandemic center on 533 pregnant women with COVID-19 infection: A prospective cohort study from Turkey.** Int J Gynaecol Obstet 2020; Sahin D, Tanacan A, Erol SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33131057>
16. **Lessons learned from first case of Cesarean delivery in a COVID-19 positive parturient in Greek region.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S121-s124Batistaki C, Galarioti V, Vasiliadou S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33100660>

17. **Peripartum cardiomyopathy mimicking COVID-19 infection.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S44-s47Garg S, Singh A, Kalita M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100645>
18. **Management of pregnant laboring women during COVID-19 pandemic.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S91-s96Jain K, Bhatia N, Grewal A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100655>
19. **Respiratory and cardiovascular effects of COVID-19 infection and their management.** J. Anaesthesiol. Clin. Pharmacol. 2020; 36:S21-s28Kapoor MC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33100642>
20. **Evaluation of SARS-CoV-2 in the female reproductive tract of COVID-19 patients: A prospective study.** J Biol Regul Homeost Agents 2020; 34Hu YY, Ji DP, Yu YY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33108863>
21. **COVID-19 and Adverse Pregnancy Outcome: A Systematic Review of 104 Cases.** J Clin Med 2020; 9Abou Ghayda R, Li H, Lee KH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33114779>
22. **Coronavirus Disease 2019 in Pregnancy: The Experience at an Urban Safety Net Hospital.** J. Community Health 2020;1-3Dhuyvetter A, Cejtin HE, Adam M, Patel A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33128667>
23. **Comparison of VEGF-A Values between Pregnant Women with COVID-19 and Healthy Pregnancies and Its Association with Composite Adverse Outcomes.** J Med Virol 2020; Yazihan N, Tanacan A, Erol SA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33107604>
24. **Maternal SARS-CoV-2 infection associated to systemic inflammatory response and pericardial effusion in the newborn: a Case-Report.** J Pediatric Infect Dis Soc 2020; Lima ARO, Cardoso CC, Bentim PRB *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33125068>
25. **Can immunity during pregnancy influence SARS-CoV-2 infection? - A systematic review.** J Reprod Immunol 2020; 142:103215Areia AL, Mota-Pinto A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33130538>
26. **Coronavirus diseases and pregnancy: COVID-19,SARS, and MERS.** Przegl. Epidemiol. 2020; 74:276-289Fathi M, Vakili K, Deravi N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33112124>
27. **The Prevention and Control Experience of Maternal Health Care from Chengu, China During the COVID-19 Epidemic.** Risk Manag. Healthc. Policy 2020; 13:2213-2217Li C, Tang L, Luo Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33116999>

to subscribe click [here](#)
